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Abstract 
Ageing is a major cause of diseases in modern society and leads to many age-related 
diseases. In addition, rising obesity in society increases the likelihood of various diseases. The 
development of genetic sequencing technologies provides a novel platform to unravel the 
complexity of ageing and metabolism. 
The Naked mole-rat (Heterocephalus glaber) is a rodent that is related to mice (Mus 
musculus) and ages very slowly, and can live for over 30 years without developing cancer. 
RNAseq analysis of H. glaber and M. musculus livers identified genes that were under- or 
over-expressed in H. glaber. Relative qPCR analysis was performed to confirm the expression 
of highly expressed genes in the naked mole-rat. 
Adenosine-to-Inosine (A-to-I) RNA editing is a post-transcriptional modification of specific 
bases that can cause an alteration in amino acid and splicing events. Recent studies indicated 
a gene-specific decline in RNA editing with age in humans in Cyfip2. Using SOLiD RNAseq, we 
sequenced the transcriptomes of 6-, 12-, and 28-month old rat cerebral cortex. We identify 
a conserved RNA editing site in Cog3. Upon analysis of known conserved RNA editing targets, 
no changes in RNA editing were observed during ageing in the rat. These results highlight the 
biological differences between rodent model organisms and humans, and their significance 
in the context of RNA editing and ageing. 
Dietary restriction of caloric intake is known to increase the lifespan of many species. 
Physiologically, these animals remain lean and show a later onset of age-related diseases. 
Through this concept, we were interested in studying Gnasxlm+/p- knockout mice, which 
remain lean due to hypermetabolism, despite increased food intake. Gnasxlm+/p- mice have a 
deletion in Gnas, which prevents expression of Xlαs. However, it is not known exactly how 
the loss of Xlαs exerts this phenotype. Due to its role in homeostasis and localisation of Xlαs 
expression, RNA from whole hypothalami of wildtype and Gnasxlm+/p- mice were analysed by 
Illumina RNAseq in order to identify expression changes that may help to explain the 
physiological symptoms. The glial cell marker Gfap was found to be downregulated 2-fold in 
Gnasxlm+/p- mice, which was confirmed by qPCR. Furthermore, in analysing the localisation of 
GFAP within the hypothalamus, we identified a distinct loss of GFAP expression in the arcuate 
nucleus, and suprachiasmatic nucleus. GFAP was not found to be decreased in postnatal (P)1 
and P5 mice, indicating that the decrease in GFAP is more likely to be an adaptation to 
chronic undernutrition as a result of hypermetabolism, than a developmental problem in the 
mice. 
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Chapter 1: Introduction 
 
Two of the largest challenges in modern society are ageing populations, and increases in 
obesity levels. Ageing is a constant process through which many species decline in health 
and fertility and have an increase in mortality. Ageing is a huge risk factor in developing the 
most challenging chronic diseases, such as diabetes, heart disease, cancer, and dementia. 
Therefore, the aim of ageing research is ultimately to prevent age-related diseases and to 
increase the time spent in good health, not just lifespan. Like ageing, obesity is a risk factor 
for many diseases. Studying the mechanisms behind the regulation of metabolism may lead 
to treatments in the future. The explosion of DNA sequencing technologies over the last 
decade means that identifying whole transcriptome gene expression changes has become 
more cost-effective, and produces more data than ever before. We sought to use these 
sequencing technologies as platforms to interrogate aspects of ageing and metabolism in 
rodent models. 
1.1 Ageing 
Ageing is a process that manifests itself physiologically. Particularly with elderly people, this 
can mean a deterioration in health. However, understanding exactly how this process occurs 
at the cellular level is much more challenging. 
Many theories have been proposed as a way to explain the process of ageing. These include 
theories based on accumulated damage, such as the free-radical theory. This idea suggests 
that during oxidative phosphorylation in the mitochondria, reactive oxygen species (ROS) are 
produced, which are able to react with and damage DNA and proteins which lead to the 
deterioration of cells. Other theories suggest that ageing is genetically engineered. These 
postulate that it is not damage accumulation that drives ageing, but that ageing is a 
developmental process that is genetically determined by our genes. 
Calorie restriction is a process that has been studied in many species. It consists of chronic 
underfeeding, but without the deleterious effects of malnutrition. In many species, calorie 
restriction has been shown to slow the ageing process, enabling individuals to live up to 50% 
longer in some species. Furthermore, the effects are observed in a wide range of species 
from yeast to non-human primates. Calorie restriction induces changes in metabolism, 
particularly in favouring metabolism of fat over that of carbohydrates. While multiple 
signalling pathways have been implicated in mediating the effects of calorie restriction, the 
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exact mechanism is not fully understood (Bordone and Guarente, 2005; Masoro, 2005; 
Speakman and Mitchell, 2011). Therefore calorie restriction has important implications for 
both ageing and metabolism – two of the key processes that are explored in this project. 
In relation to the free-radical theory, the explanation is that consuming less food results in a 
lower production of ROS, leading to lower levels of DNA damage, which enables the cells to 
live longer. 
Another important factor known to affect maximum longevity in mammals is body size (de 
Magalhães et al., 2007). Larger mammals, such as the African elephant can live for around 
65 years; whereas smaller mammals such as the mouse live for a maximum of only 4 years 
(data from AnAge) (Tacutu et al., 2013). Some species do not entirely follow this pattern – a 
notable example being humans. While large compared to rodents, humans are much smaller 
than elephants – yet at 122 years, the maximum lifespan of humans exceeds that of 
elephants. 
The increasing availability of genomic and transcriptomic data for many different species 
means that it is becoming easier than ever before to investigate not only the genetic basis of 
ageing, but in identifying similarities and differences between species. Most species show an 
age-related increase in mortality, whereby older individuals have a higher rate of mortality 
as a result of age-related diseases. However, there are some species that do not show signs 
of an age-related increase in mortality. One of these is the naked mole-rat (NMR), 
Heterocephalus glaber, which is particularly unusual in many aspects. Despite its body size, 
which is equivalent to that of a mouse, NMRs can live for over 30 years, and show a high 
resistance to developing cancer (Buffenstein, 2005; Tian et al., 2013). Therefore, like humans, 
NMRs have a much greater lifespan than would be expected for an animal of their body size. 
In addition, the NMR is a rare example of a eusocial mammal that has a queen within each 
colony. They live within burrows that contain a much lower concentration of oxygen than 
the atmosphere and maintain a very slow metabolic rate (Goldman et al., 1999). 
As a result of it interesting longevity and cancer resistance, studying the physiology and 
genetics of the NMR has become an important focus for many aspects of both ageing and 
cancer research. 
1.2 Metabolism 
Many homeostatic mechanisms exist in species in order to regulate their responses to the 
environment. One key regulation is in energy management. After a period of not eating, 
16 
 
animals begin to feel hungry. Conversely, consuming a large meal will encourage satiety. 
Understanding the regulation of energy balance is of great importance considering the rising 
obesity levels in Western societies. 
A key hormone involved in the regulation of feeding and appetite is leptin, which is produced 
from adipose tissue. A high amount of energy stored in the adipose tissue causes the release 
of leptin, which travels to the hypothalamus (Klok et al., 2007).The hypothalamus is a key 
region at the ventral side of the brain, which has crucial roles in homeostasis, circadian 
rhythm control, hormonal balances, and energy regulation. Leptin receptors on cells in the 
hypothalamus detect the levels of circulating leptin to activate neurons in the hypothalamus 
that act to suppress appetite. This forms a feedback cycle to prevent overeating. 
In contrast, ghrelin is a hormone released by the gastrointestinal tract when the stomach is 
empty. Ghrelin travels to the hypothalamus to stimulate neurons in order to increase 
appetite. The hypothalamus acts as a mediator which responds to levels of these hormones 
in order to direct biological responses. 
1.3 Second generation sequencing 
The first papers on using second-generation sequencing (SGS) technologies to sequence 
transcriptomes were published in 2008 (Lister et al., 2008; Mortazavi et al., 2008; 
Nagalakshmi et al., 2008). Until this point, SGS had only been used for genome sequencing. 
However, alternative splicing events allow for multiple transcripts to be expressed from 
single genes. After post-transcriptional and post-translational modifications, the resulting 
proteins can have widely differing functions. Therefore the transcriptome is arguably much 
more informative than the genome in terms of understanding the biological functions of 
genes. Furthermore, with the rapidly increasing amount of genomic data on gained from SGS 
technologies, it became increasingly obvious that these genes needed to be annotated and 
characterised before we can understand how their transcripts function. Costs of SGS have 
reduced at a rapid rate since the introduction of SGS platforms, which has put them at the 
forefront of a revolution in genetic analysis. 
RNAseq is a recently developed tool that employs SGS to sequence the transcriptome, as 
opposed to the genome. Rather than sequencing DNA, RNA is reverse transcribed to cDNA 
prior to sequencing. In sequencing RNA, it is possible to identify genes that are changed in 
expression between different conditions.  
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The main two SGS technologies at the time were SOLiD sequencing (Applied Biosystems) and 
Illumina sequencing. While ultimately they both produce output genomic and transcriptomic 
data, each method has its advantages and disadvantages. 
1.3.1 SOLiD Sequencing 
SOLiD sequencing uses a ligation-based method whereby 8-base probes bind to the cDNA 
library reads, which are attached to beads on the flow cell. The probes have four different 
fluorescent dyes attached to the final base. Which one is attached corresponds to the first 
two bases of the probe. After ligation, the final three bases are cleaved from the probe. This 
releases the dye, allowing the fluorescence to be detected by the machine. The next ligation 
begins at the sixth base, and the process continues for 7 cycles in total to create a sequence 
of 35 bases. The sequencing cycle is begun again after ligation of an initial probe to the 
second base rather than the first. 
Because each colour refers to a 2-base sequence, each base is sequenced twice: once in 
combination with its previous partner, and once in combination with its next partner. 
Ultimately this results in one of the main benefits of SOLiD sequencing, which is its very high 
accuracy (99.94% for SOLiD v4) compared to other systems (Liu et al., 2012). 
The result is that the read is identified not by the bases AGCT, but by a series of colours, 
which are converted to numbers 0-3. Depending on the identity of the first base, the 
colorspace read can correspond to four different sequences. Due to the length of the product 
however, during the mapping process, the correct sequence can be identified against the 
genome. 
Therefore, the main benefit of the SOLiD sequencing system is for applications where base 
accuracy is very important. In particular, applications such as genome wide quantification of 
Single Nucleotide Polymorphisms (SNPs) would require a low error rate. However, 
applications such as gene expression changes are not so dependent on such a high accuracy. 
For these applications, long reads will still map to the correct gene even with a small number 
of sequencing errors. 
1.3.2 Illumina Sequencing 
Illumina sequencing is achieved using sequencing by synthesis. cDNA libraries are 
synthesised with adaptor sequences at either termini. These are adhered to the flow cell 
which contains a lawn of adaptor sequences. One phase of bridge amplification occurs, with 
the original cDNA washed away. This attaches the cDNA to the flow cell. cDNA is then 
amplified further by bridge amplification, which causes amplified cDNA to bend down so that 
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free distal cDNA adaptor sequence can adhere to a nearby free flow cell adaptor sequence. 
With several melting and amplification steps, this results in clusters of amplified cDNA 
originating from a single cDNA molecule. Dye-tagged nucleotides are flowed across, resulting 
in fluorescence given off by each cluster depending on which base is incorporated. The 
fluorescence wavelength is converted to the corresponding base, generating the digital 
reads. 
Illumina sequencing has the main benefit of generating a huge amount of sequencing data. 
Illumina generates around 5 times as much genetic data as SOLiD (Liu et al., 2012). While 
accuracy is lower than SOLiD (98% compared to 99.94%) (Liu et al., 2012), the read length is 
longer at 100 base pairs (bp) compared to 35bp. The combination of these factors is that 
Illumina sequencing is able to generate data that has a wider genome coverage, and the 
massive amount of genomic data that it produces means that the cost per base is half that 
of the SOLiD system (Liu et al., 2012).  
 
1.4 Aims 
Building on previous work, identifying a decline in RNA editing with age in human cerebral 
cortex (Nicholas et al., 2010), we sought to use an RNA sequencing (RNAseq) approach to 
identify new conserved editing sites in the rat. Furthermore, we wanted to investigate 
whether editing of conserved RNA editing targets declines with age in the rat. 
In addition, a recent RNAseq approach was used by colleagues to identify genes that were 
overexpressed in the liver of NMRs compared to their orthologous genes in mice – in order 
to identify genes that might be involved in the resistance to cancer and slow ageing. 
RNAseq was employed to investigate an interesting phenotype in Gnasxlm+/p- mice. These 
mice have an exon deletion in the paternal copy of the imprinted gene Gnas, which encodes 
the G-protein α subunit. Interestingly, the mice are hypermetabolic and remain small and 
lean with decreased fat mass, despite consuming more food. Because of its role in energy 
balance, and a site of expression for the knocked-out XLαs, the hypothalamus was a key 
region of interest. In order to investigate genes that might be involved in the development 
of the phenotype, we aimed to use RNAseq to identify differentially expressed genes in the 
hypothalami of wildtype and Gnasxlm+/p- mice.  
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From this analysis, we identified several genes that were significantly differentially 
expressed. In order to verify these results, we chose to perform quantitative reverse 
transcriptase PCR (qPCR) on a subset of genes. 
Upon verifying the expression of Glial fibrillary acidic protein (Gfap) as being underexpressed 
2-fold in Gnasxlm+/p- mice, we wanted to analyse whether this was true of GFAP at the protein 
level. In order to do this, we employed the use of Western blots from whole hypothalamic 
lysates, and immunofluorescence on hypothalamic sections to analyse GFAP localisation. 
Furthermore, GFAP expression was analysed within the hypothalami of neonatal mice in 
order to determine whether changes in expression in the adult were due to problem during 
development of the hypothalamus, or whether it was as a result of chronic undernutrition. 
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Chapter 2: Adenosine to Inosine RNA editing does not change 
with age in the healthy male rat brain 
2.1 Introduction 
2.1.1 Adenosine-to-Inosine RNA editing 
Adenosine-to-Inosine (A-to-I) RNA editing is a post-transcriptional process modulated by 
Adenosine Deaminases that Act on RNA (ADAR) proteins that convert specific adenosine 
residues to inosine by deamination. The inosine generated during editing is read as a 
guanosine by the splicing and translation machinery of the cell, as well as sequencing 
technologies. By inducing base modification, A-to-I RNA editing can have multiple effects on 
the splicing and sequence of mRNA and therefore efficacy of a protein. A-to-I RNA editing 
directs temporal-spatial regulation of transcripts and has an important role in increasing 
proteome diversity (Schaub and Keller, 2002; Nishikura, 2010). 
2.1.1.1 RNA editing in health & disease 
Many of the previously identified targets of RNA editing correspond to genes involved in 
neurotransmission in the central nervous system (CNS). In the CNS, RNA editing allows for 
fine regulation of the neurotransmission processes. Deregulation of A-to-I RNA editing is 
known to be a contributing factor in a variety of behavioural abnormalities and 
neurodegenerative diseases in the Central Nervous System (CNS), including Dyschromatosis 
Symmetrica Hereditaria (DSH), Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and 
Huntington’s disease, epilepsy, depression, schizophrenia and suicide (Akbarian et al., 1995; 
Maas et al., 2006; Farajollahi and Maas, 2010; Simmons et al., 2010). Furthermore, it has 
been hypothesised that RNA editing could be used as a therapeutic target for CNS diseases 
(Morabito and Emeson, 2009). The most widely studied example of RNA editing in the CNS 
is of the AMPA receptor subunit GRIA2. Editing in the coding region at the Q/R site is almost 
absolute and is required for tetramerisation of the subunits, which prevents Ca2+ ions from 
permeating the ion channel. Influxes of Ca2+ ions otherwise lead to excitotoxicity that results 
in damage and death of the motor neurons. Adarb1-/- mice die a few weeks after birth after 
suffering from epileptic seizures due to neuron death and excitotoxicity by Ca2+ influx (Brusa 
et al., 1995; Higuchi et al., 2000). ALS has also been linked to disruption of GRIA2 editing at 
the Q/R site, although it is not known whether this is causative. 
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In addition to having important roles in disease, ADARs appear to play a wide role in animal 
behaviour. Knockout fruit flies for dADAR (the sole ADAR homologue) show a selective 
disadvantage through reduced mating, accompanied by cerebral degeneration, erratic flight, 
uncoordinated locomotion and tremors. However, despite these abnormalities, dADAR 
mutants had a similar longevity to wild-type (Palladino et al., 2000; Jepson et al., 2010). A 
recent study showed that ADARB1-/-/Gria2R/R mice, whereby the Gria2 allele was modified to 
encode the edited isoform in the genome, also have behavioural abnormalities, including 
impaired hearing (Horsch et al., 2011). However, like the fruit fly, these mice have a normal 
lifespan. Microarrays on ADARB1-/-/Gria2R/R mice revealed many genes altered in expression 
compared to wild type, hinting at downstream effects of a lack of ADARB1 and RNA editing. 
These studies demonstrate that ADARs have much wider roles than previously thought. 
Meanwhile, non-coding RNA species and various RNA processes are being increasingly linked 
to neurological and cognitive disorders in addition to ageing (Montano and Long, 2011; 
Qureshi and Mehler, 2011). Deregulation of RNA editing has long been associated with the 
incidence of various cancers, many of which beyond the CNS, indicating that disruption of 
RNA editing has far reaching effects in pathology (Klimek-Tomczak et al., 2006; Paz et al., 
2007; Cenci et al., 2008; Martinez et al., 2008; Galeano et al., 2010). Dysregulation of RNA 
editing by overexpression of Adarb1 results in obesity (Singh et al., 2007). In addition, Adarb1 
knockdown rat pancreatic cells showed disrupted exocytosis of, but not limited to, insulin in 
response to glucose (Yang et al., 2010).  
Since deregulation of RNA editing may in part be responsible for a decline in neurological 
function, it was hypothesised that RNA editing may have important roles in neurological 
degeneration observed in ageing. A human centenarian study identified 5 SNPs in Adarb1 
and 13 SNPs in Adarb2 (Bass et al., 1997) that were associated with extreme longevity in 
different genetic backgrounds (Sebastiani et al., 2009). This study raises further questions 
about the potential functions of ADARB2, although it could be an evolutionary relic. Though 
Adarb2-/- mice are said to be physiologically normal (Nishikura, 2010), the effect of the gene 
knockout across an organism’s entire lifespan has yet to be studied. Recently it was 
demonstrated that RNA editing of Cyfip2, involved in synaptic maintenance, significantly 
declines with age, further strengthening the link between RNA editing and ageing (Nicholas 
et al., 2010). Editing of other targets including Gabra3, involved in neurotransmission; and 
the Q/R site in Gria2, did not significantly decline with age (Carlson et al., 2000; Nicholas et 
al., 2010). This indicates that age-related changes in RNA editing may be gene-specific.  
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2.1.1.2 Bioinformatics for RNA editing 
Early studies demonstrated that bioinformatics could be exploited to identify new targets of 
A-to-I editing (Morse and Bass, 1999; Hoopengardner et al., 2003), although these studies 
only identified a handful of targets. A large-scale computational analysis later identified over 
12000 potential target sites of A-to-I editing in over 1600 genes by analysis of mismatches 
between Expressed Sequence Tags (ESTs) and cDNA sequences (Levanon et al., 2004). A 
more recent genome-wide study in humans identified many potential A-to-I editing sites in 
exons outside Alu elements by identifying mismatches between genomic DNA and cDNA, 
demonstrating that there are still many uninvestigated targets of A-to-I editing (Li et al., 
2009). Although RNA editing targets are much more prevalent in humans, many RNA editing 
targets are conserved between humans and rodents (Table 2.1). 
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Gene ID Site Genomic location Reference 
Kcna1   4:163012291  (Hoopengardner et al., 2003) 
Cyfip2   10:31403167  (Levanon et al., 2005) 
Gria2 R/G 2:172272247  (Lomeli et al., 1994) 
  Q/R 2:172288193  (Higuchi et al., 1993) 
Grik2 Q/R 20:53378633  (Barbon et al., 2003) 
  Y/C 20:53408958  (Barbon et al., 2003) 
  I/V 20:53408971  (Barbon et al., 2003) 
Htr2c A X:31041849  (Burns et al., 1997) 
  B X:31041847  (Burns et al., 1997) 
  E X:31041843  (Niswender et al., 1998) 
  C X:31041842  (Burns et al., 1997) 
  D X:31041837  (Burns et al., 1997) 
Gria3   X:3477800  (Lomeli et al., 1994) 
Gabra3   X:158405626  (Ohlson et al., 2007) 
Cog3   15:56613090  (Shah et al., 2009) 
Flna   X:160382329  (Levanon et al., 2005) 
Gria4   8:994881  (Lomeli et al., 1994) 
Igfbp7   14:33010497  (Levanon et al., 2005) 
Blcap Y/C 3:148267368  (Clutterbuck et al., 2005) 
  Q/R 3:148267359  (Clutterbuck et al., 2005) 
  K/R 3:148267329  (Clutterbuck et al., 2005) 
Adarb1 +10 20:11709472  (Rueter et al., 1999) 
  +23 20:11709485  (Rueter et al., 1999) 
  +24 20:11709486  (Rueter et al., 1999) 
C1ql1 T/A 10:92116112  (Sie and Maas, 2009) 
  102 Q/R 10:92116102  (Sie and Maas, 2009) 
  093 Q/R 10:92116093  (Sie and Maas, 2009) 
Grik1   11:27749588  (Barbon and Barlati, 2000) 
Table 2.1: Conserved exonic editing sites in vertebrate species. 
A brief review of the known conserved targets of A-to-I RNA editing 
24 
 
Prior to splicing, repeat sequences known as Short Interspersed Repeat Elements (SINEs) are 
able to fold back on one another to form imperfect dsRNA regions. These SINEs are prevalent 
throughout mammals, as is the process of ADAR-mediated RNA editing. Since most A-to-I 
targets are in introns, sites can be targeted to either remove or create splicing sites. Perhaps 
the most interesting example is of ADARB1 itself, which can edit its own pre-mRNA. This 
creates an alternative proximal 3’ acceptor site, leading to the inclusion of an extra 47bp in 
the mRNA after splicing. This results in the generation of a premature stop codon due to 
frameshift (Rueter et al., 1999). Self-regulation of ADARB1 allows control over editing levels 
(Feng et al., 2006). When in exons, editing of target sites may cause a direct alteration of the 
encoded base, altering protein functionality and increasing diversity. It has been 
hypothesised that editing may also alter efficiency of localisation to the cytoplasm and 
therefore expression (Maas et al., 2003). 
Around 90% of A-to-I editing targets are found in Alu elements, a class of SINEs, which 
generate the dsRNA substrate for ADAR deamination upon fold-back (Morse and Bass, 1999; 
Kikuno et al., 2002; Kim et al., 2004; Levanon et al., 2004). The Alu elements account for 11% 
of the human genome and therefore have a high incidence of RNA editing targets (Deininger, 
2011). Accordingly, it was identified that 85% of human pre-mRNAs were targets for A-to-I 
editing, whereas 1.4% of human mRNAs were edited (Athanasiadis et al., 2004), suggesting 
that the vast majority of editing events occur within introns, further supported by other 
analyses (Blow et al., 2004; Kim et al., 2004; Levanon et al., 2004). More recent studies have 
focussed on the use of Single Nucleotide Polymorphism (SNP) databases as a source of 
finding A-to-I editing targets. Many SNPs entered into this database were derived from their 
mRNA sequence alone. Therefore, many targets of A-to-I editing have been erroneously 
ascribed to be SNPs (Eisenberg et al., 2005a; Gommans et al., 2008). In addition, the NCBI 
Trace Archive, a repository for capillary and gel sequence data used in genome assembly, 
was recently scrutinised. As with the SNP databases, some sequences were RNA-derived. 
These sequence reads were aligned to the references genomes, identifying mismatches. 
After excluding sequencing errors, the authors discovered evidence for RNA editing, 
consistent with their distribution in SINEs and base preferences (Zaranek et al., 2010). Due 
to the rapid discovery of RNA editing targets from genome-wide studies, a new database was 
recently developed to hold this information, which will serve as a useful resource for 
researchers (Kiran and Baranov, 2010). 
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Though ADARs do not bind consensus sequences, they do display preferences for bases near 
to the target site. There is a strong preference against a G and for a U in the immediate 5’ 
position to the target site, and a strong preference for a G in the immediate 3’ position. 
Furthermore, on the sequence of the opposing side on the dsRNA structure, there is a 
preference for a C (Blow et al., 2004; Kim et al., 2004; Riedmann et al., 2008). A tool 
developed in 2011 is able to give predictions about potentially edited sites in a given 
sequence. Its algorithm, however, relies solely on preferences for the bases immediately 5’ 
and 3’ (Eggington et al., 2011). ADAR and ADARB1 both display slightly different preferences 
for these nearby bases (Lehmann and Bass, 2000; Riedmann et al., 2008). A more recent 
study has led to the discovery that editing of certain sites may be coupled to other nearby 
sites, spaced out at regular intervals. Therefore editing of a site may entirely depend on the 
presence or lack of editing at nearby sites (Ensterö et al., 2009). Importantly, ADARs are 
thought to bind to RNA sequences according to structure rather than sequence, 
demonstrating why prediction of editing sites is problematic. 
Though RNA folding bioinformatic tools exist, they are each rather limited in terms of their 
accuracy (Mathews et al., 2010). The minimum free energy state represents the most 
physically stable structure that the RNA molecule can fold into. However, often this is not 
the biological state. Computationally, calculating RNA folding is complex due to the high 
numbers of potential interactions generated by even short sequences. Prediction of RNA 
editing sites by RNA structure would likely be extremely useful, but unfortunately this area 
needs much developing before it can be used in a large scale context.  
2.2 Aims 
Through a massive increase in genomic data, it has become possible to identify Single 
Nucleotide Polymorphisms (SNPs) at a genomic level through a process called SNP calling. 
This can be used for a wide variety of analyses, including identifying SNPs prevalent in 
cancerous tissues (Yu and Sun, 2013), or in the 1000 Genomes project, which seeks to 
identify human genetic variation (Abecasis et al., 2010). More recently, researchers have 
begun to use transcriptomic data and SNP calling as a way to identify and quantify RNA 
editing sites within the genome (Picardi et al., 2010; Park et al., 2012; Picardi et al., 2012; 
Ramaswami et al., 2013; Porath et al., 2014). 
Previous research suggested a gene-specific decrease in RNA editing in the human cerebral 
cortex with age (Nicholas et al., 2010). Our aims were to sequence the transcriptomes of 
cerebral cortex from 6-, 12-, and 28-month old rats, using SOLiD v4 sequencing. This method 
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of SGS was chosen because of its high degree of accuracy compared to other whole genome 
sequencing methods (Liu et al., 2012). In doing so, we sought to employ SNP calling on the 
resulting transcriptomic data in order to identify new candidate A-to-I RNA editing sites 
within the rat transcriptome. 
In addition to identifying new sites, we wanted to investigate known RNA editing targets that 
are conserved between rats and humans. Using cerebral cortex from rats at each time point, 
we aimed to identify whether there is a decline in RNA editing for any conserved editing sites 
in the rat. In particular, we wanted to identify whether the age-related decline in RNA editing 
of Cyfip2 in humans was also conserved in the rat. Furthermore, several more conserved 
editing sites were investigated to account for the gene-specific changes observed in humans. 
These results were later published in Biogerontology (Holmes et al., 2013). 
2.3 Materials and methods 
Rat tissues used in this study were supplied from a previous experiment (Merry et al., 2008). 
All animal husbandry procedures undertaken in this study were carried out in accordance 
with the provisions of the United Kingdom Animals (Scientific Procedures) Act 1986. Male BN 
rats SubstrainBN/SsNOlaHSD) were obtained from Harlan UK at 21–28 days of age and 
maintained under barrier conditions on a 12-h light: 12-h dark cycle (08:00–20:00). The 
health status of the rats was monitored at regular intervals through the screening of sentinel 
animals. All rats were fed ad libitum and sacrificed at 6, 12, and 28 months of age. None of 
the animals exhibited any signs of pathology when sacrificed. Each age group had six rats, 
from which brain samples were taken, flash frozen, and stored at −80°C.  
RNA was extracted from cerebral cortex of rats using the RNeasy lipid tissue kit (Qiagen). The 
quality of the extracted RNA was assessed using the Agilent 2100 Bioanalyzer; all RNA 
integrity numbers (RINs) were above 8.0, indicating that the RNA had  minimal degradation. 
For RNA extraction from brain tissue, RIN>8 represents a high quality threshold (Bettscheider 
et al., 2011). The samples were pooled in pairs (leaving 3 samples per age group). Ribosomal 
RNA was removed from the pooled samples using the Eukaryote Ribominus Kit (Invitrogen) 
and confirmed with the Agilent 2100 Bioanalyzer.  
RNA-seq data was generated by SOLiD sequencing (Applied Biosystems) from these samples 
in a previous study (Wood et al., 2013). The RNA-seq results from the SOLiD system were 
output as colorspace FASTA and quality files. These were converted into FASTQ format using 
a Python script from Galaxy (http://main.g2.bx.psu.edu/). The FASTQ files were mapped to 
the Ensembl release 65 rat reference genome (RGSC 3.4 assembly, May 2010 gene build) 
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using Bowtie (Langmead et al., 2009) and settings appropriate to SOLiD data. For each 
sample, approximately 33.6 million reads were generated (range, 29.5 to 39.8 million reads). 
On average 16.7 million reads per sample were mapped to the reference genome (range, 
13.8 to 21.4 million reads, approximately 50% of reads generated were mapped). All data 
have been submitted to GEO under the accession GSE34272 (Wood et al. 2013). A mismatch 
analysis was performed on the aligned reads using Bambino in order to generate candidate 
editing sites (Edmonson et al., 2011). These candidates were selected using custom Python 
scripts for A-G mismatches within exons in genes on the positive strand, and T-C mismatches 
on the negative strand. Results were narrowed by selecting for non-synonymous mismatches 
and for those with a high number of read counts. mRNA was reverse transcribed using M-
MLV reverse transcriptase (Invitrogen) and amplified by PCR for selected candidate editing 
sites using rTaq (TaKaRa). Editing levels were then analysed by Sanger sequencing using the 
3730 DNA Analyzer (Applied Biosystems) and quantifications were calculated by peak height 
analysis (Eggington et al., 2011). 
 
2.4 Results 
Cerebral cortex from 6, 12 and 28 month old rats were studied by RNA-seq to identify 
transcriptomic differences that occur during aging (Wood et al., 2013). These data were used 
to identify mismatches between the sequenced reads and the genome. The cerebral cortex 
forms the outer layer of the cerebrum and has roles in memory, language, consciousness and 
thought processes. Furthermore, it has been used as a platform to study RNA editing in a 
previous large scale study and is therefore an appropriate region to analyse (Blow et al., 
2004). The reads generated were mapped to the 4.61 Ensembl build of the rat genome using 
Bowtie and TopHat (Langmead et al., 2009; Trapnell et al., 2009). Due to the nature of A-to-
I editing, it is possible to identify RNA editing targets by isolating reads with A/G mismatches 
between the genomic sequence and the cDNA read sequences (or T/C for negative stand 
hits). Using Bambino (Edmonson et al., 2011), we identified mismatches between the 
transcriptome and genome, which could potentially be RNA editing targets. Using self-
created Python scripts, A/G positive stand mismatches and T/C negative strand mismatches 
were isolated. Due to RNA-seq largely generating sequences from exons, it was decided to 
focus on exonic editing sites. Candidate RNA editing targets were chosen based on a number 
of factors, including a high read count for the site, a high percentage of the G or C (potentially 
edited) base at the site, and a lack of other nearby mismatch types that may indicate 
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sequencing or mapping errors. Sanger sequencing was then employed to analyse cerebral 
cortex cDNA to identify whether evidence of RNA editing mismatches would be identified by 
this method. Eleven genes were tested for Sanger sequencing analysis, plus a positive 
control, Kcna1, which has a known conserved editing site. This analysis led to the 
identification of a new editing site in rats in the Conserved oligomeric Golgi complex subunit 
3 (Cog3) at position Chr15:61477456 (rn5 rat genome build). This modification results in a 
codon change from AUU to IUU, and an amino acid change from isoleucine to valine. Editing 
of this site has previously been reported in humans (Shah et al., 2009), and more recently in 
mice (Danecek et al., 2012), demonstrating conservation of the editing site between humans 
and rodents (Figure 2.1). 
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Figure 2.1: Conservation of the editing site within Cog3 in humans, mice, and rats 
The genomic sequence for Cog3, which is expressed from the negative strand. The edited 
site is highlighted in red. 
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Using Sanger sequencing, editing levels of known conserved targets of A-to-I RNA editing 
were analysed from the cerebral cortex of rats used in the RNA-seq: Gabra3, Cyfip2, Kcna1, 
Flna, and Blcap (which has three editing sites, known as Y/C, Q/R and K/R), and the newly 
identified site in Cog3, using primers given in Table 2.2. The RNA editing enzymes, ADAR and 
ADARB1, have different specificities for base sequence and structure of their target sites 
(Riedmann et al., 2008). Therefore, different targets of RNA editing may be edited by both 
enzymes, or preferentially by just one. These differences have previously been hypothesized 
as a possible cause of the gene-specific RNA editing changes observed during aging in 
humans (Nicholas et al., 2010). The RNA editing sites studied here are targeted to different 
degrees by ADAR and ADARB1. For example, while Cyfip2 and Flna are targeted primarily by 
ADARB1 (Riedmann et al., 2008), Gabra3 is targeted by both ADARs (Ohlson et al., 2007), and 
Blcap is targeted mostly by ADAR (Riedmann et al., 2008). Therefore, it should be possible to 
identify whether any protein-specific age-related changes in RNA editing occurs in the RNA 
editing targets that were studied. 
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Gene name Oligonucleotide sequences 
Gabra3 Fwd 5’-TGTCACAAGTTTCTTTCTGGCTTA-3’ 
Rev 5’-TACCTTCTTGCCTTCCCAAG-3’ 
Cyfip2 Fwd 5’-ATGGGCTTTGGCCTCTATCT-3’ 
Rev 5’-ATGTTGTACTGGGGGCTGAT-3’ 
Kcna1 Fwd 5’-ATGAGGGAGTTAGGGCTGCT-3’ 
Rev 5’-GATCAGTTGCGGTGCAGTTA-3’ 
Flna Fwd 5’-AAAGGATGGCTCTTGTGGTG-3’ 
Rev 5’-CTATGCACCTTGGCATCAAT-3’ 
Cog3 Fwd 5’-CTTCACGGGATGTTGTATCC-3’ 
Rev 5’-TGAACTCCTCCAGTGGCTCT-3’ 
Blcap Fwd 5’-AGCTCCTGGAGAGAGAGTCG-3’ 
Rev 5’-AGCAAGTAGAAGCCCATGAA-3’ 
 
Table 2.2: Oligonucleotide sequences used for PCR amplification 
Oligonucleotides used for sequencing of the RNA editing targets, Gabra3, Cyfip2, Kcna1, Flna, 
Cog3, and Blcap. 
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The mean lifespan of the rat strain used for this study was 28.06±0.72 months (n=102), 
determined from a previous study (Merry et al., 2008). Therefore the ages of the rats used 
in this study, aged 6, 12 and 28 months represent 21.4%, 42.7% and 99.8% of the mean 
lifespan, respectively. We compared the editing levels of six human cerebral cortex samples 
from 76-80 year old individuals (mean 77.7 years) from a previous study (Nicholas et al., 
2010) to the levels of editing present in 28 month old rats. The 76-80 year old human samples 
analysed represented 99.5% of the mean human lifespan, assuming a human life expectancy 
of 78.0 years (United States Census Bureau 2012). These samples were compared based on 
their similar sample size, ages, and percentage of mean lifespan. RNA editing levels of Gabra3 
remain similar in 28-month-old rats (93.2%±1.5) and 76-80 year old humans (91.5%±2.9). 
Editing levels of Cyfip2 also remain high in 28-month-old rats (88.0%±1.3). However, editing 
of Cyfip2 declines to 70.9%±5.7 in 76-80 year old humans. Thus, age-matched 28-month-old 
rats maintain high levels of Cyfip2 editing, compared to 76-80 year old humans. 
Although we observe differences in RNA editing between humans and rats, we do not 
identify significant changes in RNA editing levels of Gabra3, Cyfip2, Kcna1, Flna, Blcap or 
Cog3 with age in rats by one-way ANOVA (Figure 2.2) or collectively by two-way ANOVA, 
F(2,128)=0.430, p=0.652. Importantly, no change was identified for Cyfip2 (r2 = 0.021), in 
contrast to humans (Nicholas et al., 2010). Therefore, RNA editing of these targets in the 
brown rat is maintained throughout the average adult lifespan.  
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Figure 2.2: RNA editing percentages of the conserved target sites  
Editing percentages of Gabra3, Cyfip2, Kcna1, Flna, Cog3, and the Y/C, Q/R and K/R sites of 
Blcap, were quantified from cerebral cortex of rats aged 6, 12 and 28 months. Quantification 
was determined by Sanger sequencing and peak height analysis. Error bars represent one 
standard deviation from the mean. Full data given in Appendix Tables 1-4. 
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2.5 Discussion 
We report a new editing site in the brown rat in Cog3 which causes an amino acid change 
from isoleucine to valine. This site has recently been identified in humans and mice, 
demonstrating its evolutionary conservation (Shah et al., 2009; Danecek et al., 2012). Cog3 
is part of a protein complex in the Golgi apparatus that localises to the membrane, and is 
required for correct protein glycosylation (Shestakova et al., 2006). It has not yet been 
identified whether editing of Cog3 can modulate its functionality, although its conservation 
between rodents and humans implies that it could have a functional role. 
Conserved targets of RNA editing were studied in the brown rat, in order to investigate 
whether an age-related decline of RNA editing is conserved from humans through to the 
brown rat. Editing levels of Gabra3, Cyfip2, Kcna1, Flna, Blcap and Cog3 were analysed in 6-
, 12- and 28-month-old rats. We demonstrate that there are no significant differences in 
editing levels between RNA editing targets at any age in rat cerebral cortex. Unlike in elderly 
humans (Nicholas et al., 2010), 28-month-old rats show no deterioration of RNA editing in 
the targets tested in this study. Thus, within the average lifespan of the rat, we see no 
evidence for changes in RNA editing with age. We cannot, however, rule out the possibility 
that RNA editing levels may decrease in rats after the age of 28 months. In this study, only 
male rats were analysed, so sex specific effects cannot be ruled out. However, no differences 
in RNA editing have been reported to date between sexes (Zhu et al., 2012), and no 
differences were observed in humans (Nicholas et al., 2010). 
At younger ages, humans and rats appear to show no differences in RNA editing of Cyfip2 
and Gabra3. In elderly humans it was identified that editing of Cyfip2 was reduced showing 
a significant decline with age (Nicholas et al., 2010). In contrast, we identify that editing levels 
of Cyfip2 are maintained in the rat across the mean lifespan, from 6- to 28-months of age. 
This suggests that the gene-specific link between RNA editing of Cyfip2 and aging is not 
conserved between humans and rats. Due to the increased lifespan within the primate 
lineage, and since RNA editing is known to be highly prevalent in the primate lineage 
(Eisenberg et al., 2005b), our hypothesis is that this gene-specific link to aging may be 
confined to primates. 
Alternatively, the decrease in RNA editing in Cyfip2 found in humans could be due to disease 
pathology. Many human patients used in the previous study died from heart failure (Nicholas 
et al., 2010). In contrast, all the rats used in our study were sacrificed when healthy. Although 
there has been no report of an association between changes in RNA editing and heart failure, 
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it remains a possibility that this could have affected RNA editing, whether directly or 
indirectly.  
Rodent models are frequently used in biogerontological studies, and although many aspects 
of aging are shared between rodents and humans, there are many important differences in 
their physiology, susceptibility to diseases, and their population demographics (Demetrius, 
2005). Furthermore, it has recently been shown that gene expression changes in response 
to inflammation are considerably different between mice and humans (Seok et al., 2013). 
This demonstrates that not only at the physiological level, but also at the underlying genetic 
level, the responses of rodent models to biological processes can be very different to those 
in humans. Since rodents are often used as model organisms for studying aging, it is vital to 
understand how biological processes, such as RNA editing, are differentially affected during 
aging, depending on the species. 
This study demonstrates that the differences in RNA editing between rodents and humans 
are an important consideration when using rodent models to study aging. In contrary to 
previous findings in humans, we report that A-to-I RNA editing of evolutionarily conserved 
targets does not decline with age in rats. Furthermore, we identify that the gene-specific link 
of RNA editing to aging, which was identified in humans, is not conserved through to the 
brown rat. We interpret that age-related changes observed in RNA editing could be specific 
to primates or humans, or that they may be a result of pathology, as opposed to aging per 
se. 
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Chapter 3: qPCR analysis of differentially expressed genes in the 
Naked mole-rat 
 
3.1 Introduction 
The naked mole-rat (NMR), Heterocephalus glaber, is a subterranean rodent native to Kenya, 
Somalia, and Ethiopia in East Africa. Its name was adopted due to its hairless appearance, 
although it is neither a mole, nor a rat. NMRs are one of only a few eusocial animals that live 
in colonies with a queen. 
In living underground in colonies, NMRs are nearly blind since they have little use for eyesight 
in the dark. Being in an underground burrow also means that the cavern contains low oxygen 
levels and high carbon dioxide levels (Larson and Park, 2009), and that NMRs have adapted 
to these conditions. Furthermore, NMRs are less able to regulate their body temperature, 
with NMRs typically having a body temperature of 30-32°C (Johansen et al., 1976). 
Maximum lifespan shows a positive correlation to species body size. Generally speaking, 
mammals with a greater body weight tend to have a greater maximum lifespan (de 
Magalhães et al., 2007). However, some species have a greater than expected maximum 
lifespan for their body size – including humans. While the predicted maximum longevity for 
humans, based on body size is 23.6 years, the maximum observed longevity is 122 years 
(Buffenstein, 2005). 
At over 30 years, the maximum recorded lifespan of the NMR is the highest of any rodent 
species. Like humans, the NMR has a greater than expected maximum longevity for its body 
size (35g). Based on body size alone, NMR maximum longevity would be predicted to be 5.7 
years. This is in contrast to its evolutionary relatives, mice and rats, which share a most recent 
common ancestor 73 million years ago (Kim et al., 2011). While mice weigh around 30g and 
live for a maximum of 4 years, rats weigh around 350g and live up to 5 years (Buffenstein, 
2005). The NMR therefore displays a strikingly long lifespan when compared to related 
species. 
Despite living for over 30 years, NMRs display negligible senescence, no age-related increase 
in mortality, and no decline in fertility (Buffenstein, 2008). They also show a high resistance 
to spontaneous and induced cancers (Seluanov et al., 2009; Liang et al., 2010). Resistance to 
cancer appears to be due to the high secretion of high molecular mass hyaluronic acid (HA) 
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by NMR fibroblasts. HA is a glycosaminoglycan that is a major component of the extracellular 
matrix. Knockdown of Has2 which produces HA, and overexpression of Hyal2 - an enzyme 
which degrades HA, both result in the loss of HA and in increased cancer susceptibility in 
mouse xenografts of NMR cells (Tian et al., 2013). 
Therefore, NMRs display a very different ageing profile to other mammalian species – 
avoiding both cancer and ageing. This has made the NMR an important target of ageing 
research. In understanding how the NMR is able to protect itself against both cancers, and 
ageing processes, it may be possible to understand how these could be applied to 
counteracting age-related diseases in humans. 
3.2 Aims 
Because of the development of second generation sequencing (SGS) technologies, there has 
been an explosion in the amount of genetic information available to researchers, and at an 
increasingly low cost. In 2011, the first full sequencing of the NMR was published, identifying 
molecular changes in genes involved in their physiology such as thermoregulation and cancer 
resistance (Kim et al., 2011). 
RNA sequencing (RNAseq) was employed by colleagues to identify changes in gene 
expression between mice and NMR. This involved mapping Illumina transcriptome 
sequencing reads from NMR liver to transcriptome contigs. In parallel, mouse liver was 
sequenced and mapped to the mouse genome. After mapping NMR contigs by BLAST to the 
mouse genome, it was possible to match NMR genes and their reads to mouse orthologs. 
From this, it was possible to identify genes that were comparatively overexpressed in the 
NMR when compared to the mouse. 
Illumina data analysis involved mapping of reads to an incomplete NMR transcriptome 
consisting of contigs generated through 454 sequencing of cDNA. Mapping of the data by 
BLAST to the mouse genome raises the potential issue of  incorrect mapping or incomplete 
contigs. Therefore, the aim of this analysis was to verify that genes identified as upregulated 
in the NMR by analysis of Illumina data were also identified as upregulated in quantitative 
reverse-transcription PCR (qPCR) analysis. This allowed an extra confirmation of the RNAseq 
results. Collectively, these findings were later published (Yu et al., 2011). 
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3.3 Materials and Methods 
3.3.1 RNA isolation and cDNA synthesis 
Tissue homogenisation of 100mg of a single naked mole-rat liver was performed using a 
TissueLyser (Qiagen) for 3 minutes at 25Hz. RNA was isolated by TRIzol/chloroform 
extraction using PureLink Mini Kit (Life Technologies) and exposed to on-column DNase I 
treatment according to the manufacturer’s protocol. First strand cDNA synthesis was 
performed using 1µg of total RNA, random primers and M-MLV reverse transcriptase (Life 
Technologies) according to the manufacturer’s protocol. 
3.3.2 PCR conditions 
Two microlitres of cDNA was amplified separately by PCR for the transcripts A2m, Sat1, Sat2, 
Hprt1, Tbp, and Crym under the following conditions: 2 minutes at 94°C, followed by 40 
cycles of 30 seconds at 94°C, 30 seconds at 58°C, and 30 seconds at 72°C, followed by 2 
minutes at 72°C. The following primers were used: A2m, 5’-GAACCGTCCTACCTCCAACA-3’ 
and 5’-TGTTGCTGACTTCAGTTCGG-3’; Sat1,  5’-TGGTATAGGATCAGAAATTTTGAAGA-3’ and 
5’-TCCATCCCTCTTCACTGGAC-3’; Sat2, 5’-TCAAGGGATTGGTTCCAAAA-3’ and 5’-
CAGGTGGGGACAGAGATGTT-5’; Hprt1,  5’-GCTTCCTTCTCCGCAGACT-3’ and 5’-
CTTCATCACGTCTCGAGCAA-3’; Tbp, 5’-GAGAGGAGCTGCTTCGGATT-3’ and 5’-
GCTCATGCCAGAGAATAGGC-3’; Crym, 5’-TCCCCCAAAGACTTGAACAC-3’ and 5’-
CTGCCCTGAAAGAGTCTGGA-3’ . PCR products were electrophoresed on a 2% agarose gel to 
confirm specific amplification prior to qPCR analysis. 
3.3.3 qPCR 
For standard curve calculations, each horizontal row of the plate was loaded with serial 
dilutions of cDNA after diluting the original cDNA product to 1:100. A negative control of 
nuclease-free water was used for each sample (Qiagen). Each sample was run in triplicate. 
For each primer set, a master mix was made containing 16µl forward primer (5µM), 16µl 
reverse primer (5µM), and 200µl Brilliant II SYBR Green QPCR Master Mix with Low Rox 
(Agilent Technologies). This was kept in a nuclease-free 1.5ml tube, covered in foil, mixed 
gently, and placed on ice until further use. 14.5µl was then aliquoted out into each well 
allocated to that gene. After running the qPCR, only primer sets with 93-107% efficiency 
(where efficiency = -1+10(-1/slope)), and R2>0.98 were used for quantitative analysis. 
Prior to loading the 96-well plate, a new file was created on the Applied Biosystems 7500 
Fast Real-Time PCR System. Each well was labelled with the cDNA and primer set. The 
temperature profile was set as: 95°C for 10 seconds, followed by 40 cycles of 95°C for 30 
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seconds and 60°C for 60 seconds. A melt curve analysis was also performed after standard 
curve analysis to check for the presence of a single product. 
The plate was sealed with the MicroAMP Optical Adhesive Film (Applied Biosystems), and 
wrapped in foil. The plate was then centrifuged at 700rpm for 2 minutes to spin the liquid 
down, before being placed in the machine. The cycle was then run. 
Mean Ct values were calculated for those transcripts with selected primer sets. ΔCt was 
calculated as the difference between the mean Ct of Sat2 and the mean Ct of the selected 
transcript. Using the formula Nrelative = EfΔCt, where Ef was the mean efficiency for all six 
transcripts, normalised expression levels relative to Sat2 were calculated. The number of 
Illumina reads per transcript was normalised to that of Sat2. 
3.4 Results 
 
To verify the expression of overexpressed genes identified by Illumina RNAseq analysis, qPCR 
analysis was undertaken. Rather than testing the comparative levels between NMR and mice, 
we wanted to more directly test the NMR RNAseq results in order to confirm that the genes 
identified as overexpressed could be confirmed by qPCR analysis. 
Primer sets were designed and tested for amplification efficiency using qPCR on serial 
dilutions of NMR liver cDNA to create a standard curve. Only primer sets with amplification 
efficiency of 93-107% and R2>0.98 were used in this study. Six sets of primers passed this for 
four genes identified as overexpressed in NMR: A2m, Crym, Sat2, Sat1, as well two control 
genes, Tbp, and Hprt1 (Table 3.1). An example of the standard curve generated for A2m is 
shown in Figure 3.1.  
Sat2 was the most stably expressed of the genes in the qPCR data, and therefore data was 
calibrated to Sat2 in order to calculate relative transcript abundances. The genes identified 
in the NMR liver as having the most mapped reads of the genes tested, A2m, Crym, and Sat1 
all showed a much greater expression than Sat2, which confirms the results from the RNAseq 
analysis (Figure 3.2). However, qPCR relative abundances show a much higher relative 
expression of these genes compared to Sat2. Indeed, expression of Sat2 itself was the lowest 
of all tested genes, despite having far more reads mapping to the gene than for the control 
genes Hprt1 and Tbp (Table 3.1). Genes identified as having a relatively low abundance from 
Illumina data also showed demonstrated lower abundances in the qPCR analysis (Figure 3.2). 
These results show confirmation that qPCR analysis is able to confirm relatively high 
expression for genes with a high number of mapped reads in the Illumina data analysis. 
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Gene Mapped reads 
A2m 202485 
Crym 19454 
Sat1 3643 
Sat2 1906 
Hprt1 260 
Tbp 104 
 
Table 3.1: Number of Illumina reads mapping to each gene to be tested by qPCR 
The number of mapped Illumina reads does not necessarily correspond to the level of 
overexpression in the NMR compared to the mouse, since this depends on the number of 
mapped reads in the mouse RNAseq. Data from (Yu et al., 2011). 
 
 
 
 
41 
 
 
Figure 3.1: Standard curve plot for A2m 
Primer sets were checked for amplification efficiency of 93-107% and a correlation 
coefficient of >0.98. In this example, efficiency was 95.8% and R2=0.998. Graph generated by 
the Applied Biosystems 7500 Fast Real-Time PCR System. 
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Figure 3.2: Comparison of transcript abundances between Illumina sequencing and qPCR 
analyses 
For both Illumina mapping counts and qPCR data, relative expression was normalised to Sat2 
because of a more stable expression across repeats. 
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3.5 Discussion 
Mice and NMRs share a most recent common ancestor 73 million years ago. Therefore, 
evolutionary adaptations have occurred that have led to functional changes and changes in 
gene family composition that make identifying orthologous genes more challenging (Kim et 
al., 2011). 
Having an incomplete NMR transcriptome set posed a challenge in mapping of the RNAseq 
data. The reads were mapped to 77,086 NMR transcriptome contigs. This was a factor in 
identifying overexpressed genes in the NMR – since genes identified as underexpressed are 
likely to be genes that are not completely covered by the contigs. This would result in 
artificially low read counts. 
After identifying genes that were potentially upregulated in the NMR, qPCR analyses 
confirmed that A2m, Crym, and Sat1 were also relatively overexpressed compared to Sat2. 
Normalising to a control gene Tbp or Hprt1 was not chosen due to the low read counts 
obtained for these genes. Because low read counts could be a consequence of poor mapping, 
normalising to a well expressed gene with low sample variation was deemed to be the most 
accurate way of comparing relative transcript abundances between RNAseq and qPCR 
analyses. 
Global gene expression patterns of orthologous genes between mice and humans are known 
to be generally conserved between species (Zheng-Bradley et al., 2010). Given this, it is likely 
that most gene expression patterns of orthologous genes are also conserved between NMR 
and mice. Identifying orthologous genes that are much more highly expressed in the NMR is 
therefore a particularly interesting finding. 
One of the most overexpressed genes identified from the RNAseq analysis was A2m, a 
protease inhibitor that has been identified as a protein that is potentially relevant to human 
ageing on the GenAge database (de Magalhães et al., 2009). Furthermore, A2m is known to 
interact with apolipoprotein E – which has genetic variants linked to human longevity 
(Garatachea et al., 2014), and is also associated with Alzheimer’s disease (Blacker et al., 
1998). In vitro, A2m has also been identified as a biomarker of ageing in fibroblasts (Ma et 
al., 2004). 
Combined with previous research, this analysis identifies multiple genes that are upregulated 
in NMRs. These findings may provide a basis for future research on these genes in the context 
of NMR ageing. 
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Chapter 4: RNAseq analysis of Gnasxlm+/p- mice 
4.1 Introduction 
4.1.1 Gnas complex locus 
One of the most documented mechanisms that can modulate ageing is dietary restriction. 
This involves giving animals a low calorie intake, which in many species, including mice, has 
been shown to significantly extend lifespan. After identifying that the decline in RNA editing 
with age is not universal across species, we chose to study an interesting mouse knockout of 
Gnas. These mice remain small and lean – aspects shared with calorie restricted animals. 
Despite this phenotype, the mice also consume more food as a result of an increased 
metabolic rate. 
 
The Gnas gene is an extremely complex imprinted locus (Figure 4.1). With several alternative 
promoters, and with extensive alternative splicing, the gene encodes several transcripts, 
which are expressed maternally, paternally, and biallelically. Some of these are coding, and 
some are non-coding. Furthermore, two cis-acting antisense transcripts are also expressed 
from the locus, which are important for regulating the expression of Gnas transcripts. 
Imprinting is a phenomenon whereby the expression of a gene is dependent upon which 
parent it was inherited from. DNA and histone methylation of the genes are different 
between the two alleles, which prevents expression of transcripts in a parent of origin-
specific manner. Despite sequence similarities, transcripts from imprinted genes can have 
extremely different effects. 
The major transcript encoded by Gnas is the G protein alpha subunit Gαs. This transcript is 
widely expressed biallelically across many tissues and cell types. However, an NH2-terminal 
variant, XLαs is expressed solely from the paternally inherited allele, and has a more 
restricted expression pattern to the brain and in endocrine tissues. XLαs contains around an 
extra 300 amino acids compared to Gαs, containing the large Gnasxl exon in place of Gnas 
exon 1 (Figure 4.1). 
Expression of XLαs is limited to neuroendocrine tissues. In the early neonatal stages of 
development, expression of XLαs is found in the SCN, PVN, DMH and VMH within the 
hypothalamus. In adult mice, XLαs is retained in these hypothalamic nuclei. Further 
expression is found in several distinct nuclei within the medulla of the brain, including in the 
solitary nucleus – a region that regulates energy control (Krechowec et al., 2012). 
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Figure 4.1: Schematic diagram of the imprinted complex Gnas locus 
Gnas encodes two principal coding transcripts, Gαs, and XLαs. Differentially methylated 
regions (DMRs, shown in green) prevent transcription of exons. Although the Gnas exon 1 
promoter can be activated on both the maternal and paternal alleles, the Gnasxl promoter 
is only utilised on the paternal copy.  
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G proteins consist of three subunits: α, β, and γ. These interact with seven-transmembrane 
G protein coupled receptors (GPCRs) located in the plasma membrane to direct cell 
responses to a stimulus. Gαs is able to interact and activate adenylyl cyclase to generate 
cAMP for downstream signal transduction. 
The G protein begins in an inactive GDP-bound state and is tethered to the membrane by the 
α and γ subunits (Figure 4.2A). Upon binding of an agonist to the GPCR, conformational 
changes result in the replacement of GDP with GTP (Figure 4.2B). The GTP-bound Gαs 
dissociates from the β and γ subunits, and activates AC, resulting in the generation of cAMP 
(Figure 4.2C). Gαs is then inactivated by GTP hydrolysis. It returns to its inactive GDP-bound 
state, and reassociates with the β and γ subunits (Figure 4.2D). There are several known 
isoforms of α, β, and γ subunits, as well as many different types of GPCRs and ACs. However 
exactly how these many variants and combinations affect downstream signalling is not well 
characterised. 
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Figure 4.2: Schematic diagram of the G protein cycle 
A. The heterotrimeric G protein (α, β, and γ) is localised to the membrane where it is bound 
to GDP. B. Upon binding of an agonist to the GPCR, conformational changes lead to the G 
protein binding GTP. C. The α subunit dissociates from the β and γ subunits and interacts 
with AC to drive the production of cAMP. D. GTPase-activating proteins hydrolyse the GTP 
back to GDP, and the α subunit reassociates with β and γ to reform the G protein. 
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Despite their sequence similarities, Gαs and XLαs are known to have very distinct functions. 
While homozygous mutations of Gnas are lethal, mice with heterozygous mutations can 
survive. Heterozygous mutations of Gnas exon 2 have opposing effects. When ablated from 
the maternal allele, mice become hypometabolic and obese (Yu et al., 2000). Conversely, 
when ablated from the paternal allele, mice become hypermetabolic and lean due to the loss 
of the paternally-expressed XLαs (Weinstein et al., 2010). 
Studies have demonstrated that, like Gαs, XLαs can activate ACs to stimulate cAMP 
production. However, exactly how XLαs exerts different downstream effects to Gαs is not 
well characterised. It is known that Gαs couples with the melanocortin-4-receptor (MC4R), 
however it has not yet been identified which receptor XLαs couples with (Shen et al., 2013). 
In vitro, XLαs has a stronger affinity than Gαs to stay localised to the plasma membrane. This 
is due to the presence of a highly charged amino acid domain coded by the Gnasxl exon. This 
includes two cysteine residues that can be palmitoylated to promote membrane anchoring. 
In doing so, XLαs is able to direct a more sustained cAMP signalling response via ACs by 
retaining its membrane-bound state (Liu et al., 2011). 
A mouse line of Gnasxl-deficient mice (Gnasxlm+/p- mice) was first described in 2004 (Plagge 
et al., 2004). The mice were generated using a targeted deletion of a 60bp segment within 
the paternal copy of the Gnasxl exon using Cre-Lox recombinase. Gnasxlm+/p- mice have a high 
perinatal mortality of over 80%. Those that survive to adulthood however, remain small, 
lean, and hypermetabolic. Gnasxlm+/p- mice showed a significant reduction in white and 
brown adipose tissue mass – despite having a greater food intake. An increase in the 
metabolic rate was mainly due to an increase in sympathetic nervous system (SNS) activity 
(Xie et al., 2006). The SNS is responsible for the fight-or-flight response, but is also constantly 
active at a low level to regulate homeostatic mechanisms. The SNS is involved in autonomic 
responses such as pupil dilation, activation of sweat glands, and increasing the heart rate. 
More recently, it was identified that in response to the activated SNS in Gnasxlm+/p- mice, they 
also show a significant increase in blood pressure and heart rate, despite no significant 
increase in activity (Nunn et al., 2013). In addition, Gnasxlm+/p- mice showed a huge decrease 
in leptin levels, as well as increased sensitivity to insulin (Xie et al., 2006). 
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4.1.2 Diseases associated with Gnas 
In humans, Gnas deficiency is responsible for several human diseases, including Albright’s 
hereditary osteodystrophy (AHO), pseudohypoparathyroidism (PHP), 
pseudopseudohypoparathyroidism (pseudoPHP), and McCune-Albright syndrome. PHP is 
divided into three types, depending on the phenotype: Type 1A, type 1B, and type 2 (Plagge 
et al., 2008).  
PHP is characterised by resistance to various hormones, particularly parathyroid hormone 
(PTH). This hormone acts to increase the Ca2+ concentration in the blood, whereas another 
hormone, calcitriol, acts to decrease it. Together, these act to retain a balanced Ca2+ 
concentration. However, due to resistance to PTH in PHP, Ca2+ levels decrease, leading to 
increased PTH and low levels of calcitriol. In addition, since PTH prevents reabsorption of 
phosphates in the proximal tubule of the kidney, blood phosphate levels are increased. 
People with type 1A PHP, also known as AHO, are also characterised by skeletal defects, such 
as short stature, rounded facies and brachydactyly of the fourth and fifth metacarpals, as 
well as a mild decrease in intelligent quotient (Garavelli et al., 2005). In addition, a lack of 
response to thyroid hormone leads to an increase in weight gain and an increased risk of 
obesity. 
PseudoPHP is characterised by the same skeletal defects as Type 1A PHP, but lacks the 
disrupted hormone patterns, hypocalcaemia, and hyperphosphataemia. Importantly, PTH 
couples to the Gαs subunit to generate a cAMP-dependent response (Liu et al., 2011). Type 
1A PHP and pseudoPHP are characterised by skeletal defects, obesity, and short stature, 
whereas type 1B PHP is phenotypically normal in this respect (Mantovani, 2011).  
Although most studies on the function of XLαs have been explored in mice, evidence suggests 
that similar mutations in humans result in similar phenotypes. A small deletion of the Gnasxl 
exon and loss Xlαs expression was identified in the case of a girl displaying severe perinatal 
growth retardation, feeding abnormalities, facial dysmorphia, and low adipose tissue 
(Geneviève et al., 2005). A later study into people with PHP 1A and PseudoPHP demonstrated 
that patients with a paternally inherited Gnas mutation had a significantly low birth weight 
compared to those with a maternally inherited Gnas mutation, likely as a consequence of 
the loss of Xlαs expression (Richard et al., 2013). Therefore, studies into the function of Xlαs 
have a clinical relevance to the understanding of these diseases in humans. 
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4.2 Aims 
Unfortunately, due to high costs for maintaining hundreds of laboratory animals over several 
years, it was not feasible for this project to determine whether Gnasxlm+/p- mice are long-
lived. However, the mice display an interesting phenotype of reduced adipose tissue and 
body weight, despite increased food intake. 
The hypothalamus is a critical region of the vertebrate brain that contains several nuclei that 
regulate many homeostatic mechanisms, such as body temperature, response to hunger and 
thirst, and maintaining the circadian rhythm. It is situated below the thalamus at the centre 
of the ventral edge of the brain. The structure is dominated by the third ventricle – a space 
running through the centre of the ventral side of the brain, which contains cerebrospinal 
fluid. 
Our aims were to identify transcriptional changes in the whole hypothalamus of Gnasxlm+/p- 
mice that may be responsible for producing the phenotype. Due to the development of SGS 
technologies, there has been a rapid increase in the amount of genomic data produced, and 
a rapid decline in cost. Due to the advantages of rapid sequencing and generation of huge 
amounts of genomic data, Illumina sequencing was employed to analyse transcriptional 
changes within the hypothalami of wildtype and Gnasxlm+/p- mice. 
4.3 Materials and methods 
Hypothalamic RNA isolates were stored at -80°C. These consisted of six isolates from 
wildtype mice, and six from Gnasxlm+/p- mice. For quality control analysis, samples were run 
on the RNA 6000 Nano chip on the Bioanalyzer 2100 (Agilent Technologies). Since rRNA 
constitutes the vast majority of RNA, degradation of samples can be quantified by the ratio 
of rRNA to smaller-sized products. An RNA Integrity Number (RIN) is calculated where >8 
represents high quality RNA with minimal degradation (Bettscheider et al., 2011). All of the 
RNA isolates showed a RIN > 8.5. 
In order for the RNAseq to be more cost-effective but still retain greater biological variability, 
RNA samples were pooled, within conditions, in pairs. This resulted in three pooled wildtype 
samples and three pooled Gnasxlm+/p- samples. 
rRNA accounts for around 90% of total RNA within mammalian cells (Chen and Duan, 2011). 
Since we are aiming to identify gene expression changes, rRNA must be removed prior to 
transcriptomic sequencing. Otherwise, only a small proportion of reads would map to genes 
other than rRNA genes. The Ribominus Eukaryote Kit for RNA-Seq (Life Technologies) 
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selectively pulls out rRNA using locked nucleic acid (LNA) probes. LNA is a chemically 
modified version of RNA, containing a methylene bridge between the 2’ oxygen and 4’ 
carbon. The sugar backbone of RNA and DNA is able to switch between two conformations. 
However, the methylene bridge in LNA constrains the sugar backbone into the North C3’-
endo-C2’-exo conformation. Consequently, LNA has a greater affinity for RNA and allows for 
greater sequence specificity. These LNA probes are tagged to biotin, which has a high affinity 
for streptavidin-bound magnetic beads that are added to the total RNA. This allows the 
separation of rRNA, which is magnetically isolated using a magnetic block, while the rest of 
the RNA is transferred to a fresh nuclease-free tube. Since the resulting RNA is now fairly 
weak, it must then be concentrated using the Ribominus Concentration Module (Life 
Technologies). 
In order to confirm the removal of rRNA from the samples, 1µl of each was run on RNA 6000 
Nano chip on the Bioanalyzer 2100 (Agilent Technologies). These resulting 
electropherograms were compared to those prior to rRNA-depletion. From this, we confirm 
that the 18S and 26S rRNA peaks are much reduced, demonstrating the rRNA-depletion. A 
small 18S peak is retained in most samples, accounting for up to 3.2% of the RNA. This is due 
to the Ribominus kit being able to remove 95-98% of rRNA. Therefore some rRNA will remain 
even after rRNA-depletion.  
The main use of the Bioanalyzer is to provide a quantitative measure of RNA quality and 
degradation. However since it measures the fluorescence intensity of RNA products against 
the migration time, it also provides estimates of sample concentration using the area 
underneath the curve on the electropherogram. Library preparation requires accurate 
quantification of RNA samples to ensure there are no biases between samples and that the 
cDNA synthesis and PCR reactions are achieved at optimal rates. Prior to library preparation, 
sample concentrations were analysed on the Qubit (Life Technologies). This uses a 
fluorescent dye, Ribogreen, which specifically binds to RNA, allowing a highly accurate 
quantification of RNA concentration. Other methods, such as the Nanodrop (Thermo 
Scientific) are unable to accurately quantify RNA at such low concentrations (O’Neill et al., 
2011). 
4.3.1 Library preparation and sequencing 
For each pooled sample, 50ng of RNA was used for library preparation using the ScriptSeq v2 
RNA-Seq Library Preparation Kit (Epicentre). Briefly, the RNA was first fragmented at 85°C 
for 5 minutes, and placed on ice. cDNA synthesis primers were annealed prior to cDNA 
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amplification by StarScript Reverse Transcriptase at 37°C for 10 minutes. StarScript Reverse 
Transcriptase was inactivated by a 95°C incubation for 3 minutes. The cDNA synthesis 
primers consist of random hexamer sequences, with a tagging sequence attached to the 5’ 
end. Terminal tagging of the 3’ end is then performed so that the fragmented cDNA is now 
tagged with specific sequences at both the 3’ and 5’ ends. These tagging sequences allow the 
library reads to adhere to the sequences bound to the flow cells of the Illumina sequencing 
slide. 
After cDNA synthesis and tagging, many impurities, such as excess primers, enzymes and 
salts, remain in solution with the desired tagged amplicons. The cDNA needs to be purified 
from these artefacts prior to sequencing to avoid interference. cDNA was purified using the 
Agencourt AMPure XP system (BeckmanCoulter), which uses Solid Phase Reversible 
Immobilisation (SPRI). These beads are paramagnetic and consist of a polystyrene core 
surrounded by two layers of magnetite. The surface is covered with carboxyl groups, which 
enables the reversible adsorption of DNA in the presence of polyethylene glycol (PEG) and 
sodium chloride. When placed near a magnetic microcentrifuge tube block, the DNA bound 
to the beads is isolated. The impurities are removed and the beads are washed twice with 
ethanol to ensure their removal. Finally the DNA is eluted with nuclease-free water prior to 
amplification. 
In order to reduce representation bias during multiplex sequencing, ScriptSeq Index PCR 
Primers (Epicentre) were used during PCR amplification of DNA. These primers are such that 
the 3’ end is complementary to the tagging sequence, and the 5’ end contains a further 
tagging sequence. In the case of the forward primer, a defined six-base index sequence is 
placed in between the two tagging sequences. Later, during sequencing, this will allow for 
identification of the sample origin of the reads. The size distribution of the library 
preparations were checked using the Bioanalyzer 2100, and showed a profile distribution 
with large enough reads for sequencing (Figure 4.4). The Centre for Genomic Research (CGR) 
(Liverpool, UK) performed size selection on the library preparations prior to loading onto the 
Illumina Genome Analyzer IIx (GAIIx), which sequences reads of 100 bases in length. 
The samples were loaded onto the slides by the CGR. These slides contain eight flow cell 
channels, referred to as lanes. Three of these were used for my samples, and five were 
loaded with samples from other researchers. With my samples, two were loaded per lane, 
and the index sequence allows for multiplexed sequencing. The lanes are coated with a lawn 
of primers, specific to the adaptor sequences on the library preparations of cDNA. Upon 
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loading of the samples, the single-stranded cDNA fragments bind randomly to the surface at 
both termini. Bridge amplification is performed, creating double-stranded DNA. Upon 
denaturation, fragments dissociate from the free terminus. These are amplified and allowed 
to re-bind to the adaptor sequences. Rounds of amplification generate clusters of cDNA that 
has been amplified from a single fragment. This is done to ensure that the fluorescent signal 
given off will be amplified to a detectable level such that the Illumina GAIIx machine can 
identify read sequences.  
After sequencing was completed, the data was extracted and subjected to quality control by 
the CGR. This included a filter for CHASTITY ≥ 0.6, which identifies clusters with a low signal 
to noise ratio. This is often the result of two clusters being so close to each other that the 
signals cannot be distinguished from one another. Resulting data was demultiplexed using 
the Illumina CASAVA 1.8.2 pipeline by the CGR. Reads that passed the CHASTITY filter were 
filtered for, producing FASTQ files separately for the sense and anti-sense reads. A quality 
control analysis was then performed using FastQC (Babraham Bioinformatics) by the CGR. 
4.3.2 Mapping and differential expression analysis 
TopHat is a bioinformatics tool that maps transcriptomic reads to a genome. It incorporates 
a program, Bowtie, which performs mapping. TopHat has the advantage of calculating exon 
junctions based on a GTF (Gene Transfer Format) file, which contains the locations of exons, 
transcripts, and genes across a genome. In doing this, TopHat is able to map reads that 
contains exon-exon boundaries. TopHat takes the FASTQ files and maps them to the genome 
and transcriptome data, and outputs a file containing the sequences and the location in the 
genome of where they have matched. 
Both sense and anti-sense FASTQ files were mapped to the mm9 build of the M. musculus 
genome (obtained from UCSC genome browser) using TopHat 1.4.1. Inner distance between 
mate pairs was set to 280 to account for the mean fragment size of 400 base pairs, calculated 
by the CGR by analysis using the Bioanalyzer 2100. Data was mapped using default settings 
to Cufflinks 1.3.0 to the GTF transcript annotation file provided by Illumina iGenomes. Data 
was later remapped using Cufflinks 2.0.2 to the GTF transcript annotation file provided by 
Illumina iGenomes. 
After the release of the mm10 build of the M. musculus genome, data was reanalysed. The 
original FASTQ files were mapped to the mm10 genome build using TopHat 2.0.4, 
incorporating a repeatmask, which filters out known repeat sequences to improve mapping 
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quality. The repeatmask file was obtained from RepeatMasker (Tarailo-Graovac and Chen, 
2009). Data was then reanalysed using Cufflinks 2.0.2 using the same settings as previously 
 
4.4 Results 
4.4.1 Quality Control and Library Preparation 
In order to identify transcriptional changes within the hypothalami of wildtype and 
Gnasxlm+/p- mice, brains of six male adult mice were extracted for each background. The 
hypothalami were dissected out, and the RNA was isolated. 
To determine the quality of the RNA, samples were run on the Bioanalyzer 2100 (Agilent 
Technologies) using the RNA 6000 Nano kit (Agilent Technologies). The Bioanalyzer measures 
RNA quality using the RNA integrity number (RIN), which is computed by comparing the 
amount of small products to large products, as well as the intensities of the 18S and 28S rRNA 
peaks. An excess of smaller products is a hallmark of RNA degradation and results in a low 
score. Sequencing highly degraded RNA of low quality results in poor quality sequencing, so 
it is imperative to ensure that RNA quality is thoroughly assessed prior to library preparation. 
The resulting plot of one of the samples illustrates the distribution of RNA product sizes after 
isolation (Figure 4.3). The 18S and 28S rRNA peaks are also observed. The high peaks 
compared to the low fast region demonstrates the low levels of degradation of the RNA 
sample. Samples with RIN>8 are deemed to be of high quality with minimal degradation. All 
of the samples used in this analysis showed a RIN>8.5 (Table 4.1). 
In order to maintain biological variation but keep costs manageable, samples were pooled in 
pairs (Table 4.1). This resulted in 3 pooled wildtype samples and 3 Gnasxlm+/p- samples. 
 
 
 
 
 
 
 
55 
 
 
Figure 4.3: Fragment size plot by 2100 Bioanalyzer (Agilent Technologies) for sample WT-
1. 
The sample was run on the RNA 6000 Nano chip. Horizontal axis (nt) denotes the nucleotide 
length, and the vertical axis (FU) denotes the fluorescent units (measure of the intensity). 
18S and 28S rRNA peaks are automatically identified by the software. The peak at 25 bases 
represents the marker that allows quantification. 
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Sample RIN Pooled sample 
WT-1 8.6 pWT-1 
WT-2 8.7 
WT-3 8.6 pWT-2 
WT-6 8.5 
WT-4 8.6 pWT-3 
WT-5 8.5 
KO-1 8.7 pKO-1 
KO-2 8.6 
KO-3 8.9 pKO-2 
KO-6 8.7 
KO-4 8.8 pKO-3 
KO-5 8.7 
Table 4.1: RIN numbers calculated by the 2100 Bioanalyzer 
The high RIN calculated by the 2100 Bioanalyzer indicated the quality of the isolated RNA. 
WT = wildtype mice; KO = Gnasxlm+/p- mice. Samples that were pooled together were 
littermates. 
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rRNA accounts for around 90% of total RNA within mammalian cells (Chen and Duan, 2011). 
Since we are aiming to identify gene expression changes, rRNA was removed prior to 
transcriptomic sequencing in order to enrich the mRNA content using the Ribominus 
Eukaryote Kit (Life Technologies). In order to confirm the removal of rRNA, samples were run 
on the Bioanalyzer 2100 (Agilent). These resulting electropherograms were compared to 
those prior to rRNA-depletion (Figure 4.4). From this, we confirm that the 18S and 28S rRNA 
peaks are much reduced, demonstrating the rRNA-depletion. A small 18S peak is retained in 
most samples, accounting for up to 3.2% of the RNA. This is due to the Ribominus kit being 
able to remove 95-98% of rRNA. Therefore some rRNA will remain even after rRNA-
depletion. However, the RNA is now heavily enriched for mRNA. 
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Figure 4.4: Plot generated by the 2100 Bioanalyzer (Agilent Technologies) after the rRNA-
depletion of pooled sample pWT-1 
The sample was run on the RNA 6000 Nano chip. Horizontal axis (nt) denotes the nucleotide 
length, and the vertical axis (FU) denotes the fluorescent units (measure of the intensity). 
Notice the difference in the scale of the y-axis between this and Figure 4.3). 
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Prior to library preparation, sample concentrations were analysed on the Qubit system (Life 
Technologies) in order to accurately quantify the amount of RNA to ensure equal initial RNA 
quantities of all samples prior to library preparation. This uses a fluorescent dye that 
specifically binds to RNA, allowing a more accurate quantification of RNA concentration 
(O’Neill et al., 2011).  
Library preparation was performed using the ScriptSeq v2 Library Preparation Kit (Epicentre). 
The RNA was fragmented and reverse transcribed to cDNA using random hexamer primers 
with a known 5’ tag. A terminal tag was then annealed to the 3’ end, producing a cDNA 
fragment flanked by 3’ and 5’ tagging sequences. The cDNA was then purified from the 
solution and was amplified by PCR using ScriptSeq Index PCR Primers (Epicentre). These 
contain a unique tagging sequence, which is used to identify the sample after sequencing. 
Samples were run once again on the Bioanalyzer 2100 to check the distribution of the size of 
the fragments within the library. An example of the distribution is shown in Figure 4.4 for 
pooled sample pWT-1. The majority of the fragments are observed to be 150-500bp in 
length, and therefore large enough for effective sequencing. 
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Figure 4.5: Plot generated by the 2100 Bioanalyzer (Agilent Technologies) after library 
preparation of sample pWT-1 
Library preparation was performed using ScriptSeq v2 Library Preparation Kit (Epicentre). 
The sample was run on the High sensitivity DNA chip. Horizontal axis (nt) denotes the 
nucleotide length, and the vertical axis (FU) denotes the fluorescent units (measure of the 
intensity).  
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cDNA from the library preparation is added to the flow cell slides of the Illumina sequencing 
machine. The flow cells consist of channels that are coated with a lawn of adaptor sequences 
to which the cDNA tagging sequences can anneal to. The cDNA undergoes one round of 
polymerisation, and the original cDNA is removed, leaving cDNA copies attached to the flow 
cell. During amplification, the cDNA reads bend down and anneal to nearby adaptor 
sequences. This amplification creates clusters of cDNA amplified from a single read. 
Fluorescently-tagged nucleotides are then flowed across. After incorporation of a 
fluorescently-tagged nucleotide within the DNA, the fluorescent dye is released. The colour 
of the fluorescence for each cDNA cluster is detected by a laser and is converted to a base. 
This continues until all 100 bases have been read. The reads are then exported to FASTQ 
format, which contains the sequence data and base quality. 
4.4.2 Mapping using TopHat 1.4.1 to mm9 mouse genome 
 
The six resulting FASTQ files were mapped individually using TopHat 1.4.1 to the mm9 build 
of the mouse genome. Cufflinks 1.3.0 was used to calculate differential expression between 
wildtype and Gnasxlm+/p- data (Trapnell et al., 2010). Cufflinks calculates the relative transcript 
abundances from the aligned reads generated by TopHat. This is done by calculating the 
Fragments per Kilobase of exon per Million fragments mapped (FPKM). Since exons and 
genes have varying sizes, this needs to be taken into account to calculate relative expression 
values. Cufflinks is used to calculate these for each individual sample. Cuffcompare is then 
used to merge the results of the FPKM analysis, grouping together results from wildtype mice 
and those from Gnasxlm+/p- mice. Finally, Cuffdiff analyses the statistical differences between 
these groups using a multiple testing correction. Figure 4.6 outlines the analysis pipeline. 
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Figure 4.6: Flow diagram of the analysis pipeline after the generation of the FASTQ raw 
data files 
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Cuffdiff analysis revealed 657 genes to be significantly differentially expressed. In order to 
identify types of genes that were differentially expressed, the 657 gene names were input 
into the Functional Analysis Tool under default settings (DAVID Bioinformatic resources). 
Using this tool, it is possible to cluster genes into similar groups, based on similar functions, 
using information such as Gene Ontology (GO) terms, and protein pathways from the KEGG 
database. The most enriched cluster contained genes encoding proteins in the ribosome. 
However, many of these annotated as predicted genes. The second most enriched cluster 
contains genes involved in the mitochondria and oxidative phosphorylation. Eleven 
differentially expressed genes were identified in the NADH dehydrogenase protein complex 
(Table 4.2). One was identified in the succinate dehydrogenase complex. Two in the 
cytochrome c reductase complex, and four in the cytochrome c oxidase complex. This is an 
interesting finding, since the phenotype of the Gnasxlm+/p- mice demonstrates an overactive 
SNS and increased metabolic rate (Xie et al., 2006). Therefore changes to the oxidative 
phosphorylation protein complexes could have important effects. However the exact role 
that differentially expressed protein complex subunits would have on the physiology of the 
mice is not clear. 
Since Gnas encodes a G-protein coupled receptor α subunit, it was also interesting to observe 
several G-protein related differentially expressed genes. These were identified by finding 
genes associated with the GO classifications GO:0007186 (G-protein coupled receptor 
signalling pathway), and GO:0004930 (G-protein coupled receptor activity). A total of 15 
genes were identified (Table 4.3). 
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gene value_1 value_2 log2(fold
_change) 
q_value Ensembl gene ID Description 
Cox7c 23.843 68.9255 1.53147 2.52E-05 ENSMUSG00000017778 cytochrome c oxidase, subunit VIIc [Source:MGI 
Symbol;Acc:MGI:103226] 
Ndufb3 9.18981 25.3052 1.46133 0.002585 ENSMUSG00000026032 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 3 
[Source:MGI Symbol;Acc:MGI:1913745] 
Ndufa3 88.5498 236.35 1.41636 6.07E-08 ENSMUSG00000035674 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3 
[Source:MGI Symbol;Acc:MGI:1913341] 
Cox7a2 23.1388 54.9341 1.24739 3.02E-05 ENSMUSG00000032330 cytochrome c oxidase, subunit VIIa 2 [Source:MGI 
Symbol;Acc:MGI:1316715] 
Ndufa1 12.3014 28.4445 1.20933 0.028788 ENSMUSG00000016427 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 
[Source:MGI Symbol;Acc:MGI:1929511] 
Uqcrb 181.043 383.533 1.08302 2.65E-07 ENSMUSG00000021520 ubiquinol-cytochrome c reductase binding protein [Source:MGI 
Symbol;Acc:MGI:1914780] 
Ndufs6 29.5758 56.574 0.935722 0.034317 ENSMUSG00000021606 NADH dehydrogenase (ubiquinone) Fe-S protein 6 [Source:MGI 
Symbol;Acc:MGI:107932] 
Ndufa6 43.8825 77.2082 0.815109 0.004458 ENSMUSG00000022450 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6 (B14) 
[Source:MGI Symbol;Acc:MGI:1914380] 
Cox5b 217.535 354.387 0.704079 0.004458 ENSMUSG00000061518 cytochrome c oxidase, subunit Vb [Source:MGI 
Symbol;Acc:MGI:88475] 
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Cox6c 363.943 578.964 0.66976 0.006656 ENSMUSG00000014313 cytochrome c oxidase, subunit VIc [Source:MGI 
Symbol;Acc:MGI:104614] 
Cox6b1 226.471 130.666 -0.79344 0.002516 ENSMUSG00000036751 cytochrome c oxidase, subunit VIb polypeptide 1 [Source:MGI 
Symbol;Acc:MGI:107460] 
Ndufb8 75.4069 41.9487 -0.84607 0.009182 ENSMUSG00000025204 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8 
[Source:MGI Symbol;Acc:MGI:1914514] 
Ndufv1 31.3465 17.3544 -0.853 0.002901 ENSMUSG00000037916 NADH dehydrogenase (ubiquinone) flavoprotein 1 [Source:MGI 
Symbol;Acc:MGI:107851] 
Uqcrh 253.017 128.384 -0.97877 1.84E-05 ENSMUSG00000063882 ubiquinol-cytochrome c reductase hinge protein [Source:MGI 
Symbol;Acc:MGI:1913826] 
Ndufa7 38.7955 18.0841 -1.10117 0.039859 ENSMUSG00000041881 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 
(B14.5a) [Source:MGI Symbol;Acc:MGI:1913666] 
Ndufa12 114.16 52.7695 -1.11328 2.57E-05 ENSMUSG00000020022 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 
[Source:MGI Symbol;Acc:MGI:1913664] 
 Table 4.2: Differentially expressed genes associated with oxidative phosphorylation 
Genes identified from the early TopHat 1.q value refers to the p value after multiple testing correction. 
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gene Wt_value Ko_value log2 
(fold_change) 
q_value Ensembl gene ID Description 
Cckbr 3.08702 10.0232 1.69905 0.005814 ENSMUSG00000030898 cholecystokinin B receptor [Source:MGI 
Symbol;Acc:MGI:99479] 
Npy5r 1.83522 5.64232 1.62034 0.049822 ENSMUSG00000044014 neuropeptide Y receptor Y5 [Source:MGI 
Symbol;Acc:MGI:108082] 
Gpr19 11.2961 22.7914 1.01266 0.009727 ENSMUSG00000032641 G protein-coupled receptor 19 [Source:MGI 
Symbol;Acc:MGI:892973] 
Gnb4 10.027 18.9292 0.91672 0.020184 ENSMUSG00000027669 guanine nucleotide binding protein (G protein), beta 4 
[Source:MGI Symbol;Acc:MGI:104581] 
Atrnl1 11.458 21.3274 0.89635 0.000431 ENSMUSG00000054843 attractin like 1 [Source:MGI Symbol;Acc:MGI:2147749] 
Glrb 89.5482 153.946 0.781691 0.000403 ENSMUSG00000028020 glycine receptor, beta subunit [Source:MGI 
Symbol;Acc:MGI:95751] 
Gpr153 11.1201 18.8224 0.759281 0.040725 ENSMUSG00000042804 G protein-coupled receptor 153 [Source:MGI 
Symbol;Acc:MGI:1916157] 
Gnai3 22.3956 36.6886 0.712114 0.014536 ENSMUSG00000000001 guanine nucleotide binding protein (G protein), alpha 
inhibiting 3  
Homer1 28.6383 45.8556 0.679154 0.000428 ENSMUSG00000007617 homer homolog 1 (Drosophila) [Source:MGI 
Symbol;Acc:MGI:1347345] 
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Cnr1 18.1007 27.1609 0.585485 0.039168 ENSMUSG00000044288 cannabinoid receptor 1 (brain) [Source:MGI 
Symbol;Acc:MGI:104615] 
Kcnk2 31.6309 45.1968 0.514886 6.94E-07 ENSMUSG00000037624 potassium channel, subfamily K, member 2 [Source:MGI 
Symbol;Acc:MGI:109366] 
Cacnb4 35.2726 50.1003 0.506271 0.001069 ENSMUSG00000017412 calcium channel, voltage-dependent, beta 4 subunit 
[Source:MGI Symbol;Acc:MGI:103301] 
Adcyap1r1 23.1971 30.117 0.376634 0.020184 ENSMUSG00000029778 adenylate cyclase activating polypeptide 1 receptor 1 
[Source:MGI Symbol;Acc:MGI:108449] 
Rgs7 56.7371 39.0058 -0.5406 0.01483 ENSMUSG00000026527 regulator of G protein signaling 7 [Source:MGI 
Symbol;Acc:MGI:1346089] 
Caly 343.135 132.086 -1.37729 0 ENSMUSG00000025468 calcyon neuron-specific vesicular protein [Source:MGI 
Symbol;Acc:MGI:1915816] 
Table 4.3: Differentially expressed genes with G-protein-related GO terms 
Genes associated with the GO classifications GO:0007186 (G-protein coupled receptor signalling pathway), and GO:0004930 (G-protein coupled receptor 
activity). Genes from the TopHat 1.4.1 mapping to the mm9 genome build. 
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Interestingly, two GPCRs were identified: Gpr19 and Gpr153. Gpr19 shows expression within 
the hypothalamus (O’Dowd et al., 1996) and is regulated by the cell cycle (Kastner et al., 
2012). Gpr153 is widely expressed within the CNS, including in the hypothalamus where 
expression is found in the Arc and PVN – two regions with important roles in the regulation 
of feeding and appetite (Sreedharan et al., 2011). In addition, antisense knockdown of 
Gpr153 in rats showed a significant reduction in food intake (Sreedharan et al., 2011). 
During the RNAseq data analysis, an updated version of Cufflinks (2.0.2) was released. In 
addition, a major update was made to the mouse genome and annotation sets, as the mm10 
version of the M. musculus genome was released. It was decided that data should be 
analysed by the latest versions in order to have the most accurate results. 
After the release of Cufflinks 2.0.2, the mapped data was reanalysed using this version, 
generating a smaller subset of significantly differentially expressed genes. Mapping to the 
mm10 genome annotation in conjunction with a repeat mask and analysis using Cufflinks 
2.0.2 was also performed, which also resulted in a reduced number of significantly 
differentially expressed genes – 289, compared to 657 in the original analysis. 
Reanalysis using Cufflinks 2.0.2 generated 289 significantly differentially expressed genes, 
compared to 657 in the original analysis. Similarly, the numbers of differentially expressed 
isoforms was found to be reduced (from 828 to 289), as well as coding sequences, splicing 
events, and promoter usage. A smaller subset of differentially expressed genetic elements 
implies that the updated version of Cufflinks was more stringent in the analysis. There was 
also a tendency for the genes with higher p values to be no longer significantly differentially 
expressed after the reanalysis. 
In order to further investigate the effect of the reanalysis, gene clusters were analysed by 
DAVID. This confirmed that the enriched ribosome and mitochondrial gene clusters were still 
present. Of the mitochondrial genes identified in the original analysis, 14 out of the 18 genes 
were still significant (Table 4,4). Four were no longer significant (Ndufb6, Sdhd, Ndufa13, 
Ndufaf2), and two new genes were identified as significantly differentially expressed 
(Ndufa6, Cox5b). In addition, analysis by the updated version of Cufflinks usually generated 
lower q values (after p values have been corrected for multiple testing). Combined with the 
result of a lower number of significantly differentially expressed genes, this suggests that the 
reanalysis using Cufflinks 2.0.2 was providing a more stringent analysis. 
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 mm9, Cufflinks 1.3.0 mm9, Cufflinks 2.0.2 mm10, Cufflinks 2.0.2 
gene log2(fc) q_value log2(fc) q_value log2(fc) q_value 
Cox7c 1.71498 6.29E-08 1.53147 2.52E-05 1.17154 0.00972951 
Ndufb3 1.50797 0.000355425 1.46133 0.00258483 1.59208 0.00190691 
Ndufb6 1.42489 0.00351278     
Ndufa1 1.38604 0.00151548 1.20933 0.0287879   
Cox7a2 1.20697 3.88E-06 1.24739 3.02E-05 1.1815 1.51E-05 
Ndufa3 1.17311 1.29E-06 1.41636 6.07E-08 1.14575 0.000159179 
Uqcrb 0.952088 1.03E-06 1.08302 2.65E-07 1.09706 1.34E-07 
Ndufs6 0.947595 0.00200254 0.935722 0.0343166 1.00665 0.0119471 
Ndufa6   0.815109 0.00445776 0.695335 0.0101563 
Cox5b   0.704079 0.00445776 0.657952 0.00212883 
Cox6c 0.908055 3.10E-05 0.66976 0.00665577 0.65322 0.00860744 
Sdhd 0.62782 0.033571     
Ndufa13 0.555144 0.0480848     
Cox6b1 -0.75371 0.00129 -0.79344 0.0025157 -0.85101 0.000142711 
Ndufaf2 -0.78284 0.0347563     
Ndufv1 -0.81522 0.000789256 -0.853 0.00290132 -1.01336 0.0151469 
Ndufb8 -0.92081 0.000345399 -0.84607 0.00918167   
Ndufa12 -0.96492 6.26E-05 -1.11328 2.57E-05   
Ndufa7 -1.13576 0.00922488 -1.10117 0.0398589   
Uqcrh -1.24347 1.55E-10 -0.97877 1.84E-05 -1.06489 7.71E-07 
 
Table 4.4: Significantly differentially expressed genes involved in oxidative 
phosphorylation through different analyses 
Blank boxes indicate that the gene was not significantly differentially expressed. fc = fold 
change. 
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4.4.3 Mapping using TopHat 2.0.4 to mm10 mouse genome 
 
During the reanalysis, an updated version of the mouse genome, mm10, was released. Since 
gene annotations were altered, data was remapped to the updated genome for the most 
accurate results. After mapping using TopHat 2.0.4, the data was analysed using Cufflinks 
2.0.2. 
The percentage of reads mapped (39.3%) to the mm10 genome was similar, but slightly 
higher than the reads mapped to the mm9 genome build (39.1%) (Figure 4.7). The results 
showed that 332 genes were identified as differentially expressed – almost half that of the 
original analysis (657), but slightly more genes than were identified in the second analysis 
(289) (Table 4.5).  Despite the reduction in the number of differentially expressed genes, the 
various analyses showed that many differentially expressed genes were shared, as displayed 
by eulerAPE (Figure 4.8) (Micallef and Rodgers, 2014). Fold changes identified were mostly 
between a 4-fold increase and a 4-fold decrease. However, many predicted and short 
nucleolar RNA (snoRNAs) showed particularly high fold changes (Figure 4.9). 
Two of the most upregulated genes identified in Gnasxlm+/p- mice were hexose-6-phosphate 
dehydrogenase (H6pd) and Hydroxysteroid 11-beta dehydrogenase 1 (Hsd11b1) 
(upregulated 4.0-fold and 3.9-fold respectively). HSD11B1 modulates the activation and 
inactivation of the glucocorticoid, corticosterone. Inactive deoxycorticosterone is converted 
to the active glucocorticoid corticosterone by HSD11B1 (Bánhegyi et al., 2009). In order to 
produce the active corticosterone, HSD11B1 requires NADPH. H6PD drives the action of 
HSD11B1 by reducing NADP+ to NADPH, while converting glucose-6-phosphate (G6P) to 
phosphogluconate (Atanasov et al., 2004; Bánhegyi et al., 2004; Bujalska et al., 2005). 
Therefore, it is an interesting finding both genes are found to be upregulated together, and 
suggests these genes could be acting in unison in an attempt to increase corticosterone. 
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 mm9, Cufflinks 
1.3.0 
mm9, Cufflinks 
2.0.2 
mm10, Cufflinks 
2.0.2 
Genes 657 289 332 
Isoforms 828 289 403 
Coding sequences 607 267 319 
Splicing events 193 34 72 
Promoter use 118 24 68 
 
Table 4.5: Number of differentially expressed genetic elements through the various 
analyses. 
All significantly differentially expressed genes identified in TopHat 2.0.4 mapping to mm10 
genome and analysis by Cufflinks 2.0.2 are given in Appendix Table 5. 
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Figure 4.7: Percentage of read mapped using TopHat 
Mapping percentages were similar between mapping with TopHat1.1.1 to the mm9 genome 
compared to TopHat 2.0.4 mapping to the mm10 genome. 
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Figure 4.8:  Euler diagram showing significantly differentially expressed genes that are 
shared between the different analyses.  
A comparison between the three analyses. 422 of the 657 genes identified as differentially 
expressed in the original analysis (TopHat 1.4.1, Cufflinks 1.3.0, mm9) were not significantly 
differentially expressed based on the later analyses. Diagram was produced using eulerAPE 
(Micallef and Rodgers, 2014). 
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Figure 4.9: Fold changes of all significantly differentially expressed genes 
Significantly differentially expressed genes from the mm10/Cufflinks 2.0.2 analysis, ordered 
from most overexpressed, to most underexpressed. 
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4.5 Discussion 
 
These results demonstrate the importance of using the latest bioinformatic software for 
RNAseq analysis. Due to the increase in sequencing data, bioinformatic tools are also 
evolving and different versions of products can give different results. In particular, the later 
analyses using TopHat v2 and Cufflinks v2 suggested a more stringent analysis (Table 4.5). 
Given that the bioinformatic tools are complex, there is a lot of room for discrepancies 
developing between different analyses. The analyses where the reads were mapped to the 
mm9 build of the mouse genome shared a large proportion of the significantly differentially 
expressed genes (Figure 4.8). However, upon mapping to the mm10 genome, almost half of 
the differentially expressed genes were newly identified (Figure 4.8). This may be a result of 
genes that were poorly annotated on the mm9 build being annotated more fully on the 
mm10 build. Since we did not attempt to identify de novo exon junctions, this will have 
resulted in reads spanning exons to be unmapped for poorly annotated genes. It could also 
be a result of using the TopHat 2.0.4 version over the TopHat 1.4.1 version and could be a 
result of changes in the mapping algorithms. Furthermore, the updated 2.0.2 version of 
Cufflinks resulted in fewer significantly differentially expressed genes than for the analysis 
using Cufflinks version 1.3.0. 
With the increase in large scale sequencing studies, it would be interesting to investigate 
how analysis using different tools and inputs can affect results. Not only are there several 
well established mapping tools available to researchers, but there are also different 
quantification tools, genome builds, and sequencing platforms. Although it was not the 
main focus of this project, this work demonstrates the complexities involved in the analysis 
of RNAseq data. Bioinformatic programs are constantly evolving, but they are also limited 
by the input of both the quality of the data, and the quality of the genome build. 
From the analysis, we identify 332 differentially expressed genes. Interestingly, some of the 
differentially expressed genes have been linked to roles in the regulation of energy usage, 
and management of body weight. Gamma-aminobutyric acid receptor-associated protein 
(Gabarap) is upregulated 2.7-fold in Gnasxlm+/p- mice. Gabarap is known to bind to the 
Angiotensin II receptor type 1 (AT1R) and increase its expression (Cook et al., 2008). 
Interestingly, one of the main functions of the AT1R is to modulate the SNS. Angiotensin II 
is able to act via the SNS to increase heart rate (Reid, 1992), which is interesting given the 
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recent observation that Gnasxlm+/p- mice show a significantly increased heart rate at night 
(Nunn et al., 2013). 
Hydroxyacyl-CoA dehydrogenase (Hadh) was identified as being 2.7-fold downregulated in 
Gnasxlm+/p- mice. Hadh is involved in the process of fatty acid oxidation. Interestingly, 
knockout mice for Hadh show evidence of hyperinsulinism, low glucose levels (Li et al., 
2010) and low body weight and decreased fat when kept on a high-fat diet (Schulz et al., 
2011). Therefore, Hadh appears to have roles in the balance of energy regulation and in the 
maintenance of body weight. 
Gnas was not identified as a significantly differentially expressed gene in Gnasxlm+/p- mice 
hypothalami. Since the Gnasxl exon is only expressed from the paternal copy, and having 
such limited expression, this was largely expected. Furthermore, no Gnas isoforms were 
identified as being differentially expressed. Because of the complexity of the Gnas locus and 
the limited expression of some exons – particularly Gnasxl – calculating the expression 
changes of rare, but biologically important, isoforms is challenging even when using the most 
advanced software. In addition, the transcriptomic coverage during sequencing is 
challenging. When expression of certain transcripts are highly localised, or expressed to very 
low levels, a very high coverage is necessary to detect significant changes between 
conditions. 
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Chapter 5: qPCR analysis 
5.1 Introduction 
Quantitative real-time reverse transcriptase PCR (qPCR) is a molecular technique that allows 
the relative or absolute quantification of cDNA. Essentially, cDNA is amplified by PCR and the 
machine detects fluorescence emitted as a product of cDNA amplification. This is done at the 
end of each cycle. Therefore by measuring the fluorescence, it is able to infer the amount of 
cDNA in the sample and assuming that the amount of cDNA product doubles each cycle, it is 
possible to infer the original starting amount, whether relative to another gene, or absolutely 
when compared to a sample of known concentration. 
There are several different methods for quantifying cDNA during qPCR. One of these is SYBR 
Green. This is an asymmetrical cyanine dye that is able to preferentially bind within the two 
strands in double-stranded DNA.  SYBR Green is excited under blue light (λmax = 497nm) and 
emits green light (λmax = 520nm). As it stains double-stranded DNA, the emission of green 
light increases as the amount of cDNA product increases during qPCR. SYBR Green is a very 
widely used method and remains the most cost-effective. However, its main disadvantage is 
that its binding to DNA is non-specific and it will bind to any double-stranded DNA product. 
Therefore it is extremely important to minimise secondary products. Using intron-spanning 
primers, which span exon-exon boundaries, prevents the amplification of any DNA 
contaminants in the cDNA sample. This can cause issues with simple loci, where there are 
few introns. Alternatively, with highly complex introns, there may not be exon-exon 
boundaries shared by all transcripts of the gene. 
Furthermore, it is important to check for other secondary products by performing a melt 
curve assay. Since DNA products have different binding properties, they also have different 
melting and annealing temperatures. In a melt curve assay, the temperature of the sample 
is slowly increased, after completion of the qPCR. The qPCR machine monitors the 
fluorescence of SYBR Green, which decreases upon melting of DNA strands. Multiple dips will 
be seen in the presence of more than one product. Finally, the primer design is paramount 
to the qPCR. Primers must be designed in such a way that they will bind specifically to the 
transcript of interest, and not to elsewhere in the genome. Furthermore, they must be 
designed to be compatible with the amplification temperature used in the qPCR protocol; to 
have similar melting temperatures to each other; and to have low complementarity to each 
other and to themselves. 
78 
 
To address the potential issue of non-specific binding, Taqman probes were developed which 
use a probe-based method to ensure fluorescence is only emitted upon amplification of the 
desired product. Taqman probes consist of a fluorophore and a quencher, linked by a region 
that will bind a specific DNA sequence. While the probe is intact and linked to the cDNA, the 
quencher prevents the fluorophore from emitting light. Upon amplification, the probe is 
degraded by the 5’ to 3’ exonuclease activity of the Taq polymerase enzyme. This releases 
the fluorophore, which becomes excited after being separated from the quencher, and emits 
light. Therefore, fluorescence is directly proportional to the amount of cDNA at the beginning 
of the reaction. This method is more expensive than SYBR Green, and different probes have 
to be used for different amplicons. 
5.2 Aims 
Having identified 332 significantly differentially expressed genes, it was important to verify 
whether these results could be duplicated by reanalysis using the qPCR method. As a 
different method of quantification, it provides an independent analysis of the RNAseq 
results. Therefore, the aims of the qPCR analysis were to employ qPCR to accurately quantify 
a selection of genes that were identified as significantly differentially expressed between 
wildtype and Gnasxlm+/p- mice in the RNAseq analysis.  
5.3 Materials and methods 
5.3.1 cDNA synthesis 
Pooled RNA samples from wildtype and Gnasxlm+/p- mice were reverse transcribed to cDNA 
using M-MLV Reverse Transcriptase (Life Technologies) according to the manufacturer’s 
instructions. 
5.3.2 Standard curves 
For standard curve calculations, each horizontal row of the plate was loaded with five-fold 
serial dilutions of cDNA after diluting the original cDNA product to 1:100. A negative control 
of nuclease-free water was used for each sample (Qiagen). Each sample was run in triplicate. 
For each primer set, a master mix was made containing 16µl forward primer (5µM), 16µl 
reverse primer (5µM), and 200µl Brilliant II SYBR Green QPCR Master Mix with Low Rox 
(Agilent Technologies). This was kept in a nuclease-free 1.5ml tube, covered in foil, mixed 
gently, and placed on ice until further use. 14.5µl was then aliquoted out into each well 
allocated to that gene. After running the qPCR (see section 4.2.4), only primer sets with 93-
107% efficiency (where efficiency = -1+10(-1/slope)), and R2>0.98 were used for quantitative 
analysis. 
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5.3.3 Relative quantification 
For relative quantification, each horizontal row of the plate was loaded with cDNA from each 
pooled sample. Because of using six rows instead of five, the master mix volume was 
increased: 20µl forward primer (5µM), 20µl reverse primer (5µM), and 250µl Brilliant II SYBR 
Green QPCR Master Mix with Low Rox (Agilent Technologies). The mix was treated and 
aliquoted identically to the standard curve protocol. Two genes, Actb and Ppia were used as 
control genes. Several control genes were tested, and those with the most consistent 
expression across samples and with the most efficient primer sets were chosen. These were 
later used to normalise the changes in expression across the samples to the changes in 
expression observed for these two genes. 
5.3.4 qPCR cycling 
Prior to loading the 96-well plate, a new file was created on the Applied Biosystems 7500 
Fast Real-Time PCR System. Each well was labelled with the cDNA and primer set. The 
temperature profile was set as: 95°C for 10 seconds, followed by 40 cycles of 95°C for 30 
seconds and 60°C for 60 seconds. A melt curve analysis was also performed after standard 
curve analysis to check for the presence of a single product. 
The plate was sealed with the MicroAMP Optical Adhesive Film (Applied Biosystems), and 
wrapped in foil. The plate was then centrifuged at 700rpm for 2 minutes to spin the liquid 
down, before being placed in the machine. The cycle was then run. 
Using the Applied Biosystems 7500 software, relative quantification of genes was normalised 
to the expression of Actb and Ppia in the pooled pWt-1 sample. 
5.4 Results 
SYBR Green was seen as the more appropriate choice, due its cost.  In order to ensure 
quantification accuracy, several steps were undertaken to check for amplification efficacy 
and amplicon purity. To check amplification efficiency, qPCRs were run on genes against 
cDNA in 10-fold serial dilutions, in triplicate. CT values were plotted against the log of relative 
concentration to set up a standard curve, from which the efficiency of the amplification could 
be tested. During a qPCR cycle, the amount of cDNA and therefore fluorescence should 
double each cycle, until factors such as dNTP availability become limiting.  
Primer pairs were designed using the Universal ProbeLibrary Assay Design Centre (Roche), 
and the OligoArchitect Primer and Probe Design Solutions (Sigma-Aldrich) such that they 
spanned exon-exon boundaries, in order to prevent amplification of any contaminant DNA. 
80 
 
Primer pairs were selected on the basis that they amplified the single product at an efficient 
rate. This was determined firstly by the analysis of standard curve information. Efficiency is 
calculated on the basis of the slope of the curve, which is a measure of the amplification rate. 
Efficiency must be within 93-107%, and the correlation of the points (R2) on the standard 
curve must be ≥0.98 in order to ensure that the product is being amplified correctly. 
Secondly, a melt curve analysis was performed after the qPCR cycles. Temperature is slowly 
increased, and the fluorescence is measured. As the product melts, SYBR green becomes 
dissociated and fluorescence intensity drops. If there is a single DNA product, this will appear 
as a single peak. Multiple peaks indicate that there is more than one product being produced, 
and any primer sets amplifying these were discarded. 
Several control genes were investigated, and those with the most stable expression across 
the six wildtype and knockout samples were chosen. Gapdh was considered, however it was 
identified as a significantly differentially expressed gene in the analysis, and therefore 
discarded as a control gene. 
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Gene Description Efficiency (%) R2 
Ppia Cyclophilin A 98.0 1.00 
Actb Β-actin 95.6 0.99 
Hadh Hydroxyacyl-CoA-dehydrogenase 104.8 1.00 
Adipor1 Adiponectin receptor 1 94.9 0.99 
Gabarap Gamma-aminobutyric acid receptor-
associated protein 
99.2 0.99 
Rgs7 Regulator of G-protein signalling 7 103.2 0.99 
Caly Calcyon neuron-specific vesicular protein 106.4 0.98 
Bex1 Brain expressed gene 1 97.9 0.99 
Gfap Glial fibrillary acidic protein 95.9 0.99 
Bcl2 B-cell lymphoma 2 101.8 1.00 
Mt2 Metallothionein 2 104.5 1.00 
Table 5.1: Genes with primer sets used for qPCR analysis 
Primer sets had an efficiency of 93-107%, and R2≥0.98 
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Gene Forward oligonucleotide Reverse oligonucleotide 
Adipor1 CAAGCACCGGCAGACAAGA TGGTGGGTACAACACCACTCAA 
Bex1 GAGGAGAAGGCAAGGATAGGC TCCCTTCTGATGGTATCTTGTGG 
Caly CCTCCGCATCTACACTGCAT CCATGGTGGATGATGGTCCT 
Gabarap GGCGAGAAAATCCGAAAGAA GATCAGAAGGCACCAGGTATTTC 
Gfap ACCAGCTTACGGCCAACAGT CCGAGGTCCTGTGCAAAGTT 
Hadh CCTGAAGCTGAAGAACGAGCTG TGCTGGCAAAGATGGTGTGT 
Rgs7 GGCAAGGCTAGAGCTAGCAGA GGCAAGGCTAGAGCTAGCAGA 
Bcl2 TGAGTACCTGAACCGGCATCT GCATCCCAGCCTCCGTTAT 
Mt2 GCAAATGTACTTCCTGCAAGAAAAG CAGCCCTGGGAGCACTTC 
S100b TCATTGATGTCTTCCACCAGTA CCACTTCCTGCTCCTTGA 
Actb GCTTCTTTGCAGCTCCTTCGT GCTTCTTTGCAGCTCCTTCGT 
Ppia CAAATGCTGGACCAAACACAA GCCATCCAGCCATTCAGTCT 
Table 5.2: Oligonucleotide sequences for primer sets 
Primer sets had an efficiency of 93-107%, and R2≥0.98 
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qPCRs were run on 1:100 dilutions of the individual cDNA samples. The cDNA was amplified 
using RNA from the same pooled samples used in the RNAseq analysis. The samples used 
were prior to the rRNA-depletion. Analysis of Adipor1, Bex1, Caly, Gabarap, Gfap, Hadh, and 
Rgs7 by qPCR suggested very little change in expression. After normalising to the expression 
of Actb and Ppia, the only gene to show a comparable gene expression change in the RNAseq 
analysis and qPCR was Gfap. qPCRs were repeated, but continually gave differing expression 
changes to the RNAseq analyses – apart from Gfap, where the qPCR analysis agreed strongly 
with the RNAseq findings. 
In order to investigate the cause of the discrepancy, it was hypothesised that it could be 
caused by the rRNA-depletion method that was applied to the RNAseq sample, but not to 
the sample used for qPCR analysis. Any bias caused by the rRNA-depletion step would have 
huge implications for the study as it would suggest that the samples that were sequenced 
were not wholly representative of the total RNA that was originally obtained. Therefore, 
qPCRs were also run on cDNA created from rRNA-depleted RNA. Genes tested in this analysis 
were Gabarap, Gfap, and Hadh, as well as the two control genes Actb and Ppia. Expression 
changes in Gabarap were not significantly different to those observed in the original qPCR 
analysis. Hadh did show a slight decrease in expression in knockout samples, and more so 
than in the original qPCR analysis. However, the change in expression was still far from the 
expression change observed in the RNAseq analyses. Gfap on the other hand was confirmed 
again to have a 2-fold expression decrease in knockout mice, which was consistent with the 
previous qPCR analysis and RNAseq analyses. 
As an intermediate filament protein that is a widely used marker of glial cells in the brain, 
Gfap has interesting characteristics. It is widely expressed in astrocytes, which could suggest 
changes in the number of these cells within the hypothalamus, or a decreased expression 
within the cells. Importantly, the presence of mRNA does not always correlate with the level 
of protein. In order to investigate whether GFAP was decreased at the protein level, the 
hypothalami of the mice were investigated in more detail. 
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Figure 5.1: Comparison of the gene expression changes observed in Gnasxlm+/p- mice obtained from RNAseq and qPCR analysis 
Asterisks indicate that the gene was not significantly differentially expressed in the RNAseq analysis. Error bars represent the standard error. 
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5.5 Discussion 
 
After identifying 332 genes as differentially expressed between Gnasxlm+/p- and wildtype 
mice, we attempted to verify the authenticity of these results by performing qPCR on cDNA 
from the pooled total RNA samples. This allowed us to investigate whether RNAseq results 
were indicative of gene expression changes in the original samples. 
qPCR analyses were performed on all six pooled samples with triplicate technical replicates 
to ensure accuracy. Gfap was found to be similarly decreased in expression 2-fold in both the 
RNAseq and qPCR analyses. However, other genes tested did not show a comparable change 
in expression to that recorded from the RNAseq analysis. 
There can be many reasons for RNAseq analysis being discordant with qPCR results. These 
include PCR amplification bias during library preparation, having large standard errors – 
usually caused by pipetting errors, or few technical replicates in qPCRs. Because the RNA that 
was sequenced was from the rRNA-depleted RNA, we wanted to investigate whether there 
was a difference between qPCR analysis of cDNA from total RNA, and cDNA from rRNA-
depleted RNA. If the rRNA-depletion step was causing a bias, perhaps by isolating some non-
rRNA fragments, it could theoretically cause issues with RNAseq quantifications. 
In order to investigate this, qPCRs were run on cDNA from rRNA-depleted RNA. 
Consequently, we identified that expression of Gabarap and Gfap was similar to the results 
obtained from cDNA from total RNA. For Hadh, rRNA-depleted qPCRs suggested a slight 
decrease in expression in Gnasxlm+/p- mice compared to qPCRs performed on total RNA. 
However, this did not match the 2.7-fold decrease identified by RNAseq (Figure 5.1). These 
results lead to the suggestion that rRNA-depletion did not cause undue bias in the genes that 
were tested by qPCR. In addition, the qPCR results generally demonstrated low standard 
errors for the genes that were analysed. Therefore there was very low variability between 
technical replicates. 
It is not entirely clear why there were discrepancies between the RNAseq results and the 
qPCR results. It could potentially be due to biases from different amounts of starting 
material. However, since there appears to be a gene-specific discrepancy between the 
results, it could be related to the primers or the less accurate method of using SYBR Green. 
In either case, it would be advised for qPCR results to be quantified via another method using 
different primers, such as using TaqMan probes. 
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One of the major issues with qPCR analysis is primer design. Since SYBR Green binds to any 
dsDNA structure, it will also produce fluorescence when bound to secondary PCR products. 
Primer design is paramount in preventing non-specific amplification. In order to combat this, 
amplicons were run by gel electrophoresis, and by melt-curve analysis on the 7500 Fast Real-
Time PCR System (Applied Biosystems), ensuring a single product of the correct size. 
Therefore, the primer sets passing the criteria set out in Table 5.1 only amplified the region 
of interest. 
In response to the explosion in RNAseq experiments over the last 5 years, our work highlights 
the necessity of validating RNAseq results using an alternative method such as qPCR. While 
we identified discrepancies in expression changes between RNAseq and qPCR analyses, the 
2-fold decrease in Gfap in Gnasxlm+/p- mice identified by RNAseq was also supported by qPCR 
analysis. It is not clear whether GFAP protein is decreased in the hypothalami of Gnasxlm+/p- 
mice. Because Gfap is a known marker of glial cells, the next step was to investigate how 
GFAP protein was affected, and whether the lack of Gfap suggested a change in glial cell 
populations, or in the amount distributed per cell. 
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Chapter 6: Protein analysis of GFAP 
6.1 Introduction 
6.1.1 GFAP 
GFAP is a type III intermediate filament (IF) protein which is expressed in glial cells within the 
central nervous system. Proteins in this group of Ifs are able to form homo and heterodimers 
with one another, but not with other types of IFs. They form part of the cytoskeleton and 
Gfap, along with other IFs, are able to direct dynamic cell responses to stress and 
homeostasis mechanisms (Hyder et al., 2011). 
GFAP expression can be induced by disease and injury to the brain. Upon brain injury, glial 
cells, particularly astrocytes, attempt to repair damage and fill the space left by dead cells. 
This is known as astrogliosis and the resulting cell mass is referred to as a glial scar. In doing 
so, cells proliferate and increase expression of the intermediate filament GFAP in order to 
alter cell morphology and extend the pseudopodia to reform the lost networked structure 
(Sofroniew, 2009). Interestingly, Gfap expression has been shown to increase during ageing 
and in the prevalence of Alzheimer’s disease (Kohama et al., 1995; Kamphuis et al., 2014). 
While GFAPα is the main isoform, several isoforms of GFAP have been identified including α, 
β, γ, δ, κ, and ζ (Kamphuis et al., 2012). These are of different molecular weights due to 
alternative splicing events. Due to the presence of different exons in each isoform, there are 
many antibodies that are specific to certain isoforms. The functional differences between 
these isoforms are not well understood. However, it has been identified that different types 
of astrocytes have a preference for particular isoforms. For example, GFAPδ is particularly 
expressed in proliferating radial glial cells within the subventricular zone, which forms the 
neurogenic niche (van den Berge et al., 2010). Furthermore, certain isoforms have been 
associated with particular pathologies such as epilepsy and Alzheimer’s disease (Boer et al., 
2010; Kamphuis et al., 2012). 
Despite its role in responding to damage and in astrogliosis, Gfap knockout mice do not show 
an impaired astrogliosis response – possibly because of the presence of another type III IF 
found in astrocytes, vimentin. However, they are more sensitive to spinal cord damage 
(Nawashiro et al., 1998), and have an impaired response to form a protective barrier around 
β-amyloid, which is deposited during Alzheimer’s disease (Xu et al., 1999). 
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6.1.2 Glial cells 
Traditionally, glial cells have been thought to be merely support cells for neurons, forming 
the structures, but having no activity in neural transmission. However, many recent studies 
have identified that glia have many important roles in the CNS – they regulate the chemical 
environment of the brain, and they can modulate neuronal activity through synapses. In 
rodents, glia account for around 60% of cells in the CNS. In humans, glia account for around 
90% of the cells. Recent studies have demonstrated that the engraftment of human glial 
progenitor cells into immuno-compromised mice increases the ability of the mice to learn 
(Han et al., 2013), highlighting the important roles that glia have on brain function. 
Neurons have traditionally been the main focus of brain research. However, over the last 
decade, research into understanding the roles of glial cells has expanded rapidly (Freeman 
and Rowitch, 2013). In particular, there have been many recent studies implicating glial cells 
in the role of energy regulation within the hypothalamus. 
There are three main classifications of glial cells: macroglia, and microglia. Microglia are the 
main immune defence mechanism in the CNS. They maintain a star-like morphology, with a 
small cell body, and thin pseudopodia extensions. These search for danger within the CNS, 
such as damaged neurons and infection. They may phagocytose viruses and bacteria and 
present antigens to T-cells to instigate an immune response. 
Macroglia consist of ependymal glia, specialised tanycytes, oligodendrocytes, and astrocytes 
– the latter of which make up the largest proportion of glial cells. Most macroglia express 
Gfap, except for oligodendrocytes. 
Ependymal cells line the periphery of the brain and the cerebral ventricles spaces. Specialised 
tanycyte cells line the wall of the third ventricle (3V) and the median eminence (ME) region 
within the hypothalamus. The 3V contains cerebrospinal fluid, containing nutrients that can 
be distributed to the parenchyma. While the cell body of the tanycytes remain in the wall of 
the 3V, the tanycytes send out long processes into the parenchyma of the hypothalamus. 
They form interactions with nuclei that are known to have important roles in the regulation 
of appetite, feeding, and energy regulation. Through these connections, the tanycytes are 
able to distribute nutrients and are hypothesised to relay signals to specific regions of the 
hypothalamus in order to direct responses. Interestingly, the tanycytes are able to undergo 
neurogenesis, producing new neurons in adult mice. Furthermore, targeted blocking of 
neurogenesis of the tanycytes resulted in weight gain (Lee et al., 2012). In addition, the ME 
region of the brain is outside of the blood-brain barrier, meaning that the tanycytes in this 
89 
 
region act as a bridge to relay hormonal changes to the brain. In particular, a signalling 
cascade is initiated in tanycytes when exposed to leptin (Balland et al., 2014). Leptin is a 
hormone that is released from fat-containing adipocytes. Leptin is released when the animal 
is full to promote satiety. Because obesity is associated with elevated leptin levels, it has 
been postulated that tanycytes may be of therapeutic importance for the treatment of 
obesity (Balland et al., 2014). 
Astrocytes are one of the most common cell types within the CNS, and they are a diverse 
group of cell. They span the entirety of the CNS and are spaced apart in an organised manner. 
Typical astrocytes have a star-like morphology, and are characterised by multiple processes 
extending away from the cell body. They widely express GFAP and vimentin – both 
intermediate filament proteins. However there are some subsets of astrocytes that do not 
express GFAP. Astrocytes have the ability to modulate neuronal activity through synapses. 
There is also increasing evidence for astrocytes having an important role in the regulation of 
energy balance, metabolism, and appetite (Bélanger et al., 2011). 
6.1.3 The hypothalamus 
The hypothalamus is a region of the brain, situated at the centre ventral edge of the brain 
above the optic chiasm (Figure 6.1, Figure 6.2). One of its functions is to connect the 
endocrine system to the nervous system via the pituitary gland. Consequently, the 
hypothalamus is responsive to and synthesises many hormones. The hypothalamus is a 
critical regulator of homeostasis, in particular in regulating body temperature, the circadian 
rhythm, thirst, appetite, feeding behaviours, and energy expenditure via the SNS. 
Several sub-regions, referred to as nuclei, comprise the hypothalamus (Figure 6.3, Figure 
6.4). Each region has specific roles in responding to hormones and signals in order to manage 
these regulatory patterns. During development, neuronal and glial networks are established 
to create circuits that act to respond to feeding, appetite, and other factors governed by the 
hypothalamus (Bouret and Simerly, 2006). However, gliogenesis and many hypothalamic 
neuronal connections do not occur until early postnatal stages. The early stages of life are 
critical in establishing the hypothalamic networks. 
6.1.3.1 Suprachiasmatic nucleus 
The suprachiasmatic nuclei (SCN) are situated within the anterior part of the hypothalamus, 
directly above the optic chiasm (Figure 6.4). It consists of two small densely packed areas of 
cells that are located close to the base of the third ventricle, which runs through the centre 
of the hypothalamus. The primary role of the SCN is in controlling the circadian rhythm. In 
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doing so, the region has a very central role to play in the regulation of homeostatic 
mechanisms, many of which are under circadian control, such as hormone levels and body 
temperature regulation. 
6.1.3.2 Arcuate nucleus of the hypothalamus 
The arcuate nucleus (Arc) is situated at the mediobasal hypothalamus (Figure 6.3). It 
surrounds the base of the 3V and is characterised by its role in appetite and feeding. 
Connections from the Arc are minimal after birth, but begin to develop postnatally (Bouret 
and Simerly, 2006). By postnatal day 6 (P6), connections extend towards the dorsomedial 
hypothalamus (DMH). By P10, connections to the paraventricular nuclei of the hypothalamus 
(PVN) are established. Only by P12 do the connections extend outwards to the lateral 
hypothalamus (LH) 
The Arc contains many types of neurons. Orexigenic neurons act to stimulate appetite, and 
express Agouti-related peptide (AgRP) or Neuropeptide Y (NPY). Anorexigenic neurons act to 
suppress appetite, and express proopiomelanocortin (POMC). They are also capable of 
stimulating energy expenditure via the SNS. These neurons are connected to other regions 
of the hypothalamus, particularly to the PVN and DMH. 
Leptin is a hormone produced by adipocytes in white adipose tissue, which is produced when 
the adipocytes accumulate fat. Leptin circulates to the hypothalamus where it binds to leptin 
receptors on AgRP/NPY and POMC-expressing neurons in the Arc. On POMC neurons, leptin 
binding stimulates the release of α-melanocyte-stimulating hormone (α-MSH) via 
downstream signalling of the Jak-Stat pathway. α-MSH is able to bind to melanocortin-4-
receptor (MC4R) to suppress appetite. 
AgRP/NPY neurons on the other hand are repressed by leptin, but stimulated by another 
hormone, ghrelin. This is secreted by cells in the gastrointestinal tract when the stomach is 
empty. Ghrelin circulates and binds to growth hormone secretagogue receptor on AgRP/NPY 
neurons. This causes the release of γ-aminobutyric acid (GABA), AgRP, and NPY, which act to 
inhibit MC4R and therefore increase appetite. 
6.1.3.3 Paraventricular nucleus 
The paraventricular nuclei (PVN) consist of two clusters of cells adjacent to the top of the 
third ventricle (Figure 6.4). This region contains many neuronal connections of significance. 
Both AgRP/NPY and POMC neurons send axons from the Arc to the PVN. 
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6.1.3.4 Development of the hypothalamus 
The progenitor cells of glia begin in the neural tube during embryonic development. Sonic 
hedgehog (SHH) is secreted from the notochord and the floor plate of the neural tube, and 
its antagonist BMP is secreted from the roof plate. This creates a morphogen gradient that 
allows cells to differentiate into different types of cells depending on their location and how 
much SHH they receive (Ingham and Placzek, 2006). This is critical in patterning the neural 
tube to direct the differentiation of cells into different cell types. 
Cells that express Shh early in development, prior to embryonic day (E)9.5, go on to produce 
neurons, tanycytes, and astrocytes towards the posterior regions of the hypothalamus, 
including the Arc and ME (Alvarez-Bolado et al., 2012). Cells expressing Shh after E9.5 and 
before E12.5 give rise to neurons and astrocytes within the tuberal central region of the 
hypothalamus, particularly within the VMH and DMH. After E12.5, nearly all Shh-expressing 
cells contribute hypothalamic astrocytes, representing a developmental change from 
neurogenesis to gliogenesis (Alvarez-Bolado et al., 2012). 
While neurogenesis occurs from around E8 to E20, gliogenesis at a slightly later stage, but 
continues postnatally for several weeks. Astrocytes begin to develop early in gliogenesis, 
with differentiation peaking around P2. Differentiation continues for around 2 weeks 
postnatally. Whereas oligodendrocytogenesis differentiate later in gliogenesis, peaking at 
around P14 (Sauvageot, 2002). 
The subgranular zone within the hippocampus has an important role in neurogenesis. Within 
the neurogenic niche, radial glial cells act as a scaffold for new neurons to migrate to the 
granule cell layer. Radial glial cells can divide asymmetrically to produce a new stem cell, and 
a neuronal precursor cell. They also express Gfap, since they are a subset of astrocyte cells. 
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Figure 6.1: Schematic diagram of the side view of the mouse brain 
The olfactory bulb is the most anterior of the brain regions. The mid-brain consists of several 
compartments, including the hypothalamus (indicated by dotted line), which is situated at 
the ventral edge of the centre of the brain. The cerebral cortex surrounds the outer portion 
of this region, and the hypothalamus is not visible from this angle. The most posterior regions 
are the cerebellum and the medulla. 
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Figure 6.2: Schematic diagram of a coronal cross-section of the mouse brain 
Cross-section showing the main regions at bregma -1.6mm. This is roughly half way along 
the length of the mouse brain. The hypothalamus is situated at the ventral edge of the brain 
and surrounds the third ventricle. Solid areas filled in black represent the ventricle spaces, 
which are filled with cerebrospinal fluid. 
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Figure 6.3: Schematic diagram of a coronal cross-section of the Arcuate nucleus  
Cross section at bregma -1.94mm. ZI = Zona incerta; LH = Lateral hypothalamus; DMH = 
Dorsomedial hypothalamus; VMH = Ventromedial hypothalamus; Arc = Arcuate nucleus; ME 
= Median eminence; 3V = Third ventricle. 
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Figure 6.4: Schematic diagram of a coronal cross-section of the SCN and PVN 
Cross section at bregma -0.70mm. LH = Lateral hypothalamus; AH = Anterior hypothalamus; 
PVN = Paraventricular nucleus; SCN = Suprachiasmatic nucleus; F = Formix, 3V = Third 
ventricle. 
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6.2 Aims 
From identifying that Gfap was downregulated 2-fold in Gnasxlm+/p- mice in both the RNAseq 
and qPCR analyses, we aimed to identify whether the same was true of GFAP protein in the 
hypothalamus. Furthermore, because of the many specialised nuclei within the 
hypothalamus – many of which involved in the regulation of appetite and feeding behaviour 
– it was also important to investigate the localisation of GFAP. Using immunofluorescence, it 
is demonstrated here that Gnasxlm+/p- mice show a decline in tanycyte projections from the 
Arc, and fewer GFAP-positive cells in the SCN. 
From these results, it was not clear whether this decline in GFAP in adult Gnasxlm+/p- mice 
was due to a developmental problem, or whether it was a response to the chronic 
undernutrition that the mice undergo as a result of an overactive SNS and hypermetabolism. 
In order to investigate this question, GFAP expression was also analysed in P1 and P5 mice 
to identify whether there is a developmental problem during gliogenesis. 
6.3 Materials and Methods 
6.3.1 Tissue fixation and extraction 
Mice were anaesthetised by Antonius Plagge via an intraperitoneal injection of 
pentobarbitone. Once brain-dead, the chest was cut and the right atrium of the heart was 
cut in order for the blood to drain from the circulatory system. The tissues of the mice were 
fixed by injecting PBS into the left ventricle, to clear the system of blood, followed by 4% 
paraformaldehyde (PFA) in PBS. To extract the brain, the skull was carefully cut open, and 
the brain was dissected out. The tissues were placed in 4% PFA overnight. They were then 
transferred to a solution of 30% sucrose for 24-48 hours at 4°C in order to dehydrate them 
prior to sectioning. 
6.3.2 Protein lysates 
Individual hypothalami were dissected from the brain tissue and homogenised and sonicated 
by Katie Burton in 400µl radio-immunoprecipitation assay lysis buffer with protease inhibitor 
(Sigma-Aldrich), PMSF (Sigma-Aldrich) and PhoSTOP (Roche). Samples were placed on ice 
and centrifuged at 12000g for 10 minutes. Lysate supernatants were separated into 100µl 
aliquots and frozen at -80°C until further use. Using the Pierce BCA Protein Assay kit (Thermo 
Scientific, 23227), protein concentration was quantified according to the manufacturer’s 
instructions. 
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6.3.3 Immunofluorescence 
Brain tissues were carefully cut to isolate the midbrain section of interest. Sectioning of adult 
Gnasxlm+/p- and wildtype mice brains was performed on the Leica CM 1950 Cryostat at -20°C 
by Katie Burton, using Shandon Cryomatrix mounting media (Thermo Scientific). Frozen 
coronal sections at a thickness of 14µm were transferred to SuperFrost Plus slides (Thermo 
Scientific) and stored at -80°C until further use. Sectioning of postnatal day 1 and postnatal 
day 5 mice (P1 and P5 respectively) for both Gnasxlm+/p- and wildtype mice brains was 
performed by myself, using the same method. 
Slides were incubated in 10mM sodium citrate for one minute at 60°C; washed three times 
in PBS at room temperature for 5 minutes; blocked for one hour at room temperature in 10% 
donkey normal serum in PBS; and incubated overnight at 4°C in 10% donkey normal serum 
in PBS, 0.25% triton, 1:500 Polyclonal rabbit anti-GFAP primary antibody (Dako Z0334) in PBS. 
Slides were then washed three times for 15 minutes in PBS at room temperature. These were 
incubated in 10% donkey normal serum in PBS, 0.25% triton, 1:1000 4’,6’-diamidino-2-
phenylindole (DAPI) and 1:1000 donkey anti-rabbit IgG Alexa488-tagged secondary antibody 
for one hour at room temperature in the dark. Slides were washed three times in PBS for 15 
minutes prior to mounting with Fluoro-gel (Electron Microscopy Sciences), drying, and 
sealing with clear nail varnish. Slides were stored in the dark at 4°C. 
6.3.4 Microscopy 
Epifluorescence microscopy was performed using the Zeiss Axioskop 40 microscope. Images 
were taken and processed using the AxioVision 4.6 software (Zeiss). 
6.3.5 Self-cast SDS-PAGE 
6.3.5.1 Anti-GFAP antibody incubation 
After transferring, the membrane was carefully removed and marked in the top corner to 
mark the side on which the protein adhered to. The membrane was washed in PBS prior to 
blocking in PBS Tween with 5% non-fat dried milk powder for one hour at room temperature. 
Membranes were sealed in a plastic bag and incubated with 2ml 1:6000 polyclonal rabbit 
anti-GFAP primary antibody (Dako Z0334) in blocking solution (PBS Tween and 5% non-fat 
dried milk powder) for one hour at room temperature on a shaker. Membranes were washed 
four times for five minutes each in PBS Tween prior to a one hour incubation in a sealed 
plastic bag with 10ml 1:10000 donkey anti-rabbit horseradish peroxidise (HRP)-tagged 
secondary antibody. Membranes were washed again in PBS Tween four times for five 
minutes each to remove excess antibody. 
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6.3.5.2 Enhanced chemiluminescence detection and exposure to film 
Enhanced chemiluminescence (ECL) was performed, in order to detect presence of the HRP-
tagged secondary antibody. This was achieved using the Amersham ECL Plus Western 
blotting reagent pack (GE Healthcare), according to the manufacturer’s instructions. Briefly, 
excess wash buffer was drained prior to incubating the membranes in a 40:1 ratio of solution 
A to solution B on the protein side of the membrane, for five minutes. Membranes were then 
drained of excess ECL reagent and wrapped protein side down in Saran wrap. A fluorescent 
marker was attached to the front of the Saran wrap so that after exposure onto film, it would 
be possible to transfer the bands of the protein ladder to the film in order to estimate the 
densities of proteins within the bands present on the membranes. These were then placed 
protein side up in a film cassette in the dark room. The length of exposure time was varied, 
depending on the strength of the signal from the blot. After exposure, the film was placed 
into a tray of developing solution (Kodak) for one minute, followed by a tray of fixer solution 
(Kodak) for one minute, before being placed into a tray of water and then hung to dry. After 
drying, the protein ladder was marked on the film by overlaying the film on top of the blot 
using the position of the fluorescent marker. 
6.3.5.3 Anti-β-actin antibody incubation 
β-actin and GFAP have similar molecular masses (42kDa and 50kDa, respectively). In 
addition, both of these primary antibodies were raised in rabbits. Therefore it was necessary 
to strip the membrane of both primary and secondary antibodies. 
Stripping was performed using a buffer containing 100mM β-mercaptoethanol, 62.5mM Tris-
HCl (pH 6.7), and 2% SDS. This was mixed under the fume hood, and decanted into an airtight 
container with the membranes and placed in a shaking water bath pre-heated at 60°C, for 
30 minutes. After stripping, the solution was poured away under the fume hood, and the 
membranes were washed in PBS Tween using large volumes of wash buffer, twice for 10 
minutes each. This is to ensure removal of the β-mercaptoethanol. 
Incubation with the polyclonal rabbit anti-actin primary antibody (Santa Cruz C11 sc-1615-R) 
was performed using the same incubation times and washing steps as for GFAP previously. 
However, the β-actin primary antibody was used at 1:1000 in blocking solution. After 
incubation with the same HRP-tagged secondary antibody as was used for GFAP, the 
membranes were subjected to ECL reagent and film exposure, as previously. 
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6.3.6 NuPAGE SDS-PAGE 
The XCell SureLock Mini-Cell Electrophoresis System (Life Technologies) was used to perform 
Western blots, in conjunction with NuPAGE Novex 4-12% Bis-Tris 1.5mm, 10 well gels (Life 
Technologies). Samples were heated to 70°C for 10 minutes, after which reducing agent was 
added (as in manufacturer’s protocol). Gels were run using MOPS buffer with antioxidant 
(Life Technologies). Samples were run with the Spectra Multicolor Broad Range protein 
ladder (Thermo Scientific), which shows apparent molecular weights of 225, 115, 80, 65, 50, 
35, 30, 25, 15 and 10 kDa when run on this gel system in MOPS buffer. Gels were run for 50 
minutes at 200V, according to the manufacturer’s suggestion. 
6.3.6.1 Blotting to membrane 
Blotting was performed using the XCell II Blot Module (Life Technologies) and self-made 
NuPAGE transfer buffer, consisting of 25mM bicine, 25mM bis-tris, 1mM EDTA (Sigma-
Aldrich), 0.05mM chlorobutanol (Sigma-Aldrich), with 10% methanol (Fisher Scientific). 20% 
methanol was used when running two gels in the same tank, according to the manufacturer’s 
suggestion, to enable sufficient transfer of protein to both membranes. Amersham Hybond-
P PVDF membrane (GE Healthcare) was pre-wetted in methanol for 10 seconds, washed in 
deionised water for five minutes. Phosphate buffered saline (PBS) was made by dissolving 
one PBS tablet (Sigma-Aldrich) in 200ml of deionised water. The PBS composition was 0.01M 
phosphate buffer, 0.0027M potassium chloride and 0.137M sodium chloride at pH 7.4. 
Membranes were equilibrated in PBS with 0.1% Tween 20 (Sigma-Aldrich) for 10 minutes 
prior to transfer. The blot module was set up such that the wetted membrane was placed on 
the anode side of the gel, surrounded by 3MM filter paper (Whatman) and blotting pads, all 
saturated in transfer buffer. The blot module was filled with NuPAGE transfer buffer 
containing antioxidant. Blots were run at 30V for one hour, as suggested by the 
manufacturer. After transfer, membranes were placed between 3MM filter paper 
(Whatman), wrapped in Saran wrap, and stored at 4°C overnight. 
6.3.6.2 Antibody incubations 
GFAP antibody incubation was performed as previously when using self-cast SDS-PAGE gels. 
However, the volume of polyclonal rabbit anti-GFAP primary antibody (Dako Z0334) in 
blocking solution was increased from 2ml to 5ml to ensure complete saturation of the 
membrane. 
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Membrane stripping was also performed as previously, with the incubation time reduced to 
five minutes. β-actin antibody incubation, ECL detection, and film exposure were performed 
identically as previously described. 
6.3.6.3 Quantification of GFAP 
Quantification was performed using image processing software, ImageJ (NIH). The tool 
allows for quantification of gels. This is achieved by analysing rectangular selections of the 
image to allow analysis lane by lane. The intensity of the bands are then converted to a graph, 
displaying peaks of intensity. By using the straight line tool, a line is drawn across the base 
of the peaks, and the wand tool is used to measure the area between the peaks and the 
straight line. The area measured on the GFAP gel image was then divided by the area 
measured from the β-actin image, for each sample. This allowed GFAP levels for each sample 
to be normalised to the β-actin control. 
 
6.4 Results 
 
RNAseq and qPCR are well established techniques for quantification of mRNA. However, for 
protein-coding genes, it is the protein which plays the active functional role, not the RNA. 
Since RNA expression does not always correlate with protein levels, understanding protein 
expression and localisation is vital in ameliorating the physiological changes that occur in the 
hypothalamus in Gnasxlm+/p- mice. Therefore, after identifying a decrease in Gfap by RNAseq 
and qPCR analyses, it was important to investigate whether the same was true of GFAP 
protein and how its expression and localisation is affected in Gnasxlm+/p- mice. 
6.4.1 Using Western blots to quantify GFAP 
 
Western blots serve as a useful method for relative quantification of protein. Using sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels, protein lysates are 
electrophoresed in order to separate protein by molecular weight. Protein samples are 
loaded into wells at the top of the gel with a loading buffer, and an electric current causes 
the protein to migrate through the gel. Much like agarose gel electrophoresis. After 
electrophoresis, the protein is transferred to a membrane that can be incubated with 
antibodies for the purpose of quantification of specific proteins. 
101 
 
There are now improved systems in which to conduct western blots. One of these is the XCell 
II Blot Module (Life Technologies), which uses pre-cast NuPAGE polyacrylamide gels (Life 
Technologies) containing Bis-Tris base. These pre-cast gels have a better reproducibility, 
since every batch is made to the same standard. When preparing standard SDS-PAGE gels, 
there is a greater chance of error which causes the result to be more variable. The NuPAGE 
gel system has the advantage of preventing protein degradation, and produces sharper 
protein bands, which is necessary for accurate quantification. 
Thus, protein lysates were next run on the NuPAGE system. A reducing agent was used this 
time to be able to better quantify the amount of GFAP as a whole. The amount of protein 
loaded was reduced from 10µg to 5µg, because otherwise the intensity of the bands for the 
monomeric proteins would be too high to detect on X-ray film. 
In order to ensure low technical variability and high reducibility, duplicates of four samples 
were run on a NuPAGE 4-12% Bis-Tris Gel of 1.5mm thickness with 10 wells (Life 
Technologies) using MOPS SDS running buffer (Life Technologies). Instead of having a 
stacking gel on top of the resolving gel, this gel has a linear gradient of acrylamide, from 4% 
at the top of the gel, to 12% at the bottom of the gel. This allows for the greatest separation 
of mid-sized proteins, such as GFAP and β-actin which have molecular masses of 50kDa and 
42kDa respectively. 
The results show a varied amount of GFAP between all samples, both for wildtype and 
Gnasxlm+/p- samples (Figure 6.5). In addition, despite using the same wildtype samples as 
previously, distinctly less GFAP was detected for the 152.1 wildtype sample than for the 
152.2 sample. Results from the self-cast gel had suggested that there was a similar amount 
of GFAP between these two wildtype samples. Levels of β-actin were shown to be similar 
across all samples (Figure 6.6). The comparable amount of β-actin between the wildtype 
samples suggest that this was not due to unequal loading (Figure 6.7). 
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Figure 6.5: GFAP levels identified in NuPAGE Western blot of protein lysates from wildtype 
and Gnasxlm+/p- mice 
X-ray image of the Western blot performed on the NuPAGE gel system after incubation with 
anti-GFAP antibody alongside the Fermentas #SM1841 ladder (L). Wildtype = WT; Gnasxlm+/p- 
= KO. Due to a different gel type and electrophoresis buffer, the protein band sizes migrate 
at different paces to the previous gel. Apparent protein band sizes are however provided by 
the manufacturer for various gel and buffer combinations, which are displayed in the figure. 
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Figure 6.6: β-actin levels identified in NuPAGE Western blot of protein lysates from 
wildtype and Gnasxlm+/p- mice 
X-ray image of the Western blot performed on the NuPAGE gel system. Wildtype = WT; 
Gnasxlm+/p- = KO. The membrane was stripped of anti-GFAP antibodies using β-
mercaptoethanol and incubated with anti β-actin antibody. This was run alongside the 
Fermentas #SM1841 ladder (L), and apparent protein sizes are indicated. 
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Figure 6.7: Comparison of GFAP and β-actin levels observed in the NuPAGE Western blot 
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In addition, to ensure a greater statistical power to detect smaller effect sizes, a larger 
number of samples was used across two separate gels. These gels were loaded, 
electrophoresed, and blotted together to reduce error and bias between samples loaded on 
the different gels. In total, hypothalamic lysates from six wildtype mice and eight Gnasxlm+/p- 
mice were run. 
While the results showed a strong signal for GFAP across most samples, three wildtype 
samples that had not been used in the previous Western blot analyses demonstrated 
strikingly low levels of GFAP (Figure 6.8). Crucially, the levels of β-actin were observed to be 
equal across samples. 
In order to quantify the relative levels of GFAP expression, a graphical analysis program, 
ImageJ was used. This tool has a specific function for analysing gel images, and creates an 
intensity graph for each lane. From this, it is possible to draw a line across the base of the 
curve, and use the area underneath the curve as a relative measure of protein levels. In order 
to normalise the samples to the levels of β-actin in each sample, the relative levels of GFAP 
were divided by the relative level of β-actin for each sample. A student’s t test on all samples 
showed a significantly greater level of GFAP in Gnasxlm+/p- hypothalami (P<0.0001). A 
significant increase was still observed when excluding the three wildtype samples 123.2, 
115.1, and 104.2 (P<0.01). However, due to the variability of results observed with the 
Western blot technique on these samples, it would be advisory for further Western blots to 
be performed. This would identify whether the result observed for wildtype samples 123.2, 
115.1, and 104.2 were truly low. Furthermore, if these results are excluded on the basis of 
technical error, only three wildtype samples remain for analysis, which does not provide a 
sound statistical base for analysis. It would also be necessary to have more hypothalamic 
lysates available for analysis, but samples were restricted due to the high perinatal mortality 
of the mice, and the use of the tissues for other purposes, such as sectioning and RNA 
extraction. 
Because GFAP is not expressed universally across the hypothalamus, accurate dissection of 
the hypothalamus is therefore important as it could result in variation of GFAP protein levels 
in whole hypothalamic lysates. 
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Figure 6.8: Combined X-ray images from the NuPAGE Western blots using all available 
lysate samples 
Performed on eight Gnasxlm+/p- hypothalamic protein lysates (KO), and six wildtype (WT) 
samples. Three wildtype samples, 123.2, 115.1, and 104.2 show extremely low GFAP levels. 
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Sample GFAP β-actin GFAP/β-actin 
125.1 KO 21516 6597 3.26 
123.1 KO 19771 6479 3.05 
115.2 KO 18513 8988 2.06 
104.3 KO 23233 8875 2.62 
123.2 WT 2267 8729 0.26 
115.1 WT 593 9217 0.06 
104.2 WT 1662 6128 0.27 
152.2 WT 14014 7043 1.99 
152.1 WT 8311 8086 1.03 
125.4 WT 10204 4530 2.25 
152.5 KO 18764 7288 2.57 
152.4 KO 16770 6427 2.61 
152.3 KO 23199 6799 3.41 
115.3 KO 16622 5933 2.80 
Table 6.1: Relative quantification of protein content observed from ImageJ analysis of 
Figure 6.8 
Numbers represent the areas underneath the curve – relative to the intensity of the gel 
bands. The final column shows the normalised expression of GFAP relative to that of the 
control β-actin. It is these normalised figures that were used for t test analysis. 
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6.4.2 Localisation of GFAP in adult mice 
The hypothalamus contains both glial cells and neurons. In addition, the hypothalamus is a 
complex region of the brain with many subregions with various distinct functions. Therefore, 
although there were conflicting results through Western blot analyses, it may be that 
changes in GFAP levels could be present, but might instead be localised to particular regions.  
Given its functions as an intermediate filament and as a marker of glial cells, it was important 
to investigate whether any changes in GFAP protein levels might be due to fewer Gfap-
expressing cells in the hypothalamus, or due to a decreased expression of GFAP within cells. 
Firstly, we wanted to investigate whether there were any differences in the localisation of 
GFAP within the hypothalamus. 
To visualise the localisation and intensity of GFAP levels in the mouse hypothalamus, slides 
of coronal hypothalamus sections from Gnasxlm+/p- mice and wildtype mice were subjected 
to immunofluorescence. Slides were incubated with a rabbit anti-GFAP primary antibody 
(Dako Z0334). This primary antibody is able to bind to all GFAP isoforms (Kamphuis et al., 
2012). Donkey anti-rabbit Alexa488-tagged secondary antibody (Jackson ImmunoResearch) 
was used and the fluorescence was analysed by epifluorescence microscopy.  Alexa488 is a 
fluorescent dye that absorbs light at wavelength 495nm and emits at 519nm. This was 
counter-stained with DAPI, a fluorescent compound that is able to bind to the minor groove 
within DNA. This emits light at 461nm and results in staining of the nuclei of cells. It is used 
as a control, but also to be able to visualise the structures within the tissue. In particular, in 
the hypothalamus, densely packed nuclei such as the SCN and the PVN are easily identified 
by the high density of cells. 
 
6.4.2.1 Ependymal cells 
 
Ependymal cells are a type of glial cell which line the edge of the brain surfaces. They line the 
surface that is in contact with cerebrospinal fluid, which they are able to produce, and absorb 
using microvilli on their surface. The ependymal cells show a high expression of GFAP in both 
wildtype mice and Gnasxlm+/p- mice (Figure 6.9). This appears as a bright green fluorescence 
coating the peripheral layer of the brain. Intensity of fluorescence against GFAP appears to 
be no different for ependymal cells between wildtype and Gnasxlm+/p- mice. 
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Figure 6.9: Immunofluorescence of the ventral side of the hypothalamus at the SCN of a 
wildtype and knockout Gnasxlm+/p- mice 
Coronal sections of mice hypothalami at -0.70mm bregma at 10X magnification. Sections 
were stained for GFAP (green) and DAPI (blue). A. Wildtype B. Gnasxlm+/p-. Ependymal cells, 
around the periphery of the brain surface widely express GFAP.  
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6.4.2.2 Tanycytes 
 
The hypothalamus is characterised by the third ventricle, which is filled with cerebrospinal 
fluid and runs through the core of the hypothalamus. The third ventricle is lined with 
tanycyte cells, which are characterised by their elongated morphology, with extensive 
projections directing away from the third ventricle to other regions of the hypothalamus. 
Towards the middle and the dorsal end of the third ventricle, α1-type tanycytes are found, 
which project towards the DMH and the VMH. Towards the ventral end of the third ventricle, 
α2 tanycytes are found in the Arc with extensive projections towards the VMH. β1 and β2 
tanycytes are found in the median eminence region, on the ventral edge of the hypothalamus 
by the Arc. 
Surrounding the middle of the third ventricle, it is possible to observe the various types of 
GFAP-expressing cells in wildtype brains (Figure 6.10). Tanycytes line the third ventricle, with 
projections directing outwards towards the DMH. In addition, it is possible to observe the 
star-like morphology of GFAP-expressing astrocytes further away from the third ventricle. 
Upon using greater magnification, the tanycyte projections can be seen more clearly 
emanating perpendicularly to the third ventricle lining (Figure 6.11). 
In addition, astrocytes are present further laterally from the third ventricle, in the DMH 
region of the hypothalamus (Figure 6.10). These cells are distributed amongst the neurons 
within the hypothalamus. This is typical of these types of glial cells, which help to maintain 
the chemical environment and modulate synaptic functions of neurons. 
In the Gnasxlm+/p- mice, there is a distinct loss of GFAP around the centre of the third ventricle 
at bregma -1.70mm. Although GFAP-expressing cells are present, the expression levels are 
very much decreased (Figure 6.12). Using a greater exposure time, it is possible to identify 
the tanycytes surrounding the third ventricle in Gnasxlm+/p- mice (Figure 6.12). The structures 
of the tanycytes are very similar to those seen in wildtype mice, suggesting that it is 
representative of an underexpression of GFAP (Figure 6.11, arrowhead). In addition, the 
tanycytes still project towards the DMH, although there is a clear reduction in GFAP 
immunofluorescence from these cells (Figure 6.12). Towards the DMH, there is a distinct loss 
of the astrocytes that characterised this region in the wildtype animals (Figure 6.10, 
arrowhead). 
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Figure 6.10: Immunofluorescence of the 3V of wildtype and Gnasxlm+/p- mice 
Coronal sections of a wildtype mouse and Gnasxlm+/p- mouse brain at bregma -1.70mm at 10X 
magnification. The ventral side of the brain is located to the bottom left of the photographs. 
Sections were stained for GFAP (green) and DAPI (blue). A. Wildtype mouse. B. Gnasxlm+/p- 
mouse. Arrowhead: astrocytic-like cell in the DMH 
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Figure 6.11: Immunofluorescence of the 3V of a wildtype mouse at greater magnification 
Photograph taken at bregma -1.70mm at 40X magnification. The ventral side of the brain is 
located to the bottom left of the photograph. Sections were stained for GFAP (green) and 
DAPI (blue). Arrowhead: tanycyte projection from the wall of the 3V. 
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Figure 6.12: Immunofluorescence of the 3V from a coronal section of a Gnasxlm+/p- mouse 
Section cut at bregma -1.70mm at 40X magnification. Sections were stained for GFAP (green) 
and DAPI (blue). Exposure time to GFAP was doubled in order to show the structures more 
clearly. 
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In one of the Gnasxlm+/p- mice, an apparent rupture of the third ventricle was identified 
towards the dorsal side (Figure 6.13). The lining of the third ventricle appears to have been 
torn, and cells expressing GFAP have migrated into the third ventricle space, likely as a 
response to the damage. This is typical of a glial scar formation, whereby astrocytes 
proliferate into regions of damage. Expression of Gfap is increased in the astrocytes in order 
to extend their processes and change their morphology to respond to the damage. The 
mouse was healthy when anaesthetised and killed and did not seem to cause any pathology. 
In addition, GFAP expression patterns in this mouse in the hypothalamus did not deviate 
from those seen in other Gnasxlm+/p- mice. This is the first time that such a phenomenon has 
been identified in Gnasxlm+/p- mice, although it is not yet known whether this is related to its 
genetic background.  
6.4.2.3 Arcuate nucleus 
 
GFAP levels increase towards the ventral side of the third ventricle, where it is surrounded 
by the Arc. At this region, the third ventricle becomes wider, allowing access to the 
cerebrospinal fluid by the cells of the Arc. Surrounding the third ventricle within the Arc, 
tanycytes send out extensive projections towards the VMH.  
Adult mouse brain sections were analysed for GFAP by immunofluorescence, in order to 
ascertain whether there were any changes in GFAP levels and its localisation within the Arc. 
Three animals of wildtype and three Gnasxlm+/p- mice were analysed. The Arc is identified by 
the slightly denser clustering of cells around the base of the third ventricle at bregma -
1.70mm. This can be observed using DAPI staining of cell nuclei to identify the region. 
Wildtype adult mice show an intense expression of GFAP within the Arc at either side of the 
base of the third ventricle. The cell morphology is typical of tanycyte cells that populate the 
third ventricle wall. Within the Arc, these cells show their longest projections, which direct 
towards the VMH (Figure 6.14). Astrocytic-like cells can be observed just outside the Arc, 
within the VMH (Figure 6.14). 
In addition, the median eminence region, located ventrally to the third ventricle, alongside 
the Arc at bregma -1.70mm, also widely expresses GFAP in wildtype mice (Figure 6.14). 
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Figure 6.13: Immunofluorescence of the 3V of a Gnasxlm+/p- mouse showing signs of 
astrogliosis 
Immunofluorescence of the ruptured third ventricle of the hypothalamus of a 14µm-thick 
coronal section of a Gnasxlm+/p- mouse brain at 10X magnification. Sections were stained for 
GFAP (green) and DAPI (blue). 
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Figure 6.14: Immunofluorescence of three adult wildtype mice showing the 3V and the Arc 
Immunofluorescence of the Arc of the hypothalamus of a 14µm-thick coronal sections from 
three wildtype mice at bregma -1.70mm 10X magnification. Sections were stained for GFAP 
(green) and DAPI (blue). See Figure 6.3 for schematic diagram. 
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Figure 6.15: Immunofluorescence of three adult Gnasxlm+/p- mice showing the 3V and the 
Arc 
Immunofluorescence of the Arc from three Gnasxlm+/p- mice at bregma -1.70mm at 10X 
magnification. Sections were stained for GFAP (green) and DAPI (blue). See Figure 6.3 for 
schematic diagram. 
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Gnasxlm+/p- mice have a much reduced amount of GFAP within the Arc and surrounding 
regions (Figure 6.15). Although tanycyte structures show a similar morphology to wildtype, 
there appear to be fewer tanycyte cells expressing GFAP in this region, and tanycyte 
projections also appear to be reduced. However due to their long projections, it is not easy 
to distinguish cells from one another using immunofluorescence in order to be able to count 
cell numbers. Noticeably, GFAP appears to be more restricted to regions close to the third 
ventricle than is observed in wildtype animals, where expression of GFAP extends towards 
the VMH (Figure 6.14). Tanycyte projections appear shorter, and fluorescence is reduced 
overall in the Arc in Gnasxlm+/p- mice. 
Upon increasing the exposure time, the tanycyte projections can be seen more clearly for 
one of the knockout mice, indicating that the cell projections do exist, but that the 
distribution of GFAP is less intense than in wildtype mice. 
6.4.2.4 Suprachiasmatic nucleus 
 
Anterior to the Arc, the SCN is another region of great importance within the hypothalamus. 
It consists of a small collection of cells adjacent to the third ventricle and is located directly 
above the optic chiasm. The SCN is responsible for the regulation of the circadian rhythm. 
Recently, it has been identified that astrocytes in the SCN play an important role in regulating 
the circadian rhythm. 
In adult wildtype mice, immunofluorescence shows GFAP expression distributed throughout 
the SCN (Figure 6.16). The morphologies of the glial cells are astrocytic, which are very 
populous within the nuclei and are distributed evenly.  
On the other hand, Gnasxlm+/p- mice show a reduced amount of GFAP within the SCN, with 
few astrocytes in the nuclei or within the surrounding regions. However, the ependymal cells 
of this region maintain their GFAP expression 
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Figure 6.16: Immunofluorescence of three adult wildtype mice showing the SCN 
Immunofluorescence of the SCN of the hypothalamus of a 14µm-thick coronal sections from 
three wildtype mice at bregma -0.70mm at 10X magnification. Sections were stained for 
GFAP (green) and DAPI (blue). 
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Figure 6.17: Immunofluorescence of three adult Gnasxlm+/p- mice showing the SCN 
Immunofluorescence of the SCN of the hypothalamus of a 14µm-thick coronal sections from 
three Gnasxlm+/p- mice at bregma -0.70mm at 10X magnification. Sections were stained for 
GFAP (green) and DAPI (blue). 
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6.4.3 Localisation of GFAP in neonatal mice 
 
After identifying changes in GFAP in adult mice, we were keen to understand changes during 
development. In particular, it was not clear whether these changes were an adaptation to 
chronic undernutrition, or whether there was a disruption during development that was 
driving these brain changes in the adults. 
In order to further understand the patterns of GFAP expression in the hypothalamus, we 
chose to investigate how this patterning occurs during postnatal development. In particular, 
it was not clear whether the lack of GFAP observed in adults was due to a response to chronic 
undernutrition, or whether there might be a developmental problem leading to an 
insufficient glial population within the hypothalamus in adults. To investigate this, breeding 
pairs were established to create new litters for study. 
Littermates were housed together and sacrificed at the same time. The first litter pair was 
sacrificed at postnatal day 1 (P1), and a second litter pair was sacrificed at postnatal day 5 
(P5). Litter size was restricted by the high death rate of Gnasxlm+/p- mice during the early 
postnatal stages. 
The progenitor cells of glia begin in the neural tube during embryonic development. Sonic 
hedgehog (SHH) is secreted from the notochord and the floor plate of the neural tube, and 
its antagonist bone morphogenic protein (BMP) is secreted from the roof plate. This creates 
a morphogen gradient that allows cells to differentiate into different types of cells depending 
on their location and how much SHH they receive (Ingham and Placzek, 2006). This is critical 
in patterning the neural tube to direct the differentiation of cells into different cell types. 
Cells that express Shh early in development, prior to embryonic day 9.5 (E9.5), go on to 
produce neurons, tanycytes, and astrocytes towards the posterior regions of the 
hypothalamus, including the Arc and ME (Alvarez-Bolado et al., 2012). Cells expressing Shh 
after E9.5 and before E12.5 give rise to neurons and astrocytes within the tuberal central 
region of the hypothalamus, particularly within the VMH and DMH. After E12.5, nearly all 
Shh-expressing cells contribute hypothalamic astrocytes, representing a developmental 
change from neurogenesis to gliogenesis (Alvarez-Bolado et al., 2012). 
Gliogenesis is a process by which the glial cells differentiate. Unlike neurogenesis, which 
occurs prior to birth in rodents, gliogenesis continues postnatally in the first two to three 
weeks of life. In humans, gliogenesis occurs during the third trimester of pregnancy. 
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While GFAP is only expressed in glial cells, during gliogenesis radial glia are able to divide 
asymmetrically to produce new neuronal precursors. During the early stages of gliogenesis, 
expression of GFAP is not only representative of differentiated glial cells, but also of 
expression within these radial glia 
During development in the subgranular zone within the hippocampus has an important role 
in neurogenesis. In particular, radial glial cells act as a scaffold for new neurons to migrate to 
the granule cell layer. Radial glial cells can divide asymmetrically to produce a new stem cell, 
and a neuronal precursor cell. They also express GFAP, since they are a subset of astrocyte 
cells. Immunofluorescence of GFAP appeared very strongly in the hippocampus of wildtype 
mice where these radial glial cells are known to be present (Figure 6.18). 
During P1, GFAP expression was observed in the wildtype hypothalamus by 
immunofluorescence, although at a lower level to that seen in wildtype adult mice (Figure 
6.19). Since gliogenesis occurs mainly postnatally, and since pup weaning and feeding during 
early life are known to have important consequences on brain development, this region has 
not yet fully developed and GFAP-expressing cells are still developing in these regions at P1. 
Limitations of sample size made it difficult to identify whether there was a difference in GFAP 
between wildtype and Gnasxlm+/p- mice at P1 stage. However, GFAP was observed in the Arc 
of Gnasxlm+/p- P1 mice. It was possible to see the tanycyte projections extending from the 
third ventricle (Figure 6.20), and that the projections are quite extensive (Figure 6.21). 
Furthermore, on closer inspection, a large collection of cells resembling astrocytes were 
observed towards the periphery of the hypothalamus, around the ME region (Figure 6.22). 
This leads to the suggestion that gliogenesis does not appear to be inhibited at the P1 stage 
in Gnasxlm+/p- P1 mice. 
At the PVN, GFAP-expressing cells are observed stretching from the PVN across to the lateral 
hypothalamus close to the zona incerta (Figure 6.23). The same phenomenon is observed in 
Gnasxlm+/p- mice (Figure 6.24). These projections are not observed in this region in adult mice, 
and may be glial cells migrating towards the hypothalamus during the early stages of 
gliogenesis. By P5, the expression of GFAP appeared more intense, both for wildtype mice 
and for Gnasxlm+/p- mice (Figures 6.25, 6.26). However, there is no discernible difference 
between the expression observed in wildtype mice and for Gnasxlm+/p- mice in the PVN at P5. 
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Figure 6.18: Immunofluorescence of the hippocampus of a P1 wildtype mouse 
Immunofluorescence of the hippocampus of a 14µm-thick coronal sections of a wildtype 
mouse at P1 at 10X magnification. Sections were stained for GFAP (green) and DAPI (blue). 
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Figure 6.19: Immunofluorescence of the Arc of a P1 wildtype mouse 
 Immunofluorescence of the arcuate nucleus of the hypothalamus of a 14µm-thick coronal 
section of a wildtype mouse at P1 at 10X magnification. Sections were stained for GFAP 
(green) and DAPI (blue). 
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Figure 6.20: Immunofluorescence of the Arc of a P1 Gnasxlm+/p- mouse 
 Immunofluorescence of the arcuate nucleus of the hypothalamus of a 14µm-thick coronal 
section of a Gnasxlm+/p- mouse at P1 at 10X magnification. Sections were stained for GFAP 
(green) and DAPI (blue). 
126 
 
 
Figure 6.21: Immunofluorescence of the Arc of a P1 Gnasxlm+/p- mouse at greater 
magnification 
 Immunofluorescence of the arcuate nucleus of the hypothalamus of a 14µm-thick coronal 
section of a Gnasxlm+/p- mouse at P1 at 40X magnification. Sections were stained for GFAP 
(green) and DAPI (blue). 
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Figure 6.22: Immunofluorescence of the ME of a P1 Gnasxlm+/p- mouse  
Immunofluorescence of the median eminence of the hypothalamus of a 14µm-thick coronal 
section of a Gnasxlm+/p- mouse at P1 at 40X magnification. Sections were stained for GFAP 
(green) and DAPI (blue). 
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Figure 6.23: Immunofluorescence of the PVN of a P1 wildtype mouse 
 Immunofluorescence of the paraventricular nucleus of the hypothalamus of a 14µm-thick 
coronal section of a wildtype mouse at P1 at 10X magnification. Sections were stained for 
GFAP (green) and DAPI (blue). 
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Figure 6.24: Immunofluorescence of the PVN of a P1 Gnasxlm+/p- mouse 
Immunofluorescence of the paraventricular nucleus of the hypothalamus of a 14µm-thick 
coronal section of a Gnasxlm+/p- mouse at P1 at 10X magnification. Sections were stained for 
GFAP (green) and DAPI (blue). 
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Figure 6.25: Immunofluorescence of the PVN of a P5 wildtype mouse  
Immunofluorescence of the paraventricular nucleus of the hypothalamus of a 14µm-thick 
coronal section of a wildtype mouse at P5 at 10X magnification. Sections were stained for 
GFAP (green) and DAPI (blue). 
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Figure 6.26: Immunofluorescence of the PVN of a P5 Gnasxlm+/p- mouse 
Immunofluorescence of the paraventricular nucleus of the hypothalamus of a 14µm-thick 
coronal section of a Gnasxlm+/p- mouse at P5 at 10X magnification. Sections were stained for 
GFAP (green) and DAPI (blue). 
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Expression of GFAP in the Arc of P5 mice was limited in both wildtype and Gnasxlm+/p- mice 
(Figures 6.27 and 6.28). Expression surrounding the third ventricle was very much limited to 
the Arc, with very limited expression observed further up the third ventricle, in both genetic 
backgrounds. 
In the SCN of P5 wildtype mice, very little expression of GFAP was observed (Figure 6.29). 
This is in contrast to the observation in adult wildtype mice that expression of GFAP is 
widespread in the SCN (Figure 6.16). Some expression of GFAP is observed around the third 
ventricle of this region, although the morphology of the projections appear more typical of 
the cells surrounding the third ventricle at the Arc, than those observed around the third 
ventricle near the SCN in adult mice. These observations suggest that the glial cells in this 
region are still developing, and that the cells may not have established themselves within the 
SCN at P5. 
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Figure 6.27: Immunofluorescence of the Arc of a P5 wildtype mouse  
Immunofluorescence of the arcuate nucleus of the hypothalamus of a 14µm-thick coronal 
section of a wildtype mouse at P5 at 10X magnification. Sections were stained for GFAP 
(green) and DAPI (blue). 
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Figure 6.28: Immunofluorescence of the Arc of a P5 Gnasxlm+/p- mouse 
Immunofluorescence of the arcuate nucleus of the hypothalamus of a 14µm-thick coronal 
section of a Gnasxlm+/p-  mouse at P5 at 10X magnification. Sections were stained for GFAP 
(green) and DAPI (blue). 
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Figure 6.29: Immunofluorescence of the SCN of a P5 wildtype mouse 
Immunofluorescence of the suprachiasmatic nucleus of the hypothalamus of a 14µm-thick 
coronal section of a wildtype mouse at P5 at 10X magnification. Sections were stained for 
GFAP (green) and DAPI (blue). 
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6.5 Discussion 
 
Gfap was identified as being consistently downregulated two-fold in Gnasxlm+/p- mice in both 
the RNAseq and qPCR analyses. However, since mRNA levels do not always correlate with 
protein levels, we decided to analyse GFAP protein in the hypothalamus. 
Western blot analyses were fairly inconclusive. Blots run on self-cast SDS-PAGE gels showed 
poorly defined bands compared to the NuPAGE SDS-PAGE Gel System (Life Technologies) 
(Figure 6.5, Figure 6.9).  In particular for wildtype animals, a high degree of variability in the 
samples was observed (Figures 6.5, 6.6, 6.7, 6.8). Repeat experiments of the Western blots 
are advisable, due to the variability observed from blot to blot and the unexplained nature 
of three new wildtype samples, 123.2, 115.1, and 104.2 (Figure 6.9). Because these three 
samples had not been run on previous SDS-PAGE gels, it is not clear whether these samples 
truly have a dramatic loss of GFAP in hypothalamus lysates, or whether it was due to 
technical error. 
The identification of both H6pd and Hsd11b1 being upregulated 4-fold is particularly 
interesting due to their close functional connection in driving the activation of 
deoxycorticosterone into the active glucocorticoid corticosterone. Corticosterone is a 
glucocorticoid hormone that is produced in the adrenal glands and has a wide range of 
functions, including immune and stress responses, as well as energy regulation (Groeneweg 
et al., 2011). Corticosterone acts to inhibit the release of Corticotropin-releasing hormone 
(CRH), which is released from the PVN in response to stress. In particular, it is able to 
stimulate the action of POMC neurons, which act to reduce appetite. After release, CRH 
travels to the ME of the hypothalamus and then to the pituitary gland. Here, it stimulates 
corticotropic cells to produce adenocorticotropic hormone (ACTH). In turn, ACTH stimulates 
the production of corticosterone, creating a feedback loop (Bonfiglio et al., 2011). This forms 
the basis of the Hypothalamic-pituitary-adrenal (HPA) axis. 
If corticosterone levels are elevated by the increased expression of H6pd and Hsd11b1, then 
this would act to suppress CRH. This could result in a reduced activation of POMC neurons 
by CRH, and therefore a reduction in its suppressive effects on appetite. Due to a reduction 
in CRH, ACTH may also be reduced, leading to less activation of corticosterone – allowing for 
only a moderate increase in corticosterone to be maintained. Gnasxlm+/p- mice show a modest 
increase in corticosterone levels, although this was not significant (Xie et al., 2006). It would 
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be interesting to see whether corticosterone levels are increased in a larger sample size of 
Gnasxlm+/p- mice, and to see whether CRH levels are reduced. 
Importantly, corticosterone acts on neurons in the PVN by promoting the release of GABA 
and inhibiting the release of glutamate. The release of the inhibitory neurotransmitter GABA 
is mediated by the G protein βγ subunits, whereas preventing the release of the excitation 
neurotransmitter glutamate is regulated by Gαs (Di et al., 2005; Di et al., 2009). As an 
inhibitory neurotransmitter, GABA acts to suppress the action of POMC neurons in the PVN, 
promoting orexigenic effects.  
Furthermore, Gαs is also known to couple to the CRH receptor (CRHR) to instigate 
downstream cAMP signalling to activate POMC expression (Bonfiglio et al., 2011; Hillhouse 
and Grammatopoulos, 2013). Whether XLαs has a role in this mechanism is not known. In 
vitro, XLαs is able to induce more sustained signalling due to its membrane anchoring (Liu et 
al., 2011). Therefore XLαs-coupled signalling could have wide implications in the feedback 
mechanism of the HPA axis. It would be interesting to know whether XLαs is able to facilitate 
the signalling cascade in response to corticosterone, or whether it is able to couple to CRHR 
like Gαs. 
 
MC4R-/- mice are a genetic model of obesity. The lack of MC4R prevents the action of the 
inhibitory effects of POMC neurons on feeding and appetite – essentially shutting down the 
feedback mechanism, leading to overfeeding and weight gain. MC4R-/- mice display 
heightened levels of GFAP within the hypothalamus, particularly in the DMH and Arc, but 
also in the VMH and LH (Hsuchou et al., 2009; Buckman et al., 2013).  
Conversely, Gnasxlm+/p-  mice have an overactive SNS (Xie et al., 2006), which burns through 
the calories that the mice consume. Despite consuming more food, the mice remain small 
and lean and show similarities to chronic undernutrition (Plagge et al., 2004). It is therefore 
a parallel finding that immunofluorescence analysis suggests that Gnasxlm+/p-  mice show a 
distinct loss of GFAP within the hypothalamus, particularly within the Arc, DMH, and SCN. 
Using an inducible knockout driven by Gfap, the leptin receptor LepR was knocked out 
specifically in Gfap-expressing cells. Interestingly, the team identified that while the number 
of Gfap-expressing cells did not change, the number of cell projections, and the length of the 
projections were significantly decreased (Kim et al., 2014). Because the Gfap-expressing cells 
are unable to respond to leptin, food intake is significantly increased. 
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Collectively, it is hypothesised that leptin action on Gfap-expressing cells in the 
hypothalamus may instigate morphological changes in tanycytes and astrocytes. Given the 
extremely low leptin levels in Gnasxlm+/p-  mice (Xie et al., 2006), it may be that this leptin-
induced change does not occur to the same degree, and renders the hypothalamic glial cells 
smaller and with shorter projections. 
In order to investigate whether there was a developmental problem causing a decrease in 
GFAP observed by immunofluorescence, early postnatal stages were analysed for GFAP 
levels in the hypothalamus. At P1 and P5 postnatal stages, no inhibition of gliogenesis was 
observed, with GFAP immunofluorescence within the hypothalamus appearing more or less 
the same for both wildtype and Gnasxlm+/p-  mice. By P5, most differentiation of astrocytes 
has occurred (Sauvageot, 2002), which account for most of the glial cells in the 
hypothalamus. However, astrocytes are still migrating at this stage (Jacobsen and Miller, 
2003). In addition, since gliogenesis continues for several weeks after birth, it would be 
interesting to identify at what stage Gnasxlm+/p-  mice begin to show changes in GFAP levels 
and localisation within the hypothalamus. Unfortunately, due to time constraints of the 
project, it was not possible to study mice beyond P5. In addition, since immunofluorescence 
is not entirely quantitative, cell count experiments would help to identify whether the 
number of GFAP-positive cells is altered in Gnasxlm+/p-  mice. Because of the morphology of 
astrocytes and tanycytes, it was difficult to distinguish cells from one another to provide this 
analysis. This can be achieved using the VectaStain ABC Kit protocol (Vector Laboratories). 
After binding of the anti-GFAP primary antibody to slide sections, a biotinylated secondary 
antibody is added, which has a high affinity for HRP-tagged Activin. After providing the 
VectaStain substrate, a brown stain appears identifying GFAP-positive cells. These can then 
be counted under light microscopy to identify any changes in GFAP-positive cell numbers in 
Gnasxlm+/p-  mice. 
 
The hypothalamus effects responses to various hormones. In female rats, a diurnal rhythm 
of Gfap in the SCN was identified that was enhanced upon treatment with estradiol 
benzoate, a synthetic form of the female hormone oestrogen (Fernandez-Galaz et al., 1999). 
The Arc responds to hormonal levels during the ovarian cycle, resulting in an increase in glial 
cell coverage, which acts to limit the action of the inhibitory GABAergic neurons (Garcia-
Segura et al., 2008). For the purposes of our study, only male mice were used for RNAseq 
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and downstream analyses. Furthermore, littermates were sacrificed at similar times during 
the day, minimising the chance of expression changes. 
During puberty, hormones such as testosterone and oestrogen act on glial cells within 
hypothalamus, in regions such as the SCN, Arc, and ME in order to regulate the production 
of gonadotropin-releasing hormone (GnRH) (Garcia-Segura et al., 2008). GnRH acts to 
stimulate the release of follicle-stimulating hormone and luteinizing hormone, which act to 
regulate testosterone production in males, and oestrogen production in females. 
Glial cells have been implicated to have important roles within the SCN – the regulator of the 
circadian rhythm (Prosser et al., 1994). More recently it was identified that vesicle trafficking 
and calcium signalling within SCN astrocytes is crucial for glial cells to be able to modulate 
circadian rhythm activity (Ng et al., 2011). 
Immunofluorescence analysis of the SCN suggested a distinct loss of glial cells within the SCN 
of Gnasxlm+/p- mice. No circadian rhythm abnormalities have been identified in Gnasxlm+/p- 
mice, although recent evidence points towards heart rate being significantly increased 
during the night (Nunn et al., 2013). However, it would be interesting to investigate whether 
the circadian rhythm of Gnasxlm+/p- mice is disrupted, particularly in adult mice by which time 
the differences in glial cell populations in the SCN are different. 
 
Our results suggest that Gnasxlm+/p- mice show a distinct loss of GFAP within the Arc, and SCN. 
We find no evidence that gliogenesis is disrupted up to P5, whereby much of the astrocytic 
differentiation has already occurred. This suggests that the loss of GFAP in the hypothalami 
of Gnasxlm+/p- mice is unlikely to be a developmental disruption. Given the evidence linking 
the action of leptin to the morphology of Gfap-expressing cells in the hypothalamus (Kim et 
al., 2014), it is a more likely proposition that the loss of GFAP is due to the chronic 
undernutrition experienced by that Gnasxlm+/p- mice as a result of an overactive SNS. 
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Chapter 7: Discussion 
 
In this study, we have used transcriptomic approaches to develop a better understanding of 
the complex biological phenomena of ageing and metabolism. 
Using qPCR, it was possible to confirm the relative transcriptional level of genes in the NMR. 
Compared to mice, these genes were shown to be overexpressed. Since gene expression 
levels tend to be conserved between relatively distantly related species such as mice and 
humans (Zheng-Bradley et al., 2010), it is likely that such changes in expression between 
orthologous genes of closely related species may not be widespread. Therefore the genes 
identified could be relevant foci for future research into the interesting phenotypes of the 
NMR. 
Further to qPCR analysis, the use of RNAseq analysis was widely employed in this study. Using 
SOLiD RNAseq combined with mismatch analysis, it was possible to identify Cog3 as a 
conserved target of RNA editing in the rat. However, the finding that RNA editing does not 
decline in rat cerebral cortex is interesting, since this does occur in humans (Nicholas et al., 
2010). This disparity between RNA editing decline in rats and humans highlights the 
important differences between humans, and their rodent model counterparts. In particular, 
there are differences in physiology, disease susceptibility, population demographics, and in 
their genetic responses to inflammation (Demetrius, 2005; Seok et al., 2013). Since rodent 
models are used to study ageing, it is important to understand how species differences in 
biological processes may affect the ageing process between species. 
The development of new technologies, such as Digital Droplet (dd)PCR (Bio-Rad) (Hindson et 
al., 2011; Hindson et al., 2013) may provide new methods for RNA editing quantification. This 
technology splits the PCR reaction into around 20000 separate droplets. Some droplets will 
contain the target cDNA, and the proportion that do can be used for quantification. A recent 
study was able to use ddPCR to identify SNPs, demonstrating its practicality (Mukaide et al., 
2014). 
Using Illumina RNAseq, it was possible to identify gene expression changes within the 
hypothalami of Gnasxlm+/p- mice. Bioinformatic analysis highlighted a downregulation in Gfap 
RNA expression within the hypothalamus. After analysing GFAP protein expression by 
immunofluorescence, we were able to identify a loss of GFAP expression within 
hypothalamic regions, including the Arc and the SCN. No differences between wildtype and 
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Gnasxlm+/p- mice were observed during P1 and P5 stages. However, because these are still 
early stages of gliogenesis, it would be important to look at later stages of development (P10, 
P15, P20) in order to characterise when the difference in GFAP localisation arises. Our results 
suggest that the observed changes in GFAP expression are unlikely to be a disruption during 
early gliogenesis. The changes are more likely to be an adaptive response to chronic 
undernutrition that manifests itself in neonatal mice, a time in which the mice develop 
problems with suckling ability (Xie et al., 2006). 
One of the main challenges with performing RNAseq on the hypothalamus was that as a 
complex region of the brain, there are many distinct but small nuclei that have diverse 
biological roles. Due to time constraints and financial costs, it was not possible to dissect out 
each nuclei and identify gene expression changes in the separate nuclei independently. 
However, this could be achieved using laser microdissection (Solga et al., 2015) in order to 
separate cell types from nuclei such as the Arc. 
Standard RNAseq performed across a tissue has its own limitations. Across the 
hypothalamus, the various nuclei and cell types pose a challenge in identifying whether gene 
expression changes are as a result of decreased expression in cells, or a reduction in the 
number of cells. As technologies improve, single cell RNAseq is becoming more common. 
Techniques such as these have the benefit of being able to identify gene expression changes 
within a single cell. Combined with laser microdissection, single cell RNAseq may provide a 
basis for research into gene expression changes within distinct cell populations, such as the 
tanycytes 
Recent advances have allowed the development of a technique that removes lipids from 
brain tissue, rendering it transparent. Using this technique, a new imaging method called 
CLARITY was developed whereby it is possible to perform immunofluorescence within the 
whole intact 3D mouse brain (Chung et al., 2013). The authors also performed 
immunofluorescence of Gfap. Rather than analysing sections of the mouse brain, as was 
performed in this project, in future it may be possible for expression patterns within tissues 
to be imaged and analysed across the whole tissue. 
This project highlights the importance of new sequencing technologies in identifying gene 
expression changes. With the advent of new technologies, the amount of sequencing data 
being produced is increasing rapidly. Techniques such as RNAseq are not only generating 
more data and becoming more widespread, but costs are constantly falling. Furthermore, 
combining this with other advanced techniques has expanded the potential of RNAseq in 
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research. The continuing development of bioinformatic tools for gene expression analysis 
has great potential for identifying biologically relevant genetic changes. Consequently, 
transcriptomic analysis has a huge potential in directing future research, particularly in 
respect to complex research areas such as ageing and metabolism. 
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Appendices 
 
 6 month old samples 
Target 8883F 8884F 8885F 8886R 8886F 8887R 8887F 8888F STDEV Mean 
Gabra3 92.75 94.69     93.02   93.92 91.54 1.20 93.18 
Cyfip2 88.32 88.44 90.93  88.39  89.23  1.10 89.06 
Kcna1 22.31 25.76 27.80  37.21  31.91 22.27 5.84 27.87 
Flna 21.15  25.91 28.18 24.71 26.11 23.77 21.32 2.58 24.45 
Cog3 27.71 25.39   26.56  24.86 22.11 2.11 25.32 
Blcap Y/C 46.59 44.33 39.73 38.69 41.70 35.09 36.57 41.97 3.85 40.58 
Blcap Q/R 27.14 25.45 22.68 29.20 23.88 26.72 19.65 23.57 2.98 24.79 
Blcap K/R 10.31 9.85 6.97   9.12   6.53 9.03 1.54 8.64 
 
Appendix Table 1: Percentages of RNA editing identified in cerebral cortex from 6-month-old rats 
F in the sample name indicates that it was sequenced using the forward primer, as given in Table 2.2. Conversely, R indicates it was sequenced using the 
reverse primer. 
 
 
 
 
 
 
 1
4
4
 
 
 12 month old samples 
Target 8910F 8911R 8911F 8912F 8913R 8913F 8914F 8915F STDEV Mean 
Gabra3 94.35   91.59 91.72   93.30 93.09 92.24 1.06 92.71 
Cyfip2 90.70  86.27 83.01  89.02 86.42 90.23 2.92 87.61 
Kcna1    18.18 22.43  23.10 27.07 30.60 4.74 24.28 
Flna 31.03 24.07 24.81 33.94 25.97 25.76 29.84 32.56 3.81 28.50 
Cog3 21.60  24.23   24.92 26.67 20.00 2.67 23.48 
Blcap Y/C 40.61 40.37 43.97 45.06 41.07 41.93 32.11 38.89 3.93 40.50 
Blcap Q/R 22.43 30.71 24.20 27.51 31.94 22.80 20.18 20.92 4.45 25.09 
Blcap K/R 6.95   9.65 10.63   8.90 8.80 7.12 1.43 8.67 
 
Appendix Table 2: Percentages of RNA editing identified in cerebral cortex from 12-month-old rats 
F in the sample name indicates that it was sequenced using the forward primer, as given in Table 2.2. Conversely, R indicates it was sequenced using the 
reverse primer. 
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 28 month old samples 
Target 8773R 8773F 8774F 8776F 8777R 8777F 8778F 8780F STDEV Mean 
Gabra3   92.34 92.35 92.65   95.45     1.51 93.20 
Cyfip2   86.04 88.31 87.58  89.30 87.27 89.57 1.33 88.01 
Kcna1   20.44 27.68 23.05  35.88 34.50 36.92 7.04 29.74 
Flna 26.02 24.90 23.26 26.04 29.41  27.41 28.25 2.08 26.47 
Cog3   24.85  26.67  27.54 24.91 16.87 4.24 24.17 
Blcap Y/C 41.08 43.33 41.85 43.81 37.65 39.96 41.38 35.11 2.91 40.52 
Blcap Q/R 31.20 24.73 24.54 25.65 28.78 20.94 24.07 18.21 4.08 24.77 
Blcap K/R   9.84 9.70 9.91   7.65 10.98 6.20 1.77 9.04 
 
Appendix Table 3: Percentages of RNA editing identified in cerebral cortex from 28-month-old rats 
F in the sample name indicates that it was sequenced using the forward primer, as given in Table 2.2. Conversely, R indicates it was sequenced using the 
reverse primer. 
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 One way ANOVA between ages 
Target p 
value 
p value (Bonferroni 
correction) 
Gabra3 0.769 6.152 
Cyfip2 0.492 3.936 
Kcna1 0.346 2.768 
Flna 0.052 0.416 
Cog3 0.654 5.232 
Blcap Y/C 0.999 7.992 
Blcap Q/R 0.983 7.864 
Blcap K/R 0.885 7.08 
 
Appendix Table 4: ANOVA analysis of RNA editing percentages 
One way ANOVA was performed, indicating that RNA editing was not significantly changed with age for any genes tested 
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gene KO FPKM WT FPKM log2(fold_change) q_value Ensembl ID Description 
Gm10233 3.03865 0 -1.79769e+308 0.010555 ENSMUSG00000068165 predicted pseudogene 10233 
[Source:MGI 
Symbol;Acc:MGI:3704447] 
SNORA22 6131.66 444026 6.17822 0 ENSMUSG00000065304 Small nucleolar RNA SNORA22  
[Source:RFAM;Acc:RF00414] 
Snora30 44.1854 1449.09 5.03544 0.029654 ENSMUSG00000064581 Small nucleolar RNA 
SNORA30/SNORA37 family  
[Source:RFAM;Acc:RF00415] 
SNORA79 111.094 3308.77 4.89644 3.18E-10 ENSMUSG00000088412 Small nucleolar RNA SNORA79  
[Source:RFAM;Acc:RF00600] 
SNORA35 266.42 5877.11 4.46333 8.60E-07 ENSMUSG00000084421 Small nucleolar RNA SNORA35  
[Source:RFAM;Acc:RF00566] 
Gm6166 7.82314 164.454 4.39379 0 ENSMUSG00000074280 predicted gene 6166 [Source:MGI 
Symbol;Acc:MGI:3645893] 
SNORA70 110.628 1942.09 4.13382 0.018619 ENSMUSG00000087916 Small nucleolar RNA SNORA70  
[Source:RFAM;Acc:RF00156] 
Gm14934 4.22012 62.963 3.89915 1.47E-08 ENSMUSG00000082035 predicted gene 14934 [Source:MGI 
Symbol;Acc:MGI:3802129] 
Gm2174 5.46429 65.9188 3.59259 2.16E-07 ENSMUSG00000058932 predicted gene 2174 [Source:MGI 
Symbol;Acc:MGI:3780344] 
SNORA38 493.916 5402.24 3.45122 0 ENSMUSG00000065653 Small nucleolar RNA SNORA38  
[Source:RFAM;Acc:RF00428] 
Gm14305, 
Gm14306 
0.501043 4.99975 3.31885 0.015848 #N/A #N/A 
SNORA48 46.6063 429.819 3.20513 0.03374 ENSMUSG00000089011 Small nucleolar RNA SNORA48  
[Source:RFAM;Acc:RF00554] 
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Hist1h4c 2.84226 25.3616 3.15753 0.0032 ENSMUSG00000060678 histone cluster 1, H4c [Source:MGI 
Symbol;Acc:MGI:2448421] 
Gm17383 6.41447 56.1118 3.1289 0 ENSMUSG00000058625 predicted gene, 17383 [Source:MGI 
Symbol;Acc:MGI:4937017] 
SNORA70 18496.3 139409 2.91402 0 ENSMUSG00000087916 Small nucleolar RNA SNORA70  
[Source:RFAM;Acc:RF00156] 
Scarna6 70.2752 526.873 2.90637 4.78E-12 ENSMUSG00000087968 Small Cajal body specific RNA 6  
[Source:RFAM;Acc:RF00478] 
Gm4724 1.49152 9.36433 2.65039 0.012859 ENSMUSG00000078897 predicted gene 4724 [Source:MGI 
Symbol;Acc:MGI:3782904] 
Gm10154 36.3201 172.951 2.25153 4.92E-13 ENSMUSG00000066116 predicted gene 10154 [Source:MGI 
Symbol;Acc:MGI:3642271] 
Eif1 36.4411 166.612 2.19286 3.44E-07 ENSMUSG00000035530 eukaryotic translation initiation factor 
1 [Source:MGI 
Symbol;Acc:MGI:105125] 
Orc5 4.87409 21.7581 2.15834 0.036365 ENSMUSG00000029012 origin recognition complex, subunit 5 
[Source:MGI 
Symbol;Acc:MGI:1347044] 
Rpl31-ps9 33.8222 141.697 2.06677 8.47E-07 ENSMUSG00000094122 ribosomal protein L31, pseudogene 9 
[Source:MGI 
Symbol;Acc:MGI:3704195] 
H6pd 1.61313 6.49417 2.00928 0.033843 ENSMUSG00000028980 hexose-6-phosphate dehydrogenase 
(glucose 1-dehydrogenase) 
[Source:MGI 
Symbol;Acc:MGI:2140356] 
Hsd11b1 6.44958 25.4623 1.98108 0.004499 ENSMUSG00000016194 hydroxysteroid 11-beta 
dehydrogenase 1 [Source:MGI 
Symbol;Acc:MGI:103562] 
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Gm9844 5.46518 21.3509 1.96596 0.005045 ENSMUSG00000050347 predicted pseudogene 9844 
[Source:MGI 
Symbol;Acc:MGI:3704288] 
Rps11 69.737 270.368 1.95493 0 ENSMUSG00000003429 ribosomal protein S11 [Source:MGI 
Symbol;Acc:MGI:1351329] 
Snapc5 5.21811 20.1511 1.94926 5.15E-07 ENSMUSG00000032398 small nuclear RNA activating 
complex, polypeptide 5 [Source:MGI 
Symbol;Acc:MGI:1914282] 
Rpl22l1 20.9724 79.7795 1.92753 2.87E-08 ENSMUSG00000039221 ribosomal protein L22 like 1 
[Source:MGI 
Symbol;Acc:MGI:1915278] 
Gm9892 0.93136 3.43611 1.88337 0.007047 ENSMUSG00000052825 predicted gene 9892 [Source:MGI 
Symbol;Acc:MGI:3701610] 
Phb2 57.9534 211.71 1.86913 9.67E-06 ENSMUSG00000004264 prohibitin 2 [Source:MGI 
Symbol;Acc:MGI:102520] 
Ambra1 25.9227 93.18 1.8458 0.043294 ENSMUSG00000040506 autophagy/beclin 1 regulator 1 
[Source:MGI 
Symbol;Acc:MGI:2443564] 
Gm13706 30.8538 106.719 1.7903 0.010687 ENSMUSG00000085838 predicted gene 13706 [Source:MGI 
Symbol;Acc:MGI:3702041] 
Gm14586 5.24509 17.6781 1.75292 0.026534 ENSMUSG00000083621 predicted gene 14586 [Source:MGI 
Symbol;Acc:MGI:3705507] 
Smek2 16.5215 54.0715 1.71052 3.80E-06 ENSMUSG00000020463 SMEK homolog 2, suppressor of mek1 
(Dictyostelium) [Source:MGI 
Symbol;Acc:MGI:2144474] 
Pdap1 28.1594 91.5695 1.70125 5.44E-12 ENSMUSG00000029623 PDGFA associated protein 1 
[Source:MGI 
Symbol;Acc:MGI:2448536] 
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Gm8430 10.8643 34.8721 1.68248 0.003336 ENSMUSG00000055093 predicted pseudogene 8430 
[Source:MGI 
Symbol;Acc:MGI:3645406] 
Gm561 12.3768 39.2545 1.66522 0.001446 ENSMUSG00000074754 predicted gene 561 [Source:MGI 
Symbol;Acc:MGI:2685407] 
Tmem101 2.30856 7.31026 1.66293 0.013841 ENSMUSG00000020921 transmembrane protein 101 
[Source:MGI 
Symbol;Acc:MGI:1923797] 
Gm13072 10.8166 34.029 1.65352 0.000127 ENSMUSG00000070572 predicted gene 13072 [Source:MGI 
Symbol;Acc:MGI:3651720] 
Rps29 210.337 648.823 1.62512 0 ENSMUSG00000034892 ribosomal protein S29 [Source:MGI 
Symbol;Acc:MGI:107681] 
Gm2026 1.58502 4.84516 1.61204 0.043396 ENSMUSG00000078886 predicted gene 2026 [Source:MGI 
Symbol;Acc:MGI:3780195] 
Rpl39 91.4318 279.247 1.61077 0 ENSMUSG00000079641 ribosomal protein L39 [Source:MGI 
Symbol;Acc:MGI:1914498] 
Ndufb3 6.15747 18.5638 1.59208 0.001907 ENSMUSG00000026032 NADH dehydrogenase (ubiquinone) 1 
beta subcomplex 3 [Source:MGI 
Symbol;Acc:MGI:1913745] 
2610001J05Rik 8.50419 25.5924 1.58947 1.91E-05 ENSMUSG00000052419 RIKEN cDNA 2610001J05 gene 
[Source:MGI 
Symbol;Acc:MGI:1913770] 
AY036118 6.65412 19.7018 1.566 0.005605 ENSMUSG00000045999 cDNA sequence AY036118 
[Source:MGI 
Symbol;Acc:MGI:2158419] 
Hist2h4 1.70069 4.99366 1.55398 0.03374 ENSMUSG00000091405 histone cluster 2, H4 [Source:MGI 
Symbol;Acc:MGI:2140113] 
Rimklb 9.37839 27.2163 1.53706 0.015824 ENSMUSG00000040649 ribosomal modification protein rimK-
like family member B [Source:MGI 
Symbol;Acc:MGI:1918325] 
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Gm4294 7.15543 20.6122 1.52639 0.021302 ENSMUSG00000078377 predicted gene 4294 [Source:MGI 
Symbol;Acc:MGI:3782472] 
SNORA8 295.273 822.076 1.47722 0.015147 ENSMUSG00000065226 Small nucleolar RNA SNORA8  
[Source:RFAM;Acc:RF00393] 
Drap1 19.1003 52.3954 1.45584 0.001026 ENSMUSG00000024914 Dr1 associated protein 1 (negative 
cofactor 2 alpha) [Source:MGI 
Symbol;Acc:MGI:1913806] 
Cstb 6.74401 18.2706 1.43785 0.013774 ENSMUSG00000005054 cystatin B [Source:MGI 
Symbol;Acc:MGI:109514] 
Gm6142 123.045 331.793 1.4311 1.59E-06 ENSMUSG00000084304 predicted pseudogene 6142 
[Source:MGI 
Symbol;Acc:MGI:3644670] 
Rpl21-ps15 36.0916 96.8072 1.42345 0.004073 ENSMUSG00000083596 ribosomal protein L21, pseudogene 
15 [Source:MGI 
Symbol;Acc:MGI:3705426] 
Rpl35a 118.761 316.151 1.41256 1.28E-06 ENSMUSG00000060636 ribosomal protein L35A [Source:MGI 
Symbol;Acc:MGI:1928894] 
Gabarap 63.1082 167.447 1.4078 7.26E-07 ENSMUSG00000018567 gamma-aminobutyric acid receptor 
associated protein [Source:MGI 
Symbol;Acc:MGI:1861742] 
Scarna13 199.094 513.302 1.36636 1.30E-08 ENSMUSG00000088789 small Cajal body-specific RNA 1 
[Source:MGI 
Symbol;Acc:MGI:4360027] 
Rps21 267.96 680.529 1.34464 1.45E-11 ENSMUSG00000039001 ribosomal protein S21 [Source:MGI 
Symbol;Acc:MGI:1913731] 
1810027O10Rik 27.8734 70.6814 1.34244 0.035806 ENSMUSG00000070394 RIKEN cDNA 1810027O10 gene 
[Source:MGI 
Symbol;Acc:MGI:1916436] 
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Rpl39-ps 86.5495 219.384 1.34186 3.37E-07 ENSMUSG00000036305 ribosomal protein L39, pseudogene 
[Source:MGI 
Symbol;Acc:MGI:3705781] 
mt-Nd3 1932.19 4841.1 1.3251 0 ENSMUSG00000064360 mitochondrially encoded NADH 
dehydrogenase 3 [Source:MGI 
Symbol;Acc:MGI:102499] 
2010107E04Rik 35.4377 88.6033 1.32208 0.00211 ENSMUSG00000021290 RIKEN cDNA 2010107E04 gene 
[Source:MGI 
Symbol;Acc:MGI:1917507] 
Mt2 13.6123 33.9086 1.31674 0.01513 ENSMUSG00000031762 metallothionein 2 [Source:MGI 
Symbol;Acc:MGI:97172] 
Hbb-b1 20.9713 52.2282 1.31641 0.001917 ENSMUSG00000052305 hemoglobin, beta adult major chain 
[Source:MGI Symbol;Acc:MGI:96021] 
Rpl31-ps8 70.577 174.753 1.30804 8.30E-07 ENSMUSG00000067870 ribosomal protein L31, pseudogene 8 
[Source:MGI 
Symbol;Acc:MGI:3647726] 
Ccdc132 22.5027 55.641 1.30605 0.027976 ENSMUSG00000001376 coiled-coil domain containing 132 
[Source:MGI 
Symbol;Acc:MGI:1920538] 
Letm2 4.64771 11.4583 1.3018 0.0003 ENSMUSG00000037363 leucine zipper-EF-hand containing 
transmembrane protein 2 
[Source:MGI 
Symbol;Acc:MGI:2444979] 
Gm6457 10.993 26.8361 1.2876 0.000633 ENSMUSG00000053740 predicted pseudogene 6457 
[Source:MGI 
Symbol;Acc:MGI:3648519] 
Usmg5 111.628 268.848 1.2681 1.49E-05 ENSMUSG00000071528 upregulated during skeletal muscle 
growth 5 [Source:MGI 
Symbol;Acc:MGI:1891435] 
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Vps29 44.4335 106.632 1.26292 0.013862 ENSMUSG00000029462 vacuolar protein sorting 29 (S. 
pombe) [Source:MGI 
Symbol;Acc:MGI:1928344] 
Rpl31 125.854 300.813 1.25711 7.36E-11 ENSMUSG00000073702 ribosomal protein L31 [Source:MGI 
Symbol;Acc:MGI:2149632] 
Gm6356 2.90718 6.94572 1.2565 0.023087 ENSMUSG00000091400 predicted gene 6356 [Source:MGI 
Symbol;Acc:MGI:3646390] 
Tmsb4x 224.954 534.658 1.24899 2.04E-11 ENSMUSG00000049775 thymosin, beta 4, X chromosome 
[Source:MGI Symbol;Acc:MGI:99510] 
Ube2w 53.5845 125.116 1.22338 0.002575 ENSMUSG00000025939 ubiquitin-conjugating enzyme E2W 
(putative) [Source:MGI 
Symbol;Acc:MGI:1914049] 
Mrps18c 22.7765 52.6535 1.20898 0.001599 ENSMUSG00000016833 mitochondrial ribosomal protein 
S18C [Source:MGI 
Symbol;Acc:MGI:1915985] 
Srsf3 53.5626 123.074 1.20023 6.73E-06 ENSMUSG00000071172 serine/arginine-rich splicing factor 3 
[Source:MGI Symbol;Acc:MGI:98285] 
Rps5 58.262 133.069 1.19154 8.22E-07 ENSMUSG00000012848 ribosomal protein S5 [Source:MGI 
Symbol;Acc:MGI:1097682] 
Tbca 13.959 31.7489 1.18551 0.012646 ENSMUSG00000042043 tubulin cofactor A [Source:MGI 
Symbol;Acc:MGI:107549] 
Cox7a2 37.9082 85.9804 1.1815 1.51E-05 ENSMUSG00000032330 cytochrome c oxidase, subunit VIIa 2 
[Source:MGI 
Symbol;Acc:MGI:1316715] 
Snrpf 14.9816 33.9021 1.17818 5.39E-05 ENSMUSG00000020018 small nuclear ribonucleoprotein 
polypeptide F [Source:MGI 
Symbol;Acc:MGI:1917128] 
Cox7c 41.9201 94.4257 1.17154 0.00973 ENSMUSG00000017778 cytochrome c oxidase, subunit VIIc 
[Source:MGI 
Symbol;Acc:MGI:103226] 
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Ndufa3 163.327 361.38 1.14575 0.000159 ENSMUSG00000035674 NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, 3 [Source:MGI 
Symbol;Acc:MGI:1913341] 
Gm14303 56.5841 122.917 1.11922 0.033843 ENSMUSG00000081344 predicted gene 14303 [Source:MGI 
Symbol;Acc:MGI:3651379] 
Hbb-b2 17.0414 36.6542 1.10494 0.01403 ENSMUSG00000073940 hemoglobin, beta adult minor chain 
[Source:MGI Symbol;Acc:MGI:96022] 
Hnrnpa2b1 48.8077 104.939 1.10437 7.31E-06 ENSMUSG00000004980 heterogeneous nuclear 
ribonucleoprotein A2/B1 [Source:MGI 
Symbol;Acc:MGI:104819] 
C430048L16Rik 5.0558 10.8668 1.10392 0.009706 ENSMUSG00000052137 RIKEN cDNA C430048L16 gene 
[Source:MGI 
Symbol;Acc:MGI:1924854] 
Tceal6 22.4886 48.2993 1.10281 2.03E-07 ENSMUSG00000031409 transcription elongation factor A (SII)-
like 6 [Source:MGI 
Symbol;Acc:MGI:1923939] 
Uqcrb 250.207 535.237 1.09706 1.34E-07 ENSMUSG00000021520 ubiquinol-cytochrome c reductase 
binding protein [Source:MGI 
Symbol;Acc:MGI:1914780] 
Rasa2 6.90981 14.7619 1.09516 0.009276 ENSMUSG00000032413 RAS p21 protein activator 2 
[Source:MGI 
Symbol;Acc:MGI:2149960] 
Kpnb1 31.6232 66.7009 1.07672 0.025467 ENSMUSG00000001440 karyopherin (importin) beta 1 
[Source:MGI 
Symbol;Acc:MGI:107532] 
Pfdn4 36.5132 76.399 1.06513 0.044235 ENSMUSG00000052033 prefoldin 4 [Source:MGI 
Symbol;Acc:MGI:1923512] 
Rpl34-ps1 372.358 778.99 1.06491 7.14E-09 ENSMUSG00000068396 ribosomal protein L34, pseudogene 1 
[Source:MGI 
Symbol;Acc:MGI:3704270] 
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Anapc13 36.4614 75.8889 1.05752 0.015888 ENSMUSG00000035048 anaphase promoting complex subunit 
13 [Source:MGI 
Symbol;Acc:MGI:1916260] 
Tmem181a 4.70879 9.751 1.05019 0.034494 ENSMUSG00000038141 transmembrane protein 181A 
[Source:MGI 
Symbol;Acc:MGI:1924356] 
Gm7887 11.5446 23.7491 1.04065 0.024464 ENSMUSG00000044211 predicted gene 7887 [Source:MGI 
Symbol;Acc:MGI:3648251] 
Capza2 118.33 243.243 1.03958 0.003418 ENSMUSG00000015733 capping protein (actin filament) 
muscle Z-line, alpha 2 [Source:MGI 
Symbol;Acc:MGI:106222] 
Shfm1 103.341 212.416 1.03948 8.89E-06 ENSMUSG00000042541 split hand/foot malformation 
(ectrodactyly) type 1 [Source:MGI 
Symbol;Acc:MGI:109238] 
Tm9sf4 21.1106 43.2414 1.03445 0.043728 ENSMUSG00000068040 transmembrane 9 superfamily 
protein member 4 [Source:MGI 
Symbol;Acc:MGI:2139220] 
Ptp4a2 72.489 147.56 1.02546 0.012245 ENSMUSG00000028788 protein tyrosine phosphatase 4a2 
[Source:MGI 
Symbol;Acc:MGI:1277117] 
Arl6ip1 45.7296 92.9429 1.02321 1.20E-07 ENSMUSG00000030654 ADP-ribosylation factor-like 6 
interacting protein 1 [Source:MGI 
Symbol;Acc:MGI:1858943] 
Ddt, Gm20441, 
Gstt3 
40.9111 82.7838 1.01686 0.002033 #N/A #N/A 
Dym 3.47473 7.03073 1.01678 0.039478 ENSMUSG00000035765 dymeclin [Source:MGI 
Symbol;Acc:MGI:1918480] 
Prdx1 94.178 189.872 1.01157 0.001604 ENSMUSG00000028691 peroxiredoxin 1 [Source:MGI 
Symbol;Acc:MGI:99523] 
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Ndufs6 40.9114 82.2007 1.00665 0.011947 ENSMUSG00000021606 NADH dehydrogenase (ubiquinone) 
Fe-S protein 6 [Source:MGI 
Symbol;Acc:MGI:107932] 
Ctxn2 9.00905 18.0793 1.00489 0.031113 ENSMUSG00000074872 cortexin 2 [Source:MGI 
Symbol;Acc:MGI:2139444] 
Gm10335 48.043 96.1099 1.00036 0.001277 ENSMUSG00000071532 predicted gene 10335 [Source:MGI 
Symbol;Acc:MGI:3641693] 
Zik1 1.8657 3.71838 0.994957 0.049002 ENSMUSG00000030393 zinc finger protein interacting with K 
protein 1 [Source:MGI 
Symbol;Acc:MGI:108070] 
Gm10132 46.153 91.0523 0.98027 0.007039 ENSMUSG00000063556 predicted gene 10132 [Source:MGI 
Symbol;Acc:MGI:3704449] 
Tmx2 93.6766 184.634 0.978903 0.011491 ENSMUSG00000050043 thioredoxin-related transmembrane 
protein 2 [Source:MGI 
Symbol;Acc:MGI:1914208] 
Fdx1l 18.0773 34.9096 0.949449 0.019322 ENSMUSG00000079677 ferredoxin 1-like [Source:MGI 
Symbol;Acc:MGI:1915415] 
Rpl5 210.84 403.644 0.936937 0.001907 ENSMUSG00000058558 ribosomal protein L5 [Source:MGI 
Symbol;Acc:MGI:102854] 
Gm10119 45.577 87.2075 0.936147 6.44E-05 ENSMUSG00000062611 predicted gene 10119 [Source:MGI 
Symbol;Acc:MGI:3642853] 
Calr 109.166 206.546 0.919936 0.002605 ENSMUSG00000003814 calreticulin [Source:MGI 
Symbol;Acc:MGI:88252] 
Rps27 277.021 524.081 0.919795 0.00109 ENSMUSG00000090733 ribosomal protein S27 [Source:MGI 
Symbol;Acc:MGI:1888676] 
Rpl15-ps3 57.7383 108.658 0.912195 0.000862 ENSMUSG00000061167 ribosomal protein L15, pseudogene 3 
[Source:MGI 
Symbol;Acc:MGI:3782952] 
Pfdn2 100.092 187.93 0.908865 0.007047 ENSMUSG00000006412 prefoldin 2 [Source:MGI 
Symbol;Acc:MGI:1276111] 
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Gm13841 60.335 112.576 0.899827 0.000573 ENSMUSG00000083833 predicted gene 13841 [Source:MGI 
Symbol;Acc:MGI:3650890] 
Tmsb10 180.094 330.458 0.875711 0.000116 ENSMUSG00000079523 thymosin, beta 10 [Source:MGI 
Symbol;Acc:MGI:109146] 
Cbln4 7.18924 13.1747 0.873858 0.011491 ENSMUSG00000067578 cerebellin 4 precursor protein 
[Source:MGI 
Symbol;Acc:MGI:2154433] 
Plp1 154.56 281.253 0.863705 0.001907 ENSMUSG00000031425 proteolipid protein (myelin) 1 
[Source:MGI Symbol;Acc:MGI:97623] 
RNase_MRP 472.047 857.457 0.861135 0.000647 ENSMUSG00000088375 RNase MRP  
[Source:RFAM;Acc:RF00030] 
Bex1 61.5529 111.416 0.856064 8.07E-05 ENSMUSG00000050071 brain expressed gene 1 [Source:MGI 
Symbol;Acc:MGI:1328321] 
AC241392.1 6.13797 11.0855 0.852837 0.007047 ENSMUSG00000094614 0 
Cetn2 29.9507 53.568 0.83878 0.026046 ENSMUSG00000031347 centrin 2 [Source:MGI 
Symbol;Acc:MGI:1347085] 
Prkar1b 86.8814 153.879 0.824674 0.033843 ENSMUSG00000025855 protein kinase, cAMP dependent 
regulatory, type I beta [Source:MGI 
Symbol;Acc:MGI:97759] 
Rpl34 108.379 190.659 0.814917 0.004624 ENSMUSG00000062006 ribosomal protein L34 [Source:MGI 
Symbol;Acc:MGI:1915686] 
Sec62 42.6543 74.3601 0.801839 2.05E-05 ENSMUSG00000027706 SEC62 homolog (S. cerevisiae) 
[Source:MGI 
Symbol;Acc:MGI:1916526] 
Rpl11 160.453 278.892 0.797557 0.014478 ENSMUSG00000059291 ribosomal protein L11 [Source:MGI 
Symbol;Acc:MGI:1914275] 
Rpl29 60.6666 105.376 0.796577 0.002923 ENSMUSG00000048758 ribosomal protein L29 [Source:MGI 
Symbol;Acc:MGI:99687] 
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Tuba1a 74.4617 128.929 0.792004 0.003418 ENSMUSG00000072235 tubulin, alpha 1A [Source:MGI 
Symbol;Acc:MGI:98869] 
2410004A20Rik, 
Gm20509, Rsl24d1 
31.4957 54.4404 0.789523 0.034225 #N/A #N/A 
Eef1a1 726.75 1253.78 0.786756 0.008062 ENSMUSG00000037742 eukaryotic translation elongation 
factor 1 alpha 1 [Source:MGI 
Symbol;Acc:MGI:1096881] 
Ube2d2 7.28257 12.5072 0.78024 0.048131 ENSMUSG00000091896 ubiquitin-conjugating enzyme E2D 2 
[Source:MGI 
Symbol;Acc:MGI:1930715] 
Rps9 116.409 199.609 0.777976 0.00352 ENSMUSG00000006333 ribosomal protein S9 [Source:MGI 
Symbol;Acc:MGI:1924096] 
Gm10163 218.514 373.094 0.771809 0.002727 ENSMUSG00000066443 predicted pseudogene 10163 
[Source:MGI 
Symbol;Acc:MGI:3704341] 
Rps23 400.956 683.473 0.769439 7.71E-05 ENSMUSG00000049517 ribosomal protein S23 [Source:MGI 
Symbol;Acc:MGI:1913725] 
Txn1 38.2081 64.8734 0.76375 0.009075 ENSMUSG00000028367 thioredoxin 1 [Source:MGI 
Symbol;Acc:MGI:98874] 
Rpl10 141.596 236.818 0.742002 0.003238 ENSMUSG00000008682 ribosomal protein L10 [Source:MGI 
Symbol;Acc:MGI:105943] 
Vbp1 56.5878 94.4358 0.738844 0.002151 ENSMUSG00000031197 von Hippel-Lindau binding protein 1 
[Source:MGI 
Symbol;Acc:MGI:1333804] 
Ppp2r2a 7.08438 11.6517 0.717824 0.018619 ENSMUSG00000022052 protein phosphatase 2 (formerly 2A), 
regulatory subunit B (PR 52), alpha 
isoform [Source:MGI 
Symbol;Acc:MGI:1919228] 
Gm12346 30.3403 49.7505 0.713473 0.002634 ENSMUSG00000083899 predicted gene 12346 [Source:MGI 
Symbol;Acc:MGI:3649810] 
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Rps17 262.317 429.926 0.712774 0.002836 ENSMUSG00000061787 ribosomal protein S17 [Source:MGI 
Symbol;Acc:MGI:1309526] 
Morc3 12.0822 19.7821 0.711315 0.004406 ENSMUSG00000039456 microrchidia 3 [Source:MGI 
Symbol;Acc:MGI:2136841] 
Vcpip1 3.83686 6.27119 0.708814 0.015848 ENSMUSG00000045210 valosin containing protein (p97)/p47 
complex interacting protein 1 
[Source:MGI 
Symbol;Acc:MGI:1917925] 
Gm15500 112.217 182.085 0.698324 0.000778 ENSMUSG00000086583 predicted pseudogene 15500 
[Source:MGI 
Symbol;Acc:MGI:3782947] 
Ngfrap1 85.7991 139.218 0.698311 0.014301 ENSMUSG00000046432 nerve growth factor receptor 
(TNFRSF16) associated protein 1 
[Source:MGI 
Symbol;Acc:MGI:1338016] 
Ndufa6 78.6703 127.388 0.695335 0.010156 ENSMUSG00000022450 NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, 6 (B14) 
[Source:MGI 
Symbol;Acc:MGI:1914380] 
Hnrnpa1 74.3747 120.23 0.692907 0.005728 ENSMUSG00000046434 heterogeneous nuclear 
ribonucleoprotein A1 [Source:MGI 
Symbol;Acc:MGI:104820] 
Naa15 7.95862 12.7386 0.678611 0.010791 ENSMUSG00000063273 N(alpha)-acetyltransferase 15, NatA 
auxiliary subunit [Source:MGI 
Symbol;Acc:MGI:1922088] 
Cox5b 386.243 609.43 0.657952 0.002129 ENSMUSG00000061518 cytochrome c oxidase, subunit Vb 
[Source:MGI Symbol;Acc:MGI:88475] 
Cox6c 584.109 918.613 0.65322 0.008607 ENSMUSG00000014313 cytochrome c oxidase, subunit VIc 
[Source:MGI 
Symbol;Acc:MGI:104614] 
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Ilf2 24.8897 39.0065 0.648164 0.018619 ENSMUSG00000001016 interleukin enhancer binding factor 2 
[Source:MGI 
Symbol;Acc:MGI:1915031] 
Asns 31.781 49.6131 0.642558 0.037589 ENSMUSG00000029752 asparagine synthetase [Source:MGI 
Symbol;Acc:MGI:1350929] 
Eif3g 33.4211 52.1072 0.640723 0.017538 ENSMUSG00000070319 eukaryotic translation initiation factor 
3, subunit G [Source:MGI 
Symbol;Acc:MGI:1858258] 
Hnrnpab 79.0291 122.839 0.636314 0.013952 ENSMUSG00000020358 heterogeneous nuclear 
ribonucleoprotein A/B [Source:MGI 
Symbol;Acc:MGI:1330294] 
Fam20b 26.3311 40.535 0.622398 0.015848 ENSMUSG00000033557 family with sequence similarity 20, 
member B [Source:MGI 
Symbol;Acc:MGI:2443990] 
Gmfb 32.5982 50.0192 0.617689 0.007331 ENSMUSG00000062014 glia maturation factor, beta 
[Source:MGI 
Symbol;Acc:MGI:1927133] 
Nop58 14.129 21.672 0.617174 0.043294 ENSMUSG00000026020 NOP58 ribonucleoprotein homolog 
(yeast) [Source:MGI 
Symbol;Acc:MGI:1933184] 
Otub1 37.3088 56.8273 0.607065 0.038156 ENSMUSG00000024767 OTU domain, ubiquitin aldehyde 
binding 1 [Source:MGI 
Symbol;Acc:MGI:2147616] 
Cwc15 45.4422 68.3745 0.589425 0.015848 ENSMUSG00000004096 CWC15 homolog (S. cerevisiae) 
[Source:MGI 
Symbol;Acc:MGI:1913320] 
Cacna2d1 21.877 32.7972 0.58416 0.034494 ENSMUSG00000040118 calcium channel, voltage-dependent, 
alpha2/delta subunit 1 [Source:MGI 
Symbol;Acc:MGI:88295] 
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Tuba1b 86.8187 129.973 0.582136 0.019159 ENSMUSG00000023004 tubulin, alpha 1B [Source:MGI 
Symbol;Acc:MGI:107804] 
Purb 21.0907 31.5531 0.581173 0.010233 ENSMUSG00000094483 purine rich element binding protein B 
[Source:MGI 
Symbol;Acc:MGI:1338779] 
Sult4a1 42.0334 62.1917 0.565185 0.024626 ENSMUSG00000018865 sulfotransferase family 4A, member 1 
[Source:MGI 
Symbol;Acc:MGI:1888971] 
Ptma 45.7414 67.674 0.565103 0.028202 ENSMUSG00000026238 prothymosin alpha [Source:MGI 
Symbol;Acc:MGI:97803] 
Rpl37 313.757 462.925 0.561129 0.018826 ENSMUSG00000041841 ribosomal protein L37 [Source:MGI 
Symbol;Acc:MGI:1914531] 
Rbm6 14.1884 20.9257 0.560563 0.031079 ENSMUSG00000032582 RNA binding motif protein 6 
[Source:MGI 
Symbol;Acc:MGI:1338037] 
Atxn10 54.6095 78.5801 0.525013 0.034402 ENSMUSG00000016541 ataxin 10 [Source:MGI 
Symbol;Acc:MGI:1859293] 
Nbea 12.8397 18.1241 0.4973 0.049903 ENSMUSG00000027799 neurobeachin [Source:MGI 
Symbol;Acc:MGI:1347075] 
Aplp1 116.634 80.105 -0.54202 0.019919 ENSMUSG00000006651 amyloid beta (A4) precursor-like 
protein 1 [Source:MGI 
Symbol;Acc:MGI:88046] 
Sst 251.568 172.569 -0.54378 0.049002 ENSMUSG00000004366 somatostatin [Source:MGI 
Symbol;Acc:MGI:98326] 
Ptn 63.7929 43.4972 -0.55248 0.033843 ENSMUSG00000029838 pleiotrophin [Source:MGI 
Symbol;Acc:MGI:97804] 
Epb4.1l3 23.4734 15.9276 -0.5595 0.042457 ENSMUSG00000024044 erythrocyte protein band 4.1-like 3 
[Source:MGI 
Symbol;Acc:MGI:103008] 
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Rasgef1a 29.3328 19.7926 -0.56755 0.043261 ENSMUSG00000030134 RasGEF domain family, member 1A 
[Source:MGI 
Symbol;Acc:MGI:1917977] 
Kcnk1 41.902 28.0906 -0.57694 0.049002 ENSMUSG00000033998 potassium channel, subfamily K, 
member 1 [Source:MGI 
Symbol;Acc:MGI:109322] 
Ttc7b 25.4221 16.9756 -0.58262 0.049002 ENSMUSG00000033530 tetratricopeptide repeat domain 7B 
[Source:MGI 
Symbol;Acc:MGI:2144724] 
Srp54a 48.1227 32.0755 -0.58525 0.030198 ENSMUSG00000021020 signal recognition particle 54A 
[Source:MGI 
Symbol;Acc:MGI:1346087] 
mt-Nd2 1021.37 678.702 -0.58966 0.015205 ENSMUSG00000064345 mitochondrially encoded NADH 
dehydrogenase 2 [Source:MGI 
Symbol;Acc:MGI:102500] 
Laptm4a 201.714 133.956 -0.59056 0.009268 ENSMUSG00000020585 lysosomal-associated protein 
transmembrane 4A [Source:MGI 
Symbol;Acc:MGI:108017] 
Myl12b 98.5096 64.8239 -0.60374 0.049002 ENSMUSG00000034868 myosin, light chain 12B, regulatory 
[Source:MGI 
Symbol;Acc:MGI:107494] 
Ckmt1 185.074 121.682 -0.60498 0.033843 ENSMUSG00000000308 creatine kinase, mitochondrial 1, 
ubiquitous [Source:MGI 
Symbol;Acc:MGI:99441] 
Tmem66 168.961 110.912 -0.60727 0.007041 ENSMUSG00000031532 transmembrane protein 66 
[Source:MGI 
Symbol;Acc:MGI:1915137] 
Atp1b1 437.145 286.516 -0.6095 0.010233 ENSMUSG00000026576 ATPase, Na+/K+ transporting, beta 1 
polypeptide [Source:MGI 
Symbol;Acc:MGI:88108] 
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Wbp4 18.4138 11.9757 -0.62068 0.047261 ENSMUSG00000022023 WW domain binding protein 4 
[Source:MGI 
Symbol;Acc:MGI:109568] 
Dctn2 44.5704 28.9034 -0.62485 0.022352 ENSMUSG00000025410 dynactin 2 [Source:MGI 
Symbol;Acc:MGI:107733] 
Cfl1 222.766 143.674 -0.63273 0.004499 ENSMUSG00000056201 cofilin 1, non-muscle [Source:MGI 
Symbol;Acc:MGI:101757] 
Gm15772 1181.45 760.353 -0.63582 0.0032 ENSMUSG00000062353 predicted gene 15772 [Source:MGI 
Symbol;Acc:MGI:3805541] 
Rpl18a 85.5791 55.0297 -0.63705 0.018619 ENSMUSG00000045128 ribosomal protein L18A [Source:MGI 
Symbol;Acc:MGI:1924058] 
Pnmal1 48.6174 31.251 -0.63757 0.01593 ENSMUSG00000041141 PNMA-like 1 [Source:MGI 
Symbol;Acc:MGI:1918941] 
6330403A02Rik 8.98449 5.72008 -0.6514 0.038439 ENSMUSG00000053963 RIKEN cDNA 6330403A02 gene 
[Source:MGI 
Symbol;Acc:MGI:2138735] 
Fads2 62.3819 39.683 -0.65261 0.020392 ENSMUSG00000024665 fatty acid desaturase 2 [Source:MGI 
Symbol;Acc:MGI:1930079] 
Snx19 9.15313 5.81575 -0.6543 0.044932 ENSMUSG00000031993 sorting nexin 19 [Source:MGI 
Symbol;Acc:MGI:1921581] 
Csnk1g2 29.7967 18.9259 -0.65479 0.034402 ENSMUSG00000003345 casein kinase 1, gamma 2 
[Source:MGI 
Symbol;Acc:MGI:1920014] 
Pja1 88.3012 55.9293 -0.65883 0.026114 ENSMUSG00000034403 praja1, RING-H2 motif containing 
[Source:MGI 
Symbol;Acc:MGI:1101765] 
Kifc2 35.691 22.5938 -0.65963 0.008894 ENSMUSG00000004187 kinesin family member C2 
[Source:MGI 
Symbol;Acc:MGI:109187] 
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Tnfrsf21 19.4854 12.3298 -0.66025 0.027421 ENSMUSG00000023915 tumor necrosis factor receptor 
superfamily, member 21 [Source:MGI 
Symbol;Acc:MGI:2151075] 
Eid1 95.3184 60.1245 -0.6648 0.003238 ENSMUSG00000091337 EP300 interacting inhibitor of 
differentiation 1 [Source:MGI 
Symbol;Acc:MGI:1889651] 
Sparc 464.698 292.689 -0.66693 0.020648 ENSMUSG00000018593 secreted acidic cysteine rich 
glycoprotein [Source:MGI 
Symbol;Acc:MGI:98373] 
Vti1b 235.887 148.104 -0.67149 0.049457 ENSMUSG00000021124 vesicle transport through interaction 
with t-SNAREs 1B homolog 
[Source:MGI 
Symbol;Acc:MGI:1855688] 
Rpl7a 78.0275 48.8241 -0.67639 0.036306 ENSMUSG00000062647 ribosomal protein L7A [Source:MGI 
Symbol;Acc:MGI:1353472] 
Gapdh 978.936 612.471 -0.67657 0.018789 ENSMUSG00000057666 glyceraldehyde-3-phosphate 
dehydrogenase [Source:MGI 
Symbol;Acc:MGI:95640] 
Tagln3 231.462 143.951 -0.68519 0.001289 ENSMUSG00000022658 transgelin 3 [Source:MGI 
Symbol;Acc:MGI:1926784] 
Ypel3 85.6891 53.0646 -0.69136 0.016405 ENSMUSG00000042675 yippee-like 3 (Drosophila) 
[Source:MGI 
Symbol;Acc:MGI:1913340] 
Ppp1r3c 18.1857 11.2202 -0.69671 0.043296 ENSMUSG00000067279 protein phosphatase 1, regulatory 
(inhibitor) subunit 3C [Source:MGI 
Symbol;Acc:MGI:1858229] 
Fam32a 28.5826 17.6337 -0.69681 0.026388 ENSMUSG00000003039 family with sequence similarity 32, 
member A [Source:MGI 
Symbol;Acc:MGI:1915172] 
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Gm12328 1647.47 1014.84 -0.69899 0.01671 ENSMUSG00000081552 predicted gene 12328 [Source:MGI 
Symbol;Acc:MGI:3651322] 
Cyc1 79.2877 48.7431 -0.7019 0.010233 ENSMUSG00000022551 cytochrome c-1 [Source:MGI 
Symbol;Acc:MGI:1913695] 
Gprc5b 27.7689 16.9072 -0.71584 0.017547 ENSMUSG00000008734 G protein-coupled receptor, family C, 
group 5, member B [Source:MGI 
Symbol;Acc:MGI:1927596] 
Cmas 54.5798 33.1457 -0.71954 0.007047 ENSMUSG00000030282 cytidine monophospho-N-
acetylneuraminic acid synthetase 
[Source:MGI 
Symbol;Acc:MGI:1337124] 
Cops4 56.7448 34.4071 -0.72178 0.015848 ENSMUSG00000035297 COP9 (constitutive 
photomorphogenic) homolog, 
subunit 4 (Arabidopsis thaliana) 
[Source:MGI 
Symbol;Acc:MGI:1349414] 
Cab39 65.3814 39.5991 -0.72341 0.006599 ENSMUSG00000036707 calcium binding protein 39 
[Source:MGI 
Symbol;Acc:MGI:107438] 
Fbxo21 17.1586 10.3796 -0.72519 0.011476 ENSMUSG00000032898 F-box protein 21 [Source:MGI 
Symbol;Acc:MGI:1924223] 
Tpi1 133.743 80.0706 -0.74012 0.048033 ENSMUSG00000023456 triosephosphate isomerase 1 
[Source:MGI Symbol;Acc:MGI:98797] 
Gap43 147.04 87.9553 -0.74137 0.000944 ENSMUSG00000047261 growth associated protein 43 
[Source:MGI Symbol;Acc:MGI:95639] 
Rpl26 215.837 127.76 -0.75651 0.033107 ENSMUSG00000060938 ribosomal protein L26 [Source:MGI 
Symbol;Acc:MGI:106022] 
Gm12033 68.8541 40.4422 -0.76768 0.003862 ENSMUSG00000078965 predicted gene 12033 [Source:MGI 
Symbol;Acc:MGI:3650772] 
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Cct7 71.5359 41.9857 -0.76877 0.000268 ENSMUSG00000030007 chaperonin containing Tcp1, subunit 
7 (eta) [Source:MGI 
Symbol;Acc:MGI:107184] 
Reep2 20.6954 12.1394 -0.76961 0.022352 ENSMUSG00000038555 receptor accessory protein 2 
[Source:MGI 
Symbol;Acc:MGI:2385070] 
Sod1 740.558 433.616 -0.7722 9.21E-05 ENSMUSG00000022982 superoxide dismutase 1, soluble 
[Source:MGI Symbol;Acc:MGI:98351] 
Ppp2cb 64.4952 37.738 -0.77317 0.003896 ENSMUSG00000009630 protein phosphatase 2 (formerly 2A), 
catalytic subunit, beta isoform 
[Source:MGI 
Symbol;Acc:MGI:1321161] 
Rab7 111.372 65.1223 -0.77416 0.014408 ENSMUSG00000079477 RAB7, member RAS oncogene family 
[Source:MGI 
Symbol;Acc:MGI:105068] 
Smarcd1 13.2763 7.69992 -0.78593 0.019919 ENSMUSG00000023018 SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily d, member 1 
[Source:MGI 
Symbol;Acc:MGI:1933623] 
Nfu1 60.971 35.2495 -0.79052 0.049002 ENSMUSG00000029993 NFU1 iron-sulfur cluster scaffold 
homolog (S. cerevisiae) [Source:MGI 
Symbol;Acc:MGI:1913290] 
Qpct 22.3182 12.8668 -0.79457 0.034661 ENSMUSG00000024084 glutaminyl-peptide cyclotransferase 
(glutaminyl cyclase) [Source:MGI 
Symbol;Acc:MGI:1917786] 
Gm5564 62.0448 35.5591 -0.80309 0.002233 ENSMUSG00000046440 predicted gene 5564 [Source:MGI 
Symbol;Acc:MGI:3645018] 
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1500011B03Rik, 
2610524H06Rik, 
Gm20499 
46.8134 26.8022 -0.80457 0.038156 #N/A #N/A 
Clptm1 26.5024 15.132 -0.80852 0.000751 ENSMUSG00000002981 cleft lip and palate associated 
transmembrane protein 1 
[Source:MGI 
Symbol;Acc:MGI:1927155] 
Ppme1 55.2024 31.4616 -0.81114 0.000266 ENSMUSG00000030718 protein phosphatase methylesterase 
1 [Source:MGI 
Symbol;Acc:MGI:1919840] 
2310003C23Rik 38.6234 21.9152 -0.81755 0.003057 ENSMUSG00000027573 RIKEN cDNA 2310003C23 gene 
[Source:MGI 
Symbol;Acc:MGI:1923675] 
Hist3h2a,Trim17 24.823 14.0648 -0.81959 0.031079 #N/A #N/A 
Fau 185.993 105.243 -0.82153 0.03214 ENSMUSG00000038274 Finkel-Biskis-Reilly murine sarcoma 
virus (FBR-MuSV) ubiquitously 
expressed (fox derived) [Source:MGI 
Symbol;Acc:MGI:102547] 
Nxph1 24.065 13.4797 -0.83615 0.022352 ENSMUSG00000046178 neurexophilin 1 [Source:MGI 
Symbol;Acc:MGI:107492] 
4930547N16Rik 59.5699 33.3343 -0.83758 0.015518 ENSMUSG00000035365 RIKEN cDNA 4930547N16 gene 
[Source:MGI 
Symbol;Acc:MGI:1922567] 
Uchl3 23.2096 12.9744 -0.83905 0.042928 ENSMUSG00000022111 ubiquitin carboxyl-terminal esterase 
L3 (ubiquitin thiolesterase) 
[Source:MGI 
Symbol;Acc:MGI:1355274] 
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Pacsin1 39.224 21.9135 -0.83991 0.010425 ENSMUSG00000040276 protein kinase C and casein kinase 
substrate in neurons 1 [Source:MGI 
Symbol;Acc:MGI:1345181] 
Vapa 72.5406 40.2635 -0.84932 0.000422 ENSMUSG00000024091 vesicle-associated membrane 
protein, associated protein A 
[Source:MGI 
Symbol;Acc:MGI:1353561] 
Cox6b1 363.621 201.591 -0.85101 0.000143 ENSMUSG00000036751 cytochrome c oxidase, subunit VIb 
polypeptide 1 [Source:MGI 
Symbol;Acc:MGI:107460] 
Eif1a 29.7026 16.3065 -0.86514 0.043294 ENSMUSG00000057561 eukaryotic translation initiation factor 
1A [Source:MGI 
Symbol;Acc:MGI:95298] 
AC148327.1 263.986 144.619 -0.86821 0.000102 ENSMUSG00000096617 0 
Gp1bb,Sept5 39.3636 21.5492 -0.86923 0.000285 #N/A #N/A 
Gm10166 77.759 42.2982 -0.87841 0.031079 ENSMUSG00000066543 predicted pseudogene 10166 
[Source:MGI 
Symbol;Acc:MGI:3641818] 
Ndfip1 825.726 448.459 -0.88069 6.53E-06 ENSMUSG00000024425 Nedd4 family interacting protein 1 
[Source:MGI 
Symbol;Acc:MGI:1929601] 
Pdhx 14.6715 7.95069 -0.88387 0.04676 ENSMUSG00000010914 pyruvate dehydrogenase complex, 
component X [Source:MGI 
Symbol;Acc:MGI:1351627] 
Mag 22.8908 12.3754 -0.8873 0.002304 ENSMUSG00000036634 myelin-associated glycoprotein 
[Source:MGI Symbol;Acc:MGI:96912] 
Trim35 14.7635 7.96348 -0.89056 0.010885 ENSMUSG00000022043 tripartite motif-containing 35 
[Source:MGI 
Symbol;Acc:MGI:1914104] 
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Ranbp3 14.9197 8.04571 -0.89093 0.007331 ENSMUSG00000002372 RAN binding protein 3 [Source:MGI 
Symbol;Acc:MGI:1919060] 
Hexim1 14.4224 7.72604 -0.90051 0.00328 ENSMUSG00000048878 hexamethylene bis-acetamide 
inducible 1 [Source:MGI 
Symbol;Acc:MGI:2385923] 
Tusc2 32.9219 17.6292 -0.90108 0.002427 ENSMUSG00000010054 tumor suppressor candidate 2 
[Source:MGI 
Symbol;Acc:MGI:1931086] 
Sfr1 66.8826 35.549 -0.91182 5.04E-05 ENSMUSG00000025066 SWI5 dependent recombination 
repair 1 [Source:MGI 
Symbol;Acc:MGI:1915038] 
Arglu1 15.83 8.34163 -0.92426 0.014834 ENSMUSG00000040459 arginine and glutamate rich 1 
[Source:MGI 
Symbol;Acc:MGI:2442985] 
Ctbp1 39.5104 20.8057 -0.92526 0.000148 ENSMUSG00000037373 C-terminal binding protein 1 
[Source:MGI 
Symbol;Acc:MGI:1201685] 
Wdr1 57.5128 30.0536 -0.93634 2.89E-06 ENSMUSG00000005103 WD repeat domain 1 [Source:MGI 
Symbol;Acc:MGI:1337100] 
Fkbp1b 27.0899 14.0146 -0.95082 0.024464 ENSMUSG00000020635 FK506 binding protein 1b 
[Source:MGI 
Symbol;Acc:MGI:1336205] 
Pcp4l1 21.0184 10.7915 -0.96175 0.009045 ENSMUSG00000038370 Purkinje cell protein 4-like 1 
[Source:MGI 
Symbol;Acc:MGI:1913675] 
Zfp62 93.4828 47.8476 -0.96625 0.028683 ENSMUSG00000046311 zinc finger protein 62 [Source:MGI 
Symbol;Acc:MGI:99662] 
Gm15501 57.5952 29.2565 -0.97719 0.006599 ENSMUSG00000087412 predicted pseudogene 15501 
[Source:MGI 
Symbol;Acc:MGI:3704296] 
 1
7
0
 
Rcl1 12.7669 6.41326 -0.99327 0.024435 ENSMUSG00000024785 RNA terminal phosphate cyclase-like 
1 [Source:MGI 
Symbol;Acc:MGI:1913275] 
Nudt3 198.284 99.5314 -0.99435 0.004073 ENSMUSG00000024213 nudix (nucleotide diphosphate linked 
moiety X)-type motif 3 [Source:MGI 
Symbol;Acc:MGI:1928484] 
Oxct1 217.768 109.235 -0.99535 0.005753 ENSMUSG00000022186 3-oxoacid CoA transferase 1 
[Source:MGI 
Symbol;Acc:MGI:1914291] 
Aff2 28.8051 14.419 -0.99836 0.013952 ENSMUSG00000031189 AF4/FMR2 family, member 2 
[Source:MGI 
Symbol;Acc:MGI:1202294] 
Ndufv1 91.337 45.2477 -1.01336 0.015147 ENSMUSG00000037916 NADH dehydrogenase (ubiquinone) 
flavoprotein 1 [Source:MGI 
Symbol;Acc:MGI:107851] 
6030419C18Rik 13.2118 6.50601 -1.02198 0.008062 ENSMUSG00000066607 RIKEN cDNA 6030419C18 gene 
[Source:MGI 
Symbol;Acc:MGI:2442108] 
Vwa1 6.0212 2.96479 -1.02212 0.028683 ENSMUSG00000042116 von Willebrand factor A domain 
containing 1 [Source:MGI 
Symbol;Acc:MGI:2179729] 
Amd-ps3 19.9873 9.82203 -1.02499 0.012455 ENSMUSG00000060096 S-adenosylmethionine decarboxylase, 
pseudogene 3 [Source:MGI 
Symbol;Acc:MGI:3704487] 
Thbs2 2.74087 1.33689 -1.03576 0.037589 ENSMUSG00000023885 thrombospondin 2 [Source:MGI 
Symbol;Acc:MGI:98738] 
2210016L21Rik 11.2131 5.43 -1.04616 0.038559 ENSMUSG00000029559 RIKEN cDNA 2210016L21 gene 
[Source:MGI 
Symbol;Acc:MGI:1919607] 
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Praf2 35.5601 17.1829 -1.04928 0.00053 ENSMUSG00000031149 PRA1 domain family 2 [Source:MGI 
Symbol;Acc:MGI:1859607] 
Chchd10 126.298 60.9237 -1.05175 7.31E-06 ENSMUSG00000049422 coiled-coil-helix-coiled-coil-helix 
domain containing 10 [Source:MGI 
Symbol;Acc:MGI:2143558] 
Gfap 60.2089 28.9459 -1.05662 2.43E-07 ENSMUSG00000020932 glial fibrillary acidic protein 
[Source:MGI Symbol;Acc:MGI:95697] 
Uqcrh 415.303 198.519 -1.06489 7.71E-07 ENSMUSG00000063882 ubiquinol-cytochrome c reductase 
hinge protein [Source:MGI 
Symbol;Acc:MGI:1913826] 
Hba-a1 218.668 104.258 -1.06859 7.10E-05 ENSMUSG00000069919 hemoglobin alpha, adult chain 1 
[Source:MGI Symbol;Acc:MGI:96015] 
Cldn11 58.393 27.7848 -1.0715 4.95E-06 ENSMUSG00000037625 claudin 11 [Source:MGI 
Symbol;Acc:MGI:106925] 
Cnot8 31.1279 14.7672 -1.07581 0.004692 ENSMUSG00000020515 CCR4-NOT transcription complex, 
subunit 8 [Source:MGI 
Symbol;Acc:MGI:1916375] 
2400001E08Rik 20.4639 9.5956 -1.09263 0.007955 ENSMUSG00000030842 RIKEN cDNA 2400001E08 gene 
[Source:MGI 
Symbol;Acc:MGI:1913758] 
Serpina3n 24.1918 11.3298 -1.09439 7.53E-05 ENSMUSG00000021091 serine (or cysteine) peptidase 
inhibitor, clade A, member 3N 
[Source:MGI 
Symbol;Acc:MGI:105045] 
Mrpl41 135.069 63.1819 -1.09612 3.39E-06 ENSMUSG00000036850 mitochondrial ribosomal protein L41 
[Source:MGI 
Symbol;Acc:MGI:1333816] 
Sccpdh 184.005 85.9126 -1.0988 0.005413 ENSMUSG00000038936 saccharopine dehydrogenase 
(putative) [Source:MGI 
Symbol;Acc:MGI:1924486] 
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Mif 140.608 65.2812 -1.10694 8.07E-05 ENSMUSG00000033307 macrophage migration inhibitory 
factor [Source:MGI 
Symbol;Acc:MGI:96982] 
Prcc 7.23394 3.29701 -1.13362 0.030198 ENSMUSG00000004895 papillary renal cell carcinoma 
(translocation-associated) 
[Source:MGI 
Symbol;Acc:MGI:2137738] 
Caly 129.765 58.7189 -1.144 1.48E-07 ENSMUSG00000025468 calcyon neuron-specific vesicular 
protein [Source:MGI 
Symbol;Acc:MGI:1915816] 
Gm7292 95.4951 42.8587 -1.15584 1.04E-06 ENSMUSG00000072829 predicted gene 7292 [Source:MGI 
Symbol;Acc:MGI:3645786] 
Tppp3 55.2844 24.7239 -1.16096 0.00012 ENSMUSG00000014846 tubulin polymerization-promoting 
protein family member 3 
[Source:MGI 
Symbol;Acc:MGI:1915221] 
Ankrd34a 7.10011 3.1725 -1.16222 0.026534 ENSMUSG00000049097 ankyrin repeat domain 34A 
[Source:MGI 
Symbol;Acc:MGI:3617846] 
Tonsl,Vps28 124.811 55.5577 -1.16768 3.44E-07 #N/A #N/A 
Car2 78.2557 34.7263 -1.17217 2.67E-08 ENSMUSG00000027562 carbonic anhydrase 2 [Source:MGI 
Symbol;Acc:MGI:88269] 
C030046I01Rik 15.655 6.93717 -1.1742 0.003488 ENSMUSG00000035781 RIKEN cDNA C030046I01 gene 
[Source:MGI 
Symbol;Acc:MGI:1924814] 
Dyrk1a 54.3097 24.065 -1.17427 0.005408 ENSMUSG00000022897 dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 1a 
[Source:MGI 
Symbol;Acc:MGI:1330299] 
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Vtn 35.6159 15.3805 -1.21142 0.014254 ENSMUSG00000017344 vitronectin [Source:MGI 
Symbol;Acc:MGI:98940] 
H3f3b 142.822 61.4378 -1.21702 1.38E-05 ENSMUSG00000016559 H3 histone, family 3B [Source:MGI 
Symbol;Acc:MGI:1101768] 
Gm15920 181.262 77.8861 -1.21864 0.000678 ENSMUSG00000080893 predicted gene 15920 [Source:MGI 
Symbol;Acc:MGI:3801934] 
Drg2 54.0491 22.8711 -1.24074 0.043722 ENSMUSG00000020537 developmentally regulated GTP 
binding protein 2 [Source:MGI 
Symbol;Acc:MGI:1342307] 
Wibg 14.213 5.98364 -1.24812 0.013774 ENSMUSG00000064030 within bgcn homolog (Drosophila) 
[Source:MGI 
Symbol;Acc:MGI:1925678] 
Cldn10 23.3534 9.80055 -1.2527 0.013783 ENSMUSG00000022132 claudin 10 [Source:MGI 
Symbol;Acc:MGI:1913101] 
Syt5 51.0936 21.3181 -1.26106 7.78E-08 ENSMUSG00000004961 synaptotagmin V [Source:MGI 
Symbol;Acc:MGI:1926368] 
Arf3 82.8923 34.5175 -1.26391 0.008894 ENSMUSG00000051853 ADP-ribosylation factor 3 
[Source:MGI Symbol;Acc:MGI:99432] 
Creld2 15.7127 6.50684 -1.2719 0.002814 ENSMUSG00000023272 cysteine-rich with EGF-like domains 2 
[Source:MGI 
Symbol;Acc:MGI:1923987] 
S100b 136.941 56.6325 -1.27385 5.36E-10 ENSMUSG00000033208 S100 protein, beta polypeptide, 
neural [Source:MGI 
Symbol;Acc:MGI:98217] 
Gpr12 11.5666 4.73839 -1.2875 0.002037 ENSMUSG00000041468 G-protein coupled receptor 12 
[Source:MGI 
Symbol;Acc:MGI:101909] 
Eif4g2 189.493 76.9924 -1.29936 0.004499 ENSMUSG00000005610 eukaryotic translation initiation factor 
4, gamma 2 [Source:MGI 
Symbol;Acc:MGI:109207] 
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Cadm3 44.4792 17.8522 -1.31703 0.034494 ENSMUSG00000005338 cell adhesion molecule 3 [Source:MGI 
Symbol;Acc:MGI:2137858] 
1110008F13Rik 20.6297 8.26058 -1.32041 0.015518 ENSMUSG00000027637 RIKEN cDNA 1110008F13 gene 
[Source:MGI 
Symbol;Acc:MGI:1914638] 
Sh3gl3 45.2781 18.0535 -1.32653 0.002643 ENSMUSG00000030638 SH3-domain GRB2-like 3 [Source:MGI 
Symbol;Acc:MGI:700011] 
Mff 105.21 41.9486 -1.32657 0.01204 ENSMUSG00000026150 mitochondrial fission factor 
[Source:MGI 
Symbol;Acc:MGI:1922984] 
Gm15427 26.2251 10.4101 -1.33295 0.020145 ENSMUSG00000081051 predicted pseudogene 15427 
[Source:MGI 
Symbol;Acc:MGI:3642341] 
SCARNA20 2278.39 895.726 -1.34688 0.031079 ENSMUSG00000089209 Small Cajal body specific RNA 20  
[Source:RFAM;Acc:RF00601] 
Necab2 15.7905 6.1062 -1.37071 0.020708 ENSMUSG00000031837 N-terminal EF-hand calcium binding 
protein 2 [Source:MGI 
Symbol;Acc:MGI:2152211] 
Gfer 11.115 4.28969 -1.37356 0.003488 ENSMUSG00000040888 growth factor, erv1 (S. cerevisiae)-like 
(augmenter of liver regeneration) 
[Source:MGI 
Symbol;Acc:MGI:107757] 
Mrpl48-ps 20.9756 7.86971 -1.41433 0.020708 ENSMUSG00000078480 mitochondrial ribosomal protein L48 
pseudogene [Source:MGI 
Symbol;Acc:MGI:3050089] 
Hadh 17.9244 6.69126 -1.42157 6.41E-05 ENSMUSG00000027984 hydroxyacyl-Coenzyme A 
dehydrogenase [Source:MGI 
Symbol;Acc:MGI:96009] 
 1
7
5
 
Tmem63b 27.7818 10.2526 -1.43815 0.019159 ENSMUSG00000036026 transmembrane protein 63b 
[Source:MGI 
Symbol;Acc:MGI:2387609] 
Rtn4rl1 4.30095 1.56947 -1.45438 0.009276 ENSMUSG00000045287 reticulon 4 receptor-like 1 
[Source:MGI 
Symbol;Acc:MGI:2661375] 
Erh 85.9793 30.8921 -1.47675 0.000116 ENSMUSG00000021131 enhancer of rudimentary homolog 
(Drosophila) [Source:MGI 
Symbol;Acc:MGI:108089] 
Ube2s 89.5018 31.8918 -1.48873 5.06E-09 ENSMUSG00000060860 ubiquitin-conjugating enzyme E2S 
[Source:MGI 
Symbol;Acc:MGI:1925141] 
Gm9843 73.4298 25.9946 -1.49815 0.000102 ENSMUSG00000050299 predicted gene 9843 [Source:MGI 
Symbol;Acc:MGI:3708621] 
Gpbp1l1 49.3353 16.5199 -1.57842 0.004499 ENSMUSG00000034042 GC-rich promoter binding protein 1-
like 1 [Source:MGI 
Symbol;Acc:MGI:1924360] 
Rbbp6 64.5126 21.0892 -1.61308 0.002423 ENSMUSG00000030779 retinoblastoma binding protein 6 
[Source:MGI 
Symbol;Acc:MGI:894835] 
Gm11353 26.8346 8.66772 -1.63037 0.00137 ENSMUSG00000060198 predicted gene 11353 [Source:MGI 
Symbol;Acc:MGI:3649794] 
Mpnd 44.2849 14.1666 -1.64432 8.07E-05 ENSMUSG00000003199 MPN domain containing [Source:MGI 
Symbol;Acc:MGI:1915297] 
Hba-a2 645.713 204.785 -1.65679 0 ENSMUSG00000069917 hemoglobin alpha, adult chain 2 
[Source:MGI Symbol;Acc:MGI:96016] 
Tsc22d4 38.7625 12.1985 -1.66796 0.012455 ENSMUSG00000029723 TSC22 domain family, member 4 
[Source:MGI 
Symbol;Acc:MGI:1926079] 
 1
7
6
 
Hist1h1c 18.8825 5.93611 -1.66946 3.09E-05 ENSMUSG00000036181 histone cluster 1, H1c [Source:MGI 
Symbol;Acc:MGI:1931526] 
Gm10108 56.4492 17.3242 -1.70417 0.028937 ENSMUSG00000062038 predicted pseudogene 10108 
[Source:MGI 
Symbol;Acc:MGI:3642431] 
Lrrc4b 35.533 10.675 -1.73493 3.38E-12 ENSMUSG00000047085 leucine rich repeat containing 4B 
[Source:MGI 
Symbol;Acc:MGI:3027390] 
RNaseP_nuc 506.951 148.426 -1.7721 4.92E-12 ENSMUSG00000088874 Nuclear RNase P  
[Source:RFAM;Acc:RF00009] 
Pvalb 96.614 27.0589 -1.83613 1.76E-13 ENSMUSG00000005716 parvalbumin [Source:MGI 
Symbol;Acc:MGI:97821] 
Ppp1r14a 40.2998 10.9388 -1.88132 0.000233 ENSMUSG00000037166 protein phosphatase 1, regulatory 
(inhibitor) subunit 14A [Source:MGI 
Symbol;Acc:MGI:1931139] 
Rpl17-ps5 313.336 84.7551 -1.88634 0 ENSMUSG00000081855 ribosomal protein L17, pseudogene 5 
[Source:MGI 
Symbol;Acc:MGI:3704246] 
Timm23 418.651 83.9938 -2.31739 1.08E-05 ENSMUSG00000013701 translocase of inner mitochondrial 
membrane 23 homolog (yeast) 
[Source:MGI 
Symbol;Acc:MGI:1858317] 
U12 379.431 58.8483 -2.68877 0.01513 ENSMUSG00000088188 U12 minor spliceosomal RNA  
[Source:RFAM;Acc:RF00007] 
Snora74a 2191.22 263.94 -3.05345 0 ENSMUSG00000065649 small nucleolar RNA, H/ACA box 74A 
[Source:MGI 
Symbol;Acc:MGI:3646921] 
Gm10268 16.8519 1.80542 -3.2225 0.026534 ENSMUSG00000066475 predicted gene 10268 [Source:MGI 
Symbol;Acc:MGI:3642637] 
 1
7
7
 
U11 1263.25 119.118 -3.40668 0.000105 ENSMUSG00000077317 U11 spliceosomal RNA  
[Source:RFAM;Acc:RF00548] 
AC150277.1 7465.48 582.269 -3.68048 0 ENSMUSG00000092819 0 
Snora7a 1688.57 115.675 -3.86765 0.009075 ENSMUSG00000064563 small nucleolar RNA, H/ACA box 7A 
[Source:MGI 
Symbol;Acc:MGI:3819512] 
 
Appendix Table 5. Significantly differentially expressed genes  
Significantly differentially expressed genes identified after mapping of the Illumina sequencing reads via TopHat 2.0.4 to the mm10 build of the mouse 
genome. Differential expression testing was performed using Cufflinks 2.0.2. Genes are ordered from most upregulated in Gnasxlm+/p- mice (KO) compared 
to wildtype (WT) mice. 
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